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ONCOLOGY NURSES’ ATTITUDES TOWARD CANCER CLINICAL TRIALS 
AND THEIR PERCEPTIONS OF PATIENTS’ UNDERSTANDING 
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Clinical trials in oncology that evaluate new cancer tr atments are essential. 
However, in the United States only 2%-4% of eligible adult cancer patients participate in 
the National Cancer Institute’s clinical trials annually. Oncology nurses have a major role 
in the care of patients contemplating enrollment into cancer clinical trials, yet little is 
known about their attitudes, beliefs, and perceptions.  
The Modified Nursing Attitude Survey and a demographic form were used to 
collect data. This study discovered significant predictors to attitudes and perceptions; 
however, all R² (coefficient of determination) values were very low, which indicates that 
some other unknown variables could be better predictors than those used in this study. On 
average, oncology nurses reported positive attitudes towards cancer clinical trials. 
However, statistically significant differences were found between nurses grouped by 
primary work setting and primary position. Additionally, as a whole, these nurses 
perceived that patients have enough information to make decisions regarding clinical trial 
participation, but they somewhat disagreed that: clinical research should be conducted 
only in cancer centers, oncologists and nurses put too much pressure on patients to 
participate, and patients are often unaware that their reatment is part of a research 
protocol. Significant differences in these perceptions were found between: primary work 
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setting, number of years in cancer nursing, and whether or not the nurse works with these 
patients. Consistent with prior research, oncology nurses perceive that experimental 
cancer treatments should have a large benefit before being offered. Moreover, there were 
statistically significant differences in this perceived benefit among the nurses grouped by 
number of years in cancer nursing, primary work setting, and education level. More 
research is needed to explore the reasons for these differences in attitudes and 
perceptions. 
This study explored nurses’ attitudes and perceptions regarding cancer clinical 
trials.  Since their attitudes may ultimately dictate their behaviors towards clinical trials, 
this study has far reaching implications for nursing education, nursing practice, and the 
conduct of clinical trials.  By investigating oncology nurses’ attitudes and perceptions 
toward cancel clinical trials this study begins to assess the behavior of oncology nurses 
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CHAPTER I: INTRODUCTION 
A. Background 
History of Human Subject Research 
Experiments performed by the Nazis on concentration-camp inmates are some of 
the most well-known atrocities to date. Out of this orror came the first formalized set of 
ethical rules for the conduct of human experimentation. In the aftermath of the war, the 
Nuremberg Tribunal prosecuted the perpetrators and, in 1946, developed a set of ethical 
principles that have come to be known as the Nuremberg Code. The Code sets out 10 
ethical principles for the conduct of clinical trials. The first is the most important: “The 
voluntary consent of the human subject is absolutely essential.” Moreover, this consent 
must be obtained “without the intervention of any element of force, fraud, deceit, duress, 
over-reaching, or other ulterior form of constraint or coercion” (Nuremberg Military 
Tribunal, 1949, p. 181).  
 In June 1966, Henry K. Beecher, an anesthesiologist at Harvard Medical School, 
published an article entitled “Ethics and Clinical Research” in the New England Journal 
of Medicine (Beecher, 1966). In his article, he listed more than 22 clinical trials that 
appeared to be highly unethical, in which investigators risked their patients’ lives without 
fully informing them of the dangers and without obtaining their permission. The “Ethics 
and Clinical Research” article had a significant role in the development of requirements 
for informed consent of research subjects. 
 In 1970, the Tuskegee experiment was revealed. Starting in 1930 and continuing 
for four decades, investigators began examining, but not treating, a group of 400 African-
American men who had syphilis. The investigators were interested in watching the 
 
 





natural course of the disease. In 1930, the existing treatments for syphilis were complex 
and not very effective, so the investigators felt they were justified in not treating the men. 
Penicillin as a highly effective cure for syphilis became available widely in 1945. 
However, many of the men were left untreated until the situation was uncovered in 1970 
(Finn, 1999).  
 The publicity from the Tuskegee Syphilis Study prompted the National Research 
Act of 1974 that created the National Commission for the Protection of Human Subjects 
of Biomedical and Behavioral Research (National Cancer Institute, 1979). One charge to 
the Commission was to identify the basic ethical principles that should underlie the 
conduct of biomedical and behavioral research involving human subjects and to develop 
guidelines to assure that such research is conducted in accordance with those principles 
(Public Law 93-348, 1974).  
In carrying out the above charge, the Commission was directed to consider the 
following: the boundaries between biomedical and behavioral research and the accepted 
and routine practice of medicine; the role of assesment of risk-benefit criteria in the 
determination of the appropriateness of research involving human subjects; appropriate 
guidelines for the selection of human subjects for participation in such research; and the 
nature and definition of informed consent in various research settings (National Cancer 
Institute, 1979). 
 The Belmont Report summarizes the basic ethical princi les identified by the 
Commission for the Protection of Human Subjects of Bi medical and Behavioral 
Research (National Cancer Institute, 1979). It is the outgrowth of an intensive four day 
period of discussions held in February 1976 at the Smithsonian Institution‘s Belmont 
 
 





Conference Center and supplemented by monthly deliberations of the Commission that 
were held over a period of nearly 4 years. It is a statement of basic ethical principles and 
guidelines that should assist in resolving the ethical problems that surround the conduct 
of research with human subjects (Office of Behavioral and Social Sciences Research, 
2003).  
The three basic ethical principles for the conduct of clinical trials discussed in the 
Belmont Report are respect for persons, beneficence, and justice (National Institutes of 
Health, 1979). In applying those principles, the authors recommended that consideration 
be given to three requirements:  
1. Informed consent: In order to provide fully informed consent, a potential 
research subject must first be given full information about the research project. Second, 
that information must be presented in a comprehensible way, taking into account the 
patient‘s intellectual capacities. Third, the consent must be truly voluntary, and free from 
coercion and undue influence.  
2. Assessment of risks and benefits: The dangers of any clinical trial must not 
exceed its potential benefits.  
3. Selection of subjects: There must be fair procedur s for the selection of 
research subjects (National Institutes of Health, 1979).  
Therapeutic Clinical Trials 
 A clinical trial is clinical research “designed to answer a question that has 
therapeutic implications for patients” (Hubbard, 1985, p. 67). The most familiar clinical 
trials in oncology are the ones that evaluate new methods of screening, prevention, 
diagnosis, or treatment of cancer (National Institutes of Health, 2006). Clinical trials are 
 
 





generally divided into four main phases. Each has a sep rate and particular goal, and each 
successive phase builds upon the previous one (Grady, 1991).  
Phase I studies. Phase I studies are unblinded and uncontrolled. They are 
designed to evaluate the maximum tolerated dose (MTD) and the safety of a new drug or 
combination of drugs and a given administration schedule in human subjects (Johansen, 
Mayer, & Hoover, 1991; Yoder, O’Rourke, Etnyre, Spears, & Brown, 1997). MTD and 
treatment schedule are the endpoints of a Phase I trial, thus antitumor or disease response 
may not be noted (Jenkins & Hubbard, 1991; Johansen et al., 1991).  
Patients eligible for these trials are generally those with less than three months to 
live and have no alternative available treatment options. Some patients will receive a 
treatment which has no benefit to them, since these trials offer no guarantee of efficacy. 
However, there is an important characteristic that can be of value to patients. There is the 
possibility that the new treatment, which looks promising in the laboratory, may continue 
to invoke its same promising characteristics in humans (Sadler, Lantz, Fullerton, & Dault, 
1999). These trials offer patients a ray of hope even though the Phase I trial is concerned 
only with establishing the MTD. Qualitative studies conducted with patients enrolled into 
Phase I clinical trials discovered hope as a recurrnt theme (Cox, 1999; Cox & Avis, 
1996; Moore, 2001; Schutta & Burnett, 2000; Yoder et al., 1997). 
Phase II studies. At the completion of a Phase I study, the MTD is established. It 
is at this dose level that Phase II studies are design d to determine the activity and 
efficacy of a drug or treatment against a specific disease. The timing and frequency of 
objective tumor measurements before, during, and after treatment must be specified and 
strictly followed (Sadler et al., 1999).  
 
 





If the findings from the Phase II study show promise that the intervention is 
equivalent to, or better than, currently available th rapies, then the intervention is moved 
into Phase III evaluation.  
Phase III studies. Once a medication demonstrates efficacy in Phase II testing, 
Phase II studies are conducted. Phase III studies are large randomized, controlled studies 
(they may be blinded, but not always) designed to test the investigational agent(s) against 
the accepted standards of care. Survival, quality-of-life, and cost-effectiveness are 
assessed in a Phase III trial (Jenkins & Hubbard, 1991). 
Patients who are eligible for a Phase III clinical trial typically are at an earlier 
stage of diagnosis than in previous phases, and conform to narrowly defined inclusion 
and exclusion criteria for participation (Sadler et al., 1999).  
At the completion of a Phase III trial there will be a more thorough understanding 
of the new therapies’ benefits and potential adverse reactions. Upon successful 
completion of a Phase III trail, the sponsor of the trial (pharmaceutical company, or 
government agency, etc.) can request Food and Drug Administration (FDA) approval to 
market the therapy for the specified condition evaluated in the trial (Sadler et al., 1999).  
Phase IV studies. After a treatment receives FDA approval, Phase IV studies, 
commonly known as post-marketing studies, are conducte . They “assess the rate of 
serious side effects and evaluate additional therapeutic uses of the therapy” (Grady, 
Cummings, & Hulley, 2001 p. 170). These studies could include, but would not be 
limited to, examining different doses or schedules of administration than were previously 
used in Phase II studies, use of the drug in other patient populations or other stages of the 
disease, or use of the drug over longer time periods t  assess long-term safety. 
 
 





B. The Problem 
The majority of advances in cancer treatment come in small steps achieved 
through clinical trials in which new drugs and treaments are carefully studied on human 
subjects. Thus, the ethics of research, especially regarding the rights of patients, becomes 
vital to this endeavor. Clinical trials are an important step in helping translate potentially 
beneficial basic research findings into clinical practice (Grunfeld, Zitelsberger, Coristine, 
& Aspelund, 2002). It is vital to recruit as many eligible patients as possible for studies, 
and to do so in an ethical manner. Clinical trials n oncology that evaluate new treatments 
are essential. However, in the United States (US) only two to four percent (N = 28,000-
56,000) of all newly diagnosed adult cancer patients a nually participate in National 
Cancer Institute (NCI) clinical trials (Lara, et al., 2001). This is despite estimates that 
12%–44% (N = 168,000-616,000) of adults with cancer are eligible for entry (Morrow, 
Hickok, & Burish, 1994). According to the NCI, this is in sharp contrast to he enrollment 
of pediatric cancer patients into clinical trials, which approaches 50-80% (N = 6,200 – 
9920) (Ries, et al., 1999; Sateren, et al., 2002). This strong enrollment of children with 
cancer is due in part to the fact that most children are treated at academic medical centers 
with experts’ in pediatric oncology (Sateren, et al., 2002). 
A total of 1,399,790 new cancer cases and 564,830 deaths from cancer are 
expected in the U.S. in 2006 (Jemal, et al., 2006). This is a greater concern when age-
adjusted death rates are considered. Cancer in the U.S is the leading cause of death 
among men and women under age 85 (Jemal, et al., 2006). A total of 476,844 people 
under age 85 died from cancer in the U.S. in 2003, compared with 436,258 deaths from 
heart disease (Jemal, et al., 2006). Therefore, recruitment and retention of adult 
 
 





participants into oncology clinical trials is critical to the outcome and success of clinical 
trial research. However, concerns exist about the ability of clinical investigators to 
provide sufficient information to patients regarding research trial participation so that 
patients can recognize the distinction between resea ch and therapy (Bok, 1995). The 
shortage of clinical trial participants often result  in early trial closure, increased cost, 
compromised generalizability of the findings, and delays in the development and 
adoption of new treatments (Barrett, 2002). 
Today, the vast majority of clinical trials relate to treatment decisions. When 
patients consider treatments, they base their decisions upon many factors, including 
available information (Llewellyn-Thomas, McGreal, & Theil, 1995). Nealon, Blumberg, 
and Brown (1985) reported on an unpublished NCI pilot study investigating the 
educational needs of cancer patients considering clical trials and to develop ways to 
meet these needs. At the time there were few educational materials that explained clinical 
trials to patients and families. The NCI conducted an assessment with the following 
participants (N = 53): 16 cancer patients currently in trials and 4 family members, 4 NCI 
cancer control staff, 18 physicians (7 NCI staff and 11 community physicians), 8 
oncology nurses, 2 oncology social workers, and 1 healt  educator (Nealon, Blumberg, & 
Brown, 1985). Patients reported that although they do not know what to ask, when they 
do ask questions, they are more likely to ask a nurse than a doctor. Therefore, patients 
considering investigational therapy may receive much of their information about options 
from nurses. From the experience of this investigator, this remains true today. It is 
ethically essential for healthcare professionals to provide patients with the information 
required to promote informed decisions (Beauchamp & Childress, 2001).  
 
 





Oncology nurses participate in all aspects of clinial trials as direct care givers, 
research nurses, research partners, and primary invest gators. They also administer 
experimental agents to patients, manage side effects, and obtain informed consent 
(Ehrenberger & Lillington, 2004; Joshi & Ehrenberger, 2001; Rosse & Krebs, 1999). 
Oncology nurses have a major role in cancer clinical trials, such as direct caregivers, 
patient advocates, educators, counselors, as well as facilitators of clinical trials. Yet, not 
much is known about their attitudes, beliefs, and perceptions.  
C. Purpose 
  The purpose of this study was to examine oncology nurses’ attitudes toward 
cancer clinical trials and to identify nurses’ perceptions of patients’ understanding of the 
clinical trial process and desire for information and, reasons for patient participation in 
clinical research. This study investigated factors which may influence oncology nurses’ 
attitudes and perceptions.  They included the nurses’ age, educational preparation, length 
of time in oncology nursing, whether of not the nurse actually cares for patients 
contemplating enrollment or currently enrolled in a clinical trial, primary position, and 
work setting. 
D. Research Questions 
The following research questions guided this inquiry: 
 1. What are oncology nurses’ attitudes toward the benefits of cancer clinical 
trials? 
 2. What are nurses attitudes about how effective a research drug or experimental 
therapy should be shown to be before it is offered to patients? 
 
 





3. What are the nurses’ perceptions regarding patients’ understanding and 
knowledge of the treatment regimen?  
4. What factors do nurses perceive influence a patient’s decision to participate in a 
cancer clinical trial? 
5. What are nurses’ perceptions of patients’ decision-making processes and the 
desire for information regarding clinical trial participation?  
6. What are the perceptions of nurses regarding where clinical research should be 
conducted and the role of oncologists and nurses in clinical trials? 
7. Do the demographic variables of age, education level, number of years in 
oncology, whether or not the nurse actually works with patients contemplating enrollment 
or currently enrolled in a clinical trial, primary work setting, and primary position of 
oncology nurses serve as significant predictors of attitudes and perceptions as measured 
by the modified Nurse’s Attitude Survey (NAS)? 
E. Definition of Terms 
The key terms used throughout the research were operationalized and defined as 
follows: 
Oncology Nurses  
Conceptual definition: A person skilled or trained in “treating human responses of 
patients and families with cancer diagnoses or who are at risk for developing cancer. It 
encompasses the role of direct caregiver, educator, consultant, administrator, and 
investigator” (Oncology Nursing Society [ONS], 2004, p. 7). 
Operational definition: Registered nurses (RNs) who are members of the 
Oncology Nursing Society (ONS) who reside in the United States only, who permit ONS 
 
 





to release their addresses, who self-report that they are employed full, or part-time, and 
self-report their primary functional area as patient care or research and self-report a 
primary position other than researcher/principal investigator. 
Attitudes  
Conceptual definition: “Summary evaluations of objects (e.g., oneself, other 
people, issues, etc.) along a dimension ranging from p sitive to negative” (Petty, 
Wegener, & Fabrigar, 1997, p. 611). The evaluations of these psychological objects are 
captured in such attribute dimensions as good-bad, h rmful-beneficial, pleasant-
unpleasant, and likable-dislikable (Ajzen, 2001; Ajzen & Fishbein, 2000). Attitudes are 
made up of the beliefs that persons accumulate over their lifetimes (past experiences). 
Operational definition: For this study, attitude was measured as the mental 
position oncology nurses have with regard to the importance of conducting clinical 
research in oncology. Specifically, their agreement or disagreement with statements that 
clinical research improves patient care, is important for future standards of care in 
oncology, encourages patients’ to participate in research, and the patients’ preferences to 
be treated on a clinical trial, as measured on the NAS (Burnett, et al., 2001; see Appendix 
A).  
Perceptions  
Conceptual definition: A representation of one’s reality, with a process of 
interpreting information from sensory data and memory, that gives meaning to one’s 
experience and influences one’s behavior (King, 1981).  
Operational definition: Perceptions were measured as oncology nurses’ 
perceptions of patients’ understanding of cancer clinical trials, treatment of their cancer, 
 
 





and their desire for information. Specifically, the nurse’s agreement or disagreement with 
statements that patients are well informed regarding participation in clinical trials, 
patients’ awareness that their treatment is part of a research protocol, patients’ understand 
their treatment plans and prognoses, and patients dsire to be informed as reported on the 
NAS (Appendix A). 
Cancer Clinical Trials 
Conceptual definition: A type of research study that ests how well new medical 
approaches work in people. These studies test new methods of screening, prevention, 
diagnosis, or treatment of cancer (NCI, 2006). This includes any study that is provided in 
the context of a research protocol, which has been approved by an Institutional Review 
Board (IRB) and where a patient has signed an informed consent document. This includes 
Phase I, II, III, and IV clinical trials. 
Operational definition: A cancer clinical trial was defined as any study testing a 
method of cancer treatment. Moreover, a study that is provided in the context of a 
research protocol, which was approved by an IRB and patients have signed informed 
consent documents. This includes Phase I, II, III, and IV clinical trials.  
F. Assumptions and Limitations 
Assumptions 
 The following assumptions were made: 
1. There is variation among individual nurses’ knowledge regarding cancer 
clinical trials. 
2. There is no deceit or coercion, when nurses provide patients with information 
and education regarding cancer clinical trials. 
 
 





3. Nurses responded honestly to all questions. 
Limitations 
 The limitations of the study were: 
1. Response bias may have existed using a survey method of data collection 
(Dillman, 2000). It is unknown if people who responded to the survey may be different 
from those who do not. 
2. Individuals may have provided socially desirable responses. They may have 
responded in a particular manner, regardless of what is a fair representation of their 
attitudes or perceptions. 
3. The sample of oncology nurses who were recruited from the ONS membership 
may not represent all cancer nurses in the nation.  
G. Significance 
Clinical trials are essential to bring potentially beneficial basic research into 
clinical practice and provide new methods of screening, prevention, diagnosis, or 
treatment of cancer (Grunfeld, et al., 2002; NCI, 2006). In the U.S., very small 
percentages (2-4%) of adult cancer patients participate in clinical trials (Lara, et al., 2001) 
despite estimates that 12-44% of patients are eligible (Morrow, et al., 2004). Therefore, 
there are more patients who could, but do not, participate in cancer clinical trials. This 
shortage of clinical trial participants compromises the generalizability of findings and 
delays development and adoption of new cancer treatments (Barrett, 2002). The delays 
potentially could be detrimental to patients with a cancer diagnoses.  
Oncology nurses have a key role in the clinical andresearch settings by serving as 
direct caregivers, patient advocates, educators, counselors, as well as facilitators of 
 
 





clinical trials. As such, nurses have a major role in cancer clinical trials, yet not much is 
known about their attitudes and perceptions on this subject. Only one study was reported 
addressing nurses’ attitudes toward cancer clinical trials. Burnett et al. (2001) addressed 
nurses’ attitudes toward cancer clinical trials in a comprehensive cancer center. The 
investigators conducted a descriptive study with a 59-item self-report survey. The 
objective was to identify nurses’ attitudes and beliefs toward cancer clinical trials and 
their perceptions about factors influencing patients’ participation. Four hundred 
seventeen nurses employed at a NCI-designated cancer cent r were surveyed, and 250 
nurses (60%) responded. The authors found 96% of nurses reported that participation in 
clinical trials is important to improving standards of care; however, only 56% of nurses 
believed that cancer patients should be encouraged to participate in trials and 35% of 
nurses reported that they would prefer treatment in a clinical trial if they had cancer.  
This discrepancy is alarming considering that patients considering enrollment into 
a clinical trial or presently are enrolled in one, r ceive important information about 
treatment options from nurses. Additionally, NCI investigators found that many cancer 
patients may not know what to ask, but, when they do, they are more likely to ask a nurse 
than a physician (Nealon, Blumberg, & Brown, 1985). Oncology nurses’ attitudes and 
perceptions are important factors that impact upon the nurses’ role in patient care. 
Additionally, attitudes and perceptions impacts professional nursing issues, such as 
nursing practice and nursing education. Nurses’ attitudes and perceptions regarding 
cancer clinical trials ultimately may dictate their behaviors towards patients enrolled in or 
contemplating enrollment in such trials. By investiga ng oncology nurses attitudes and 
 
 





perceptions toward cancer clinical trials this, study begins to assess the behavior of 
oncology nurses towards cancer patients.  
There is a paucity of research that addresses nurses’ attitudes and perceptions 
towards clinical trials. This is curious, since nurses administer the experimental agents 
used in clinical trials and provide direct care for these patients and their families. Most 
literature regarding attitudes and perceptions of cancer clinical trials has focused on the 
attitudes and understanding of physicians, patients, a d the public (Cassilith, Lusk, 
Miller, & Hurwitz, 1982; Comis, Miller, Aldigé,  Krebs, & Stoval, 2003; Daugherty et 
al., 1995; Ellis, Bulow, Tattersall, Dunn, & Houssami, 2001; Meropol, et al., 2003). 
There is an important gap in knowledge regarding oncology nurses’ attitudes and 
perceptions towards cancer clinical trials, the clini al trial process, and informational 
need of potential research participants. 
 It is hoped that the results gained from this study will begin to close the gap in 
knowledge and add to nurses’ understanding of clinical trials. This study potentially 
identified discrepancies between the majority of nurses’ reporting that research is 
important for advancing oncology standards of care and the smaller number who actually 
recommend a research protocol to a patient.  
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CHAPTER II: REVIEW OF THE LITERATURE 
 The following review of the literature provided the theoretical and research 
background for the issues that are addressed by the research questions. Despite an 
extensive literature search of published works (CINAHL, MEDLINE, PsycINFO, EBM 
Reviews, Health and Psychosocial Instruments database, ProQuest Digital Dissertations), 
with Medical Subject Headings (MeSH) search terms, “nurses’ attitudes”, “nurses’ 
perceptions’”, and “cancer clinical trials”,  only one study was found regarding nurses’ 
attitudes and perceptions of cancer clinical trials (Burnett et al., 2001). Consequently, this 
literature review consists mainly of findings from related studies.  
 First, the organizing framework that guided this study is discussed, as well as a 
review of healthcare literature incorporating the framework. Additionally, its relevance to 
the proposed research explained. Next, a review of literature pertaining to attitudes and 
perceptions related to clinical trials is discussed. Finally, the role of the oncology nurse in 
the context of the care of patients enrolled in, or contemplating enrollment into, cancer 
clinical trials is explained.  
A. Organizing Framework 
 Ajzen’s and Fishbein’s (1980) Theory of Reasoned Action (TRA) provides the 
framework that guided this study. The roots of the theory come from the field of social 
psychology. Social psychology attempts, among other things, to explain how and why 
attitude impacts behavior. Beginning in the 1930s, psychologists began to argue actively 
about what components should comprise the attitude concept. Although there was 
agreement that all attitudes contain an evaluative component, theorists disagreed about 
whether beliefs (cognitions) and behaviors should be included within the attitude concept. 
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The prevailing view among cognitive social psychologists was that “attitude” has both 
affective and belief components and that attitudes and behavior should be consistent (e.g., 
people with positive attitudes should behave positively toward the attitude object; Ajzen 
& Fishbein, 1980).  
Social psychologists theorized that attitude included behavior and cognition and 
that attitude and behavior positively were correlated. In 1935, Gordon Allport proposed 
that the attitude-behavior concept was multi –dimensio al, rather than unidimensional, as 
previously thought (Allport, 1935; Azjen & Fishbein, 1980). Attitudes, as part of the 
attitude-behavior concept, are multi dimensional systems consisting of beliefs about the 
attitude object, feelings about the attitude object, and action tendencies toward the object 
(Azjen & Fishbein, 1980).  
One of the most famous early studies conducted by  sociologist Richard LaPiere, 
was studying if people behave consistently with their attitudes. LaPiere traveled across 
the United States with a Chinese couple. The group sto ped at over 200 hotels and 
restaurants, where the Chinese couple was refused service at only one location. Six 
months later, LaPiere wrote to these same establishments inquiring as to whether or not 
they served Chinese guests. The responses he received indicated that 92% of the 
establishments did not accommodate Chinese guests (LaPiere, 1934). LaPiere concluded 
that different sets of social forces influenced attitudes and behaviors. This showed a 
contradiction between the attitude responses to the le ter and the actual behavior toward 
the Chinese couple (Fazio & Roskos-Ewoldsen, 1994). This study demonstrated that,  
attitude was not a good predictor of behavior. By the late 1960s, social psychologists no 
longer believed they had a theory to explain the relationship between attitude and 
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behavior. It was in this context that Ajzen and Fishbein created the Theory of Reasoned 
Action (1967). The theory proposes that personal attitudes have a major influence on the 
intent to engage in different behaviors (Ajzen & Fishbein, 1980). The theory views men 
and women as a rational organisms utilizing information at their disposal to judge, 
evaluate, and decide his course of action. Therefore, the intent towards choosing a given 
behavior is a function of an individual’s attitude towards the behavior.  
Attitudes are composed of the beliefs that individuals accumulate over their 
lifetime. Some beliefs are formed from direct experience, some are from outside 
information, and others are inferred, or self-generated. However, only a few of these 
beliefs actually influence attitude. These beliefs are called “salient beliefs” and are the 
“immediate determinants of a person’s attitude” (Ajzen & Fishbein, 1980, p. 63). An 
attitude, then, is an individual’s salient belief about whether the outcome of their actions 
will be positive or negative. If individuals have positive salient beliefs about the outcome 
of their behavior, then they are said to have a positive attitudes about the behavior. And, 
vice-versa, if individuals have negative salient beliefs about the outcome of their 
behavior, they are said to have negative attitudes. The beliefs are rated for the probability 
that engaging in the behavior will produce the believed outcome. This is called the 
“belief strength.” These two factors, belief strength and the evaluation, are then 
multiplied to give the attitude (Ajzen & Fishbein). 
The TRA attempts to predict human behavior, based on concepts of personal 
beliefs, attitude towards the behavior, perceived bliefs of others, and subjective norms 
(see Figure 1).  




Figure 1. Model of reasoned action. (Ajzen & Fishbein, 1980) 
Therefore, an individual’s belief could ultimately determine one’s attitudes, 
intentions and behaviors. In combination, attitude toward the behavior, subjective norm, 
and perception of behavioral control lead to the formation of behavioral intention (Ajzen, 
2001). As a general rule, the more favorable the attitude and subjective norm, and the 
greater the perceived control, the stronger should be the person’s intention to perform the 
behavior in question. Finally, given a sufficient degree of actual control over the 
behavior, people are expected to fulfill their intentions when the opportunity arises 
(Ajzen, 2001). A person’s intention, then, becomes a function of personal and social 
influence. Both attitudinal and subjective factors a e important determinants of intention, 
but the relative weight of each component varies with the individual (Ajzen & Fishbein, 
1980). As suggested by its name, the TRA proposes that people engage in a deliberate 
and thoughtful process in deciding how to behave (Sanbonmatsu & Fazio, 1990).  
This study focused on the attitudes of oncology nurses towards cancer clinical 
trials and their perceptions of patient understanding and reasons for patient participation 
Behavior 
Intention 






Perceived Beliefs of 
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in clinical research. Concepts of the theory define the nurse’s own beliefs, as well as, the 
perceived beliefs of those groups that are in a position to influence the ideas and actions 
of the nurse. These beliefs and actions pertain to the nurse’s relationship with the patient 
contemplating enrollment or already enrolled in a cancer clinical trial. Therefore, the 
combination of the nurse’s beliefs and the group belief could lead one to action, 
depending upon which set of beliefs are more valued (or is perceived to lead to a positive 
outcome) by the nurse, thus forming an attitude on the part of the nurse.  
One way to begin to assess the actions of nurses towards patients is to investigate 
their attitudes. The nurses’ attitudes regarding cancer clinical trials may ultimately dictate 
their behavior towards patients enrolled in or contemplating enrollment in a cancer 
clinical trial. Within the practice of oncology nursing, these behaviors can include direct 
patient care, coordination of care, patient education, and patient advocacy.  
In this study the measurement of attitudes (and perceptions) were assessed via a Likert 
scale to discern positive and negative attitudes. Having negative attitudes towards cancer 
clinical trials may impact the nurse’s objectivity in his/her role as patient educator or 
patient advocate and determine the nurse’s behavior in these situations. Nurses perceive 
their roles differently from other healthcare professionals in that, in addition to focusing 
on clinical judgments and decision making, they concentrate on patient advocacy and 
caring (Krisjansdottir, 1992). This caring focus enables nurses to ensure adequate 
communication with patients about treatment regimens. Nurses may be more aware of 
patients’ attitudes towards clinical trial research, because of the unique patient-nurse 
relationship. Nurses’ attitudes may influence patient’s opinions regarding participation 
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and may reflect patients concerns in this area. The nursing role and type of caring focus 
outlined above are all part of the nurse-patient relationship.  
B. The Use of the TRA in Health Care Literature 
Nursing Research Examining Attitudes 
In nursing research the TRA has been shown to be a viable theory examining the 
attitudes of nurses and patients. Renfroe, O’Sullivan, and Mcgee (1990) developed a 
causal model, using the components of the TRA, for explaining nursing documentation 
behavior. They utilized the TRA to assess the relationship of nurses’ attitudes, subjective 
norms, and behavioral intentions to their documentation behaviors. Subjective norm is 
defined as a “person’s assessment of whether or not people important to him or her feel 
the behavior should be performed” (Ajzen, 2001, p. 32) Behavioral intention is related to 
attitudes and subjective norms. The more favorable the attitude and subjective norm, and 
the greater the perceived control, the stronger the person’s intention should be to perform 
the behavior in question (Ajzen). The purpose of the study was to develop and test the 
TRA that explained documentation behavior of nurses. A convenience sample of all staff 
nurses (N = 108) at three different hospitals, on all units (excluding emergency room, 
operating room, labor and delivery, and psychiatric units) within three hospitals in the 
Southeast was used. The authors collected data using a questionnaire that they developed 
to measure each component of the causal model, attitude, subjective norm, behavioral 
intent, and documentation behavior. Prior to shift report, each nurse completed the 
questionnaire and returned it to investigators. After the shift, the investigators returned to 
the unit to score the documentation for one patient assigned to each nurse that shift. 
Documentation behavior “was based on what should be ocumented in any hospitalized 
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patient’s chart during an eight hour shift” (Renfroe, O’Sullivan, and Mcgee, 1990, p.52). 
Attitude toward documentation did not relate significantly to intention to document 
optimally. Subjective norms had a significant effect on behavioral intent. Attitude and 
subjective norm accounted for 46.1% of the variance i  behavioral intent. Behavioral 
intent had a significant effect on documentation behavior, accounting for 15.2% of the 
variance. It appears that subjective norm, which is t e influence of others, directs the 
intention to document and thus relates to subsequent documentation. The authors’ 
recommendations for practice, based on the study fin ings, include the communication of 
high ideals and expectations of important others to the staff nurse to improve the 
documentation quality.  
Using the TRA as a theoretical framework for their study, Stuppy, Armstrong, 
and Casals-Ariet (1998) examined the attitudes of healt  care providers, medical and 
nursing students (N = 513) towards tattooed adults and adolescents. Thi  was a 
descriptive correlational, comparative study, with a demographic form and the Armstrong 
Tattoo Scale (ATS) distributed to convenience samples of physicians, registered nurses, 
licensed vocational nurses, and medical and nursing students. The ATS is a semantic 
differential scale consisting of 16 contrasting adjectives representing beliefs about 
persons with tattoos. Items for the ATS were generated from the clinical experience of 
the investigators, interviews with tattoo artists, tattooed people, and from the literature. 
Adjective pairs on the ATS included such items as ugly-beautiful, impulsive-deliberate 
and crude-refined. Each item was scored from 1 (strongly agree at the negative end) to 7 
(strongly agree at the positive end). Data were coded so that a higher score reflected more 
positive attitudes. Possible scores ranged from 16 to 112, when responses to all items 
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were summed. An expert panel of doctorally prepared faculty investigators and 
sociologists reviewed the instrument for content validity. A pilot study with 161 nursing 
students determined initial construct validity. Exploratory principal component analysis 
indicated that 10 items represented an evaluation dimension and six items related to an 
activity dimension about attitudes toward tattooed p rsons. Respondents were asked to 
record their attitudes towards five groups of peopl. Groups to be rated were professional 
men, nonprofessional men, professional women, nonprofessional women and adolescents 
(13–18 years old). The type of tattooed person to be rated was listed as the heading for 
the 16 item ATS (e.g., “Professional women who have t ttoos are . . .”). For the five 
groups internal consistency reliability of the ATS ranged from a Cronbach’s alpha of 0.92 
to 0.95. The authors found no respondent group had mean scores reflecting a positive 
attitude towards tattooed persons. This study suggests that tattooed persons, especially 
adolescents, may be at risk of being negatively perceived, when they seek health care.  
Clarke and Aish (2002) explored the health beliefs and attitudes of a group of 
smokers with vascular disease who participated in a smoking cessation program (Group 
1) and a group who declined participation (Group 2). The authors used Ajzen and 
Fishbein’s TRA, Keeney’s Expected Utility Decision Theory (Keeney, 1992), and 
Prochaska and DiClemente’s Transtheoretical Model of Change (DiClemente, 1997) to 
describe the influence of this smoking cessation program on beliefs and attitudes about 
smoking in Group 1. Smokers completed a smoking beliefs questionnaire with vascular 
disease at baseline and after 13 weeks of a smoking cessation intervention. Smokers who 
did not want to participate in the smoking cessation program also completed this 
questionnaire (Group 2). Statistically significant differences differentiated people who 
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enrolled in the smoking cessation program from those who did not. Subjects in Group 2 
smoked less per day, were less educated, were less oft n diagnosed as having peripheral 
arterial disease, were found to be more in the precont mplation stage of change in 
smoking cessation, cared more about what their physician and family thought they should 
do, and perceived themselves to be at less risk for developing more severe circulatory 
problems if they did not quit smoking. After 13 weeks, participants in both Groups 1 and 
2 were found to smoke significantly less per day. No support was found for the 
expectation that the smoking intervention would influence stage of change in smoking 
behavior or attitudes and beliefs about the risks of smoking to the participants’ health 
after 13 weeks. 
Nursing Research Examining Behaviors 
The TRA has also been used in nursing research as a b is for studying the 
behaviors of nurses, healthcare workers, students, a d patients. Selected college students 
(n = 256) and sexually transmitted disease (STD) clinic patients (n = 71) of the same age 
were compared for knowledge about AIDS, use of condoms, sexual behaviors and 
intentions to engage in various sexual practices (Strader & Beaman, 1991). The TRA 
model was used to elicit beliefs about condom use and significant referents that influence 
decisions on condom-use. Of the 256 college students, 87% were sexually active. College 
students had significantly fewer sexual partners in a 30-day period than STD patients, but 
in a 6-month period the mean number of sexual partners was the same for both groups. 
Significant difference was found in frequency of cond m use for subjects with more than 
one partner. Among the college student sample, 60% did not use condoms compared with 
32% of STD patients. Eighteen percent of college students reported intention to engage in 
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anal intercourse. No STD patients reported such intention. No statistical difference was 
found between groups on overall knowledge about AIDS and both groups manifested 
adequate knowledge of basic AIDS-related facts. Significant differences between groups 
were found in rank order of beliefs about using condoms as well as the referents that 
influenced decision-making. Beliefs about disease, pr gnancy, worry, and the influences 
of sexual partners and friends had the strongest impact on college students. Sexual 
partners and mothers had a strong influence on STD patients’ decisions-making, while 
“disease,” “pregnancy,” “decreases feeling” and “decreases partner’s pleasure” were 
among the beliefs influencing condom use. 
Miller, Wikoff, and Hiatt (1992) tested five variables of the TRA. The variables 
measured were attitudes, perceived beliefs of others, motivation to comply, intentions, 
and compliance behavior. The purpose of the study was to test the sufficiency of these 
variables to predict compliance with the medical regimen of hypertensive patients (N = 
56). The subjects were a convenience sample of patients at an outpatient Veterans 
Administration (VA) Medical Center hypertensive clinic. The authors used the Miller 
Attitude Scale (Miller, Wikoff, McMahon, Garrett, &Johnson, 1982) to measure 
favorable and unfavorable attitudes towards performing medical regimen prescriptions. 
The Perceived Belief of Others Scale (Miller, Johnson, Garrett, Wikoff, & McMahon, 
1982) was used to assess the subjects’ beliefs about which prescriptions of the medical 
regimen people thought were most important to them and to which they should be 
compliant. The Motivation to Comply Scale (Ajzen & Fishbein, 1980) was used to 
measure motivation to comply with the regimen’s presc iption. Intentions were measured 
by the Health Intention Scale designed to assess subjects’ intentions to perform the 
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medical regimen. Finally, behavior was measured by the Health Behavior Scale which 
measured subjects’ compliance to the medical regimen. The authors reported the results 
using the Pearson Product moment correlations among the five variables (attitudes, 
perceived beliefs of others, motivation to comply, intentions, and compliance behavior). 
The results demonstrated the TRA sufficient for the prescriptions of diet, smoking, 
activity and stress, but not for medication. Findings indicated that compliance behavior 
was directly influenced by intention which, in turn, was influenced directly by attitude 
and motivation to comply and, indirectly, by perceived beliefs of others and were 
mediated by motivation to comply with the prescriptions of diet, activity, smoking, and 
stress. For the medication prescription, attitude and motivation to comply directly 
influenced regimen compliance. 
Dunkle and Hyde (1995) used the TRA to identify factors that influence physical 
therapist and registered nurse (RN) students’ intentions toward working with elderly 
individuals. Based on the TRA a survey instrument was developed to assess student 
intention to work with elderly individuals and factors influencing this intention. Later 
graduates were contacted to determine whether job selection matched intention. For all 
students, factors influencing intention were students’ attitudes and students’ perceptions 
regarding their families’ expectations about the students’ working with elderly persons. 
Intention had a positive correlation with job selection. Important underlying beliefs 
influencing students’ attitudes, include the advantages of getting to know elderly patients 
and their families and caring for pleasant patients. The authors concluded that the results 
support using a theory-based model to identify predictors of job selection among physical 
therapist and nursing graduates.  
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The TRA and the Theory of Planned Behavior (TPB), another theoretical model 
by Ajken and Fishbein, were tested as predictors of health care workers’ glove use when 
there is a potential for blood exposure (Levin, 1999). The TPB is an extension to the TRA 
and includes and additional element of “perceived bhavioral control,” in order to 
account for situations where an individual has lessthan complete control over the 
behavior. Perceived behavioral control indicates that a person’s motivation is influenced 
by the perceived difficulty of the behaviors, as well as the perception of how successfully 
the individual can, or can not, perform the activity. If individuals hold strong control 
beliefs about the existence of factors that will facilitate a behavior, then they will have 
high perceived control over a behavior. Conversely, individuals will have a low 
perception of control if they hold strong control be iefs that impede the behavior (Ajzen, 
1985). Levin (1999) surveyed a random sample of nurses and laboratory workers (N = 
527) who completed a 26-item questionnaire. Using structural equation modeling 
techniques, intention, attitude, and perceived risk were significant predictors of behavior. 
Perceived control and attitude were the significant determinants of intention. The TRA 
was the most parsimonious model, explaining 70% of the variance in glove use behavior. 
The TPB was a viable model to study behavior related to glove use and reducing 
workers’ risks to blood borne diseases.  
   Poss (1999) developed a Spanish-language, quantitative research instrument 
designed to study Mexican migrant farm-workers participation in tuberculosis screening. 
The instrument was pilot tested with19 Mexican migrant farm-workers to study their 
tuberculosis screening behaviors. The Tuberculosis Interview Instrument (TII) was 
developed from the results of a qualitative study and concepts from a theoretical 
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framework consisting of a combination of the Health Belief Model (HBM) (Becker, 
Radius, & Rosenstock, 1978; Rosenstock, Strecher, & Becker, 1994) and the Theory of 
Reasoned Action (TRA). After its development, the TII was subjected to translation and 
back-translation procedures to insure the equivalency of the English and Spanish 
versions, and it was reviewed for content validity.  
In another study, Poss (2000) recruited a convenience sample of Mexican migrant 
farm workers (N = 206), after a presentation of a tuberculosis education program, 
participants were followed during the administration and reading of tuberculosis skin 
tests. The purpose of the study was to analyze the relationship between variables 
(susceptibility, severity, barriers, benefits, cues to action, normative beliefs, subjective 
norm, attitude, and intention) from the HBM and theTRA and participation by Mexican 
migrant farm workers in a tuberculosis screening program. Participants were interviewed 
in Spanish by the principal investigator, using the TII. Most subjects were male, aged 18–
27 years, and had less than a sixth-grade education. Of the 206 subjects, 152 (73.4%) 
received the skin test, 149 (98%) had the skin test read, and 44 (29.5%) had positive skin 
tests. Based on logistic regression analysis, the model that best predicted intention 
included cues to action, subjective norm, susceptibility, and attitude. Participation in 
screening was best predicted by a model containing only two variables, intention and 
susceptibility. In this study, logistic regression a alysis revealed that a more 
parsimonious model than the full HBM and TRA model accurately predicted both 
intention and behavior. Kleier (2004) tested the TRA to determine the behavior of nurse 
practitioners (NPs) regarding teaching testicular self-examination (TSE). The researcher 
utilized an instrument, developed by Minnick (1980), to explore relationships between 
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variables that applied the concepts in the TRA. The variables were attitudes, perceptions 
of and motivation to comply with opinions of others, behavioral intention to teach TSE, 
and TSE teaching behavior. A cross-sectional, exploratory, mailed survey was used to 
survey a random sample of 1,490 members of the American Academy of Nurse 
Practitioners, 621 NPs responded. After eliminating surveys that were not usable because 
of missing data, final analyses were carried out on 532 surveys, for a response rate of 
36%. The author concluded that NPs had positive attitudes toward teaching TSE and 
were engaged in such teaching. They perceived that o er NPs, physicians, and patients 
also valued TSE teaching. Attitude, perception of and motivation to comply with the 
opinions of significant others, and behavioral intention were associated with each other 
and predictive of TSE-teaching behavior. The findings supported the explanatory and 
predictive ability of the TRA.  
Nonresearch Articles 
Additionally, review articles have been written citing the TRA in the development 
of models to predict health behaviors. Fleury (1992) reviewed the primary motivational 
theories that were used to explain cardiovascular risk reduction. Specifically, the 
application of the Heath Belief Model, Heath Promotion Model, the TRA, TPB, and Self- 
Efficacy Theory to the initiation and maintenance of cardiovascular health behavior was 
addressed. 
In evaluating the behavioral aspects of clinical tri ls, Morrow, et al. (1994) 
reviewed the literature on accrual in oncology clini al trials to characterize the extent of 
the problem of low accrual, identify reasons for it, and suggest ways to improve it. The 
authors examined four theories of health behavior (the Health Belief Model, Subjective 
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Expected Utility Theory, Protection Motivation Theory, and the TRA) and found that all 
suggest central concepts involved in understanding patient health-related behavior.  
McGahee, Kemp, and Tingen (2000) developed a model f r smoking prevention 
in preteen children, because they determined the lack of a well-defined theoretical basis a 
weakness in the research conducted on smoking prevention programs designed for 
preteen children. The authors used the TRA as well as other literature to develop their 
model.  
Finally, Poss (2001) discussed the development of a new model developed as the 
theoretical framework for an investigation of the factors affecting participation by 
Mexican migrant workers in tuberculosis screening. The new model was developed by 
synthesizing the Health Belief Model (HBM) and the TRA. Intention to take part in 
tuberculosis screening was best explained by a model c ntaining four variables: 
subjective norm, attitude, susceptibility, and cues to action (operationalized as attendance 
at an educational program). The best model for predicting behavior (actual participation 
in screening) required only two variables: intentio and susceptibility. In both cases, 
variables derived from both the HBM and the TRA were necessary to predict the 
dependent variable.  
C. Attitudes and Perceptions  
Attitudes and perceptions are related concepts. As previously defined (in chapter 
1), attitudes are evaluations of psychological objects (e.g., oneself, other people, issues, 
etc.) captured in such attribute dimensions as good-bad, harmful-beneficial, pleasant-
unpleasant, and likable-dislikable (Ajzen, 2001, Ajzen & Fishbein, 2000).  
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Perceptions are a representation of one’s reality, w h a process of interpreting 
information from sensory data and memory, which gives meaning to one’s experience 
and influences one’s behavior (King, 1981). It is the basis by which one’s opinions or 
views are formed and, thereby, give rise to actions.  
In the nurse-patient relationship, perception is a crucial component of the nurse’s 
assessment of the patient and clinical situation (Ki g, 1981). King states that nursing is “a 
process of human interactions between nurse and client whereby each perceives the other 
and the situation; and through communication, they set goals, explore means, and agree 
on means to achieving goals” (King, 1981, p. 144). The perceptions of the nurse must be 
in agreement with the patient’s perceptions for mutual goal setting to occur. Only then 
can patients collaborate with the nurse to set goals, explore the means and agree on the 
strategies to attain mutual goals. The nurse must perceive accurately the patient and 
clinical situation to work toward a common goal.  
Attitudes are perceptions that persons accumulates ov r their lifetime (past 
experiences). King also states that perceptions are related to factors such as past 
experiences and educational background (King, 1981). This suggests that perceptions are 
subjective in nature and, consequently, nurses’ perceptions may be very different from 
the patients’ perceptions. In this study the subjectiv  nature of perception was explored as 
oncology nursing experience and education were analyzed as predictors that could 
influence perceptions and attitudes. Additionally, attitudes guide behavior, the more 
favorable the attitude and subjective norm, and the greater the perceived control, the 
stronger the person’s intention to perform a behavior (Ajzen & Fishbein, 1980). 
According to King (1981), perceptions also influenc behavior. As an example, the nurse 
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and patient meet in some situation, perceive each other, make judgments about each 
other, take some mental action, and react to each one’s perceptions of the other (Gonot, 
1989; King, 1981). When interactions lead to transactions, “goal attainment behaviors” 
are exhibited (King, 1981, p. 60). Underlying the interaction process is that reciprocally 
congruent behavior, which the behavior of one person influences the behavior of the 
other and visa versa (Gonot, 1989; King, 1981). Therefore, individuals’ attitudes and 
perceptions influence their behavior.  
As stated above, attitudes and perceptions are related and interconnected 
concepts. Beginning with experience, events occur, and those events have a real or 
imagined vital and affective meaning to individuals. That experience produces a set of 
structured or unstructured beliefs and expectations. The beliefs and expectations have a 
motivational force. The objects from which an indivi ual forms a belief are that which an 
individual experiences. That which one experiences is, o to speak, the objective term of 
the process. The affective motivations and reactions t  experience are the subjective 
terms of the process. These are the attitudes that emerge. One’s attitudes consciously or 
unconsciously determine how one will perceive like experiences in the future (G. Husted, 
February 6, 2006, personal communication).  
Attitudes and Decision Making 
Attitudes were also studied as a base for decision-making in the psychology 
literature. Sanbonmatsu and Fazio (1990) examined th  role of attitudes in memory-based 
decision-making. They conducted two experiments to represent some of the conditions 
under which attitudes guide memory-based decision making. Participants in both 
experiments were undergraduates fulfilling a requirement for an introductory psychology 
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course (Experiment 1, n = 98; Experiment 2, n = 270). Experiment 1 examined the effect 
of fear of invalidity (a motivational variable) and time pressure (an opportunity variable) 
on the likelihood that a memory-based decision will be guided by attitudes. The primary 
dependent measure for both experiments was the partici nts’ decision as to which store 
they would shop for a camera. The general description of one store, “Smith’s Department 
Store,” was favorable with the exception of the camera department, which was 
unfavorable. The other stores general description, “Brown’s Department Store,” was 
unfavorable with the exception of the camera departmen , which was favorable. They 
made the decision to purchase a camera under high or low time pressure, and under 
conditions of high or low fear of invalidity. The rsults from experiment 1 revealed the 
majority of participants (81 out of 98) evaluated Smith’s more positively than Brown’s. A 
2 x 2 (fear of invalidity X time pressure) between subjects analysis of variance (ANOVA) 
was performed on the subjects camera decisions. Particip nts’ low in fear of invalidity 
were more likely to choose Smith’s than participants experiencing high fear of invalidity. 
The authors concluded that as the motivation to make a correct decision or the 
opportunity to access the relevant available knowledge decreases, the likelihood of an 
attitude-based decision increases.  
In contrast to Experiment 1, in Experiment 2, the participants explicitly were 
instructed to form differentiated attitudes toward each department of each store, as well 
as general attitudes toward each store. The differenc  between Experiment 1 and 2 was 
with the participants in the differentiated attitude condition. As in experiment 1 the 
majority of participants (231 out of 270) evaluated Smith’s more positively than 
Brown’s. The participants’ camera shopping decision were then evaluated using a 2 x 2 
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x 2 (differentiation X fear of invalidity X time pressure) using between-subjects 
ANOVA. The authors concluded that attitudes guide decisions, and hence behavior, by 
affecting one’s appraisals (perceptions) of decision alternatives. Attitudes provide a ready 
means of “sizing up” or appraising objects and events (Sanbonmatsu & Fazio, 1990, p. 
620). In the context of decisions, the authors found attitudes provided a ready assessment 
of choice alternatives and they enabled an individual to make a decision rapidly and 
effortlessly. They also state that if a behavior wee to be based on a number of specific 
beliefs and attitudes, then measuring those beliefs and attitudes is an effective way of 
predicting behavior.  
Nurses’ Attitudes and Perceptions 
The investigator was only aware of one study reported that addressed nurses’ 
attitudes toward cancer clinical trials. Burnett, e al. (2001) addressed nurses’ attitudes 
toward cancer clinical trials in a comprehensive cancer center. They conducted a 
descriptive study with a 59-item self report survey. The objective was to identify nurses’ 
attitudes and beliefs toward cancer clinical trials and their perceptions about factors 
influencing patients’ participation in these trials. Four hundred seventeen nurses 
employed at a NCI designated cancer center were surv yed, and 250 nurses (60%) 
responded. The authors found 96% of nurses reported that participation in clinical trials is 
important to improving standards of care; however, only 56% of nurses believed that 
patients should be encouraged to participate in cancer clinical trials. In multiple 
regression analyses, older age (40 years of age or older) and being a research nurse were 
significant predictors of positive attitudes toward clinical trials. Work setting also was a 
significant predictor of nurses’ perceptions of patients’ understanding of treatment. 
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Research nurses had the highest mean score (23.2 out of 30) compared to intensive care 
unit/bone marrow transplant (ICU/BMT) nurses, who had the lowest mean score (18.6 
out of 30; p = 0.0001). Overall, nurses reported that an investigational therapy should 
have at least a 50% chance of success prior to being offered to patients. The authors’ 
recommendations for future research were to replicate the study with other 
comprehensive cancer center nurses, to conduct a study with nurses from settings other 
than comprehensive cancer centers, to compare the findings between the groups, and to 
study current nursing educational methods and models of nurse-physician interaction in 
research settings.  
In a descriptive study of oncology physicians’ and nurses’ attitudes of offering 
clinical trial results to study patients, Partridge, et al. (2004) identified oncology nurses 
and physicians through the Cancer and Leukemia Group B (CALGB) database [CALGB 
is a federally funded network to conduct cancer clini al trials]. Surveys were mailed to 
1,977 members and 796 (40.3%) responded. Responders i cluded 125 (15.7%) nurses, 
650 (81.7%) physicians, and 21 (2.6%) individuals who identified themselves as “other” 
(psychologists, epidemiologists, etc). This study was primarily descriptive. 
Approximately 62% of respondents reported offering results to patients less than one-
fifth of the time. Almost 79% of responders felt trial results should be offered to most 
study subjects. Patients want to know trial results according to 72.4% of respondents, and 
62.2% of them did not believe that routinely offering results would have a negative 
impact on many patients. The study was limited by the use of a questionnaire that was not 
prospectively validated (Partridge, et al., 2004). Additionally, nonresponse rates differed 
among specialty groups. Fifty-two percent of nurses surveyed responded compared with 
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42% of medical subspecialists, 35% radiation oncologists, and 33% surgeons (p<0.001 
for all four groups, p = 0.0014 for physicians only). The authors state that future studies 
should evaluate the process and effects of sharing results with study participants and they 
developed a model that includes the views of all parties involved. They feel this type of 
research may improve communication between health cre providers and patients, and 
increase patient satisfaction with the care received during a clinical trial (Partridge et al., 
2004).  
In Greece researchers examined Greek nurses’ attitudes toward truth-telling 
practices when working with cancer patients and their psychological status regarding the 
difficulties they faced in their day-to-day communication with these patients (Georgaki, 
Kalaidopoulou, Liarmakopoulos & Mystakidou, 2002). The researcher designed 
questionnaire had 19 questions, including both multi-item scales and single item 
measures. The response options were “yes,” “sometimes,” or “no.” The questionnaire 
was mailed to head nurses in Athen’s oncology hospital  and oncology departments of 
general hospitals. These nurses were asked to distribute it to their nurses. Two hundred 
staff nurses were asked to participate, 148 nurses (74%) completed and returned the 
questionnaire. The results revealed that 75.7% of respondents believed that only some 
cancer patients should be told the truth of their diagnosis and prognosis and a larger 
percentage (89.1%) believed that the truth should be told to relatives. Most respondents 
(66.2%) reported that it is difficult to engage in open communication with the patients, 
because their education did not provide sufficient training in communication skills. 
Eighty four percent reported that they do not reveal that the disease is incurable, 58.1% 
believed that only the patient’s physician should reveal the truth. These results indicated 
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that although many Greek nurses believe that the pati nts should be informed and know 
their condition, lack of training in communication skills is a major obstacle to achieving 
this.  
Chang (2004) conducted a review of the nursing literature of published works 
(CINAHL, MEDLINE, PsycInfo, EBM reviews) exploring nurses’ perceptions of Phase I 
clinical trials in pediatric oncology. The author fund no literature related to this topic, 
except for the one previously discussed by Burnett et al. (2001) that reported nurses’ 
attitudes toward adult clinical trials.  
Patient, Public, and Physician Attitudes and Perceptions 
Attitudes of patients and the public were evaluated in a study conducted over 20 
years ago by Cassileth, Lusk, Miller, and Hurwitz (1982). One hundred and four patients 
with cancer, 84 cardiology patients and a control gup of 107 members of the general 
public completed an anonymous self-report questionnaire consisting of 10 multiple-
choice questions and one open-ended item. Respondents’ opinions on the purpose and 
ethicality of clinical research were obtained. Responses to the questionnaire items did not 
differ by each group (patients with cancer, cardiology patients, general public) nor by 
demographic variables such as age or sex. Therefore, data were reported on the total 
sample of 295 respondents. Seventy-one percent of respondents believed that patients 
should serve as research subjects and 52% of respondents stated the main reason they 
would participate in medical research would be to get the best medical care. Thirty-six 
percent of respondents felt patients received better car  when the treatment plan is 
determined by their physician. Thirty-eight percent felt patients received better or equal 
care when their treatment is based on a research protocol. A large percentage of 
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respondents (70%) thought that physicians have prior kn wledge of which one of the 
investigated treatments is best. Since a large percentage expressed this belief, it can be 
inferred that many people do not understand the nature of clinical trials. This is an area 
where oncology nurses can assist patients with the information and education regarding 
the purpose of clinical trials.  
Patients’ Attitudes 
Ellis et al. (2001) conducted a cross sectional survey of women (N = 545) 
attending a breast clinic for screening mammography or diagnostic assessment plus 
women with newly diagnosed breast cancer, the purpose was to assess attitudes toward 
and willingness to participate in randomized clinical trials of breast cancer treatment. A 
questionnaire was developed using information obtained from focus group interviews in 
conjunction with a review of the literature. The questionnaire contained information from 
the following areas:  
1. Demographic data, including age, marital status, education, occupation, 
ethnicity, and medical/allied health training. 
2. The Hospital Anxiety and Depression Scale (HADS) a questionnaire that 
contains seven items assessing symptoms of anxiety and seven items assessing 
symptoms of depression (Moore et al., 1991; Zigmond & Snaith, 1983). 
3. Women’s preferences for the amount of information they wish to receive from 
their doctor using a three-item scale previously described by Cassileth, Zupkis, 
Sutton-Smith (1980) and their level of involvement in clinical decision-making 
using a five-item scale (Degner, et al., 1997; Degner & Sloan, 1992). 
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4. Knowledge about the need for clinical trials and about the manner i  which 
randomized clinical trials are conducted, which was measured using a 7-item scale 
developed by the authors of the study. 
5. Attitudes toward randomized clinical trials, which was measured using a 36-
item scale developed from focus group data and a review of the literature that 
measured the impact of individual items on women’s willingness to participate in 
randomized clinical trials on a seven-point Likert scale (7 = very likely to join a 
trial, 4 = would not influence my decision, 1 = very unlikely to join a trial). 
6. General willingness to participate in randomized clinical trials.                  
 7. Reasons to consider joining/not joining a clinical trial.  
The findings suggested that women who have a better understanding of issues about 
clinical trials had more favorable attitudes toward clinical trials and were more willing to 
consider participation.   
Daugherty et al. (1995) conducted a pilot survey study of the perceptions of 
cancer patients and their physicians involved in Phase I cancer trials. Thirty cancer 
patients who had given informed consent to participate in a Phase I clinical trial and 
eighteen oncologists were surveyed. Eighty-five percent of patients reported that they 
participated in a Phase I trial, because of possible therapeutic benefit. Ninety-three 
percent of patients said they understood all or most of the information provided about the 
trial; however, only 33% were able to state the purpose of the trial in which they were 
participating. The authors concluded that cancer patients who participate in Phase I trials 
are strongly motivated by the hope of therapeutic benefit. Cancer patients who participate 
in Phase I trials appeared to have an adequate knowledge of the risks of experimental 
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therapy. However, only a minority of patients appear to have an adequate understanding 
of the purpose of Phase I trials. 
Comis, et al. (2003) conducted a study to understand the attitudes of American 
adults toward participation in cancer clinical trials. A national probability sample of 
1,000 adults aged 18 or older living in noninstitutional settings were interviewed via 
telephone by Harris Interactive. The results indicated that the primary problem with 
accrual is not the attitudes of patients, but the loss of potential participants is the result of 
the unavailability of an appropriate clinical trial. The authors also state that many patients 
hold mistaken views of the nature of clinical trials, and that many significantly 
overestimate the efficacy of standard therapies in making their decisions.  
In a study describing and comparing the perceptions of cancer patients and their 
physicians regarding Phase I clinical trials, Meropol et al. (2003) surveyed eligible 
patients who were offered Phase I trial participation, had accepted, but had not yet begun 
treatment (n = 328). Each patient’s physician also was a study s bject (n = 48). Patients 
and physicians completed questionnaires with domains including perceptions of potential 
benefit and harm from treatment (experimental and standard), relative value of quantity 
and quality and length of life, and perceived content of patient-physician consultations. 
Patients had high expectations regarding treatment outcomes (e.g., median 60% benefit 
from experimental therapy). Patients predicted a higher likelihood of both benefit and 
adverse reactions from treatment (experimental and standard) than their physicians (p < 
0.0001 for all comparisons). Although 95% of patients reported that quality of life was at 
least important as length of life, only 28% reported that changes in quality of life with 
treatment were discussed with their physicians. In co trast, 73% of physicians reported 
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that this topic was discussed (P < 0.0001). The authors conclude that this discrepancy in 
reports of consultation content, particularly given patients’ stated values regarding quality 
of life, raise the possibility that such communication is suboptimal.  
There were other studies which suggest that patient understanding about clinical 
trials can be improved through the provision of greater amounts of information 
(Aaronson et al., 1996; Davis, Nealon, & Stone, 1993; Simes et al., 1986).  
 The study by Aaronson et al. (1996) is the only study which used a nursing 
intervention to evaluate improving the informed conse t process. The authors evaluated a 
strategy of providing additional information to patients considering entry into Phase II or 
III trials at the Netherlands Cancer Institute (N = 180). Patients were randomized to the 
standard consent interview, or the standard interview followed by a telephone call several 
days later from a clinical trials nurse to further discuss the information provided in the 
consent interview. As compared with patients provided only with verbal and written 
information from their treating physician (control group), those who also received 
information from an oncology nurse (intervention group) were better informed about the 
potential side effects of the proposed treatment, the clinical trial context in which the 
treatment was to be given, and many of the essential det ils of the clinical trial. The 
largest gains were observed in the percentage of patients aware of randomization 
procedures and of the right to withdraw from the trial. Patients in the intervention group 
were slightly more likely to decline participation (24% vs. 13%). The authors conclude 
that this type of nursing intervention, as an adjunct to established informed consent 
procedures had a positive effect on cancer patients’ awareness of the most salient issues 
that surround the Phase II and III clinical trials in which they are asked to participate. 
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While this trial occurred outside the U.S., this int tution is an active member of the 
national clinical trials group in the U.S. The nursing intervention that was described was 
consistent with U.S nursing practices. This study represented a beginning attempt at 
formalizing a unique role of the nurse in the informed consent process, as focused on 
knowledge and education of patients.  
 Davis et al. (1993) randomized patients considering e try into Phase III clinical 
trials to receive either standard information about clinical trials or standard information 
plus a NCI booklet explaining clinical trials. Two h spitals tested the booklet with 
patients who were eligible for a specific clinical trial, and two hospitals tested the booklet 
with patients who were theoretically eligible for a clinical trial (with a cancer site and 
stage for which a trial existed). Patients were assigned randomly: 203 experimental 
subjects received the booklet, and 194 control subjects were not given the booklet until 
after completing a 2-week post-test examining attitudes, knowledge, and beliefs about 
clinical trials. Overall patients who received the booklet were more knowledgeable about 
clinical trials, but there were no differences in participation rates.  
Simes et al. (1986) randomized patients eligible for entry into randomized 
chemotherapy trials to ether full or individualized information disclosure. Patients in the 
full disclosure group had significantly greater knowledge about their illness and treatment 
and about the research plan. There were no significa t differences between groups, 
although patients in the full disclosure group were a slightly more likely to decline trial 
participation (18% vs. 7%). 
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D. Oncology Nurses Role 
Oncology nursing practice is delineated by the ONS in “Statement on the Scope 
and Standards of Oncology Nursing Practice” (ONS, 2004). Oncology nursing 
encompasses the role of direct caregiver, educator, consultant, administrator, and 
investigator (ONS, 2004). Additionally, oncology nurses act as patient guides and 
advocates by “assisting patients and families to seek information, ensuring informed 
consent regarding treatment decisions, and promoting the maximal level of patient-
desired independence” (ONS, 2004, p. 8). An ONS professional performance standard of 
relevant to this study is standard five, ethics, which states, “The oncology nurse uses 
ethical principles as a basis for decision making ad patient advocacy” (ONS, 2004, p. 
37).  
Oncology Nurses’ Role in Clinical Trials 
Nurses have a critical role with informed consent. They help patients become 
more effective partners in the clinical trial decision-making process by explaining how 
scientific advances are made, describing the patients’ roles and rights in the studies, and 
providing sources for more information (Sadler et al., 1999).  
Patient advocacy includes assisting patients in defining their own goals and 
purposes for participating in a clinical trial (McEnvoy, Cannon, & MacDermott, 1991). 
Depending upon the practice setting, oncology nurses have responsibility for recruiting 
participants, explaining informed consent, monitoring participant responses, documenting 
data, and serving as a liaison with multidisciplinary teams (Liaschenko & DeBruin, 
2003). This demonstrates the multifaceted role of oncology nurses in the conduct of 
clinical trials. The ONS (1998) position statement o  cancer research and cancer clinical 
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trials states that “coordination of clinical trials (e.g., coordination of clinical sites, 
development of standardized treatment orders, sympto  management, patient education 
and advocacy, facilitation of informed consent, assistance with participant accrual and 
retention) is best accomplished by RNs who have been educated and certified in 
oncology nursing” (p. 973). As clinicians, nurses are expected to be direct caregivers 
(Grady, 1991; McEvoy, Cannon, & MacDermott, 1991) and coordinators of care 
(Hazelton, 1991; McEvoy et al.), as well as educators and patient advocates (Bujorian, 
1988; Grady; McEvoy et al.; Rosse & Krebs, 1999). As research nurses, they are 
expected to be facilitators, liaisons, (Engelking, 1992), and data collectors (Cassidy & 
MacFarlane, 1991 ;Grady).  
Ocker and Plank (2000) reviewed the nursing literature, analyzed job descriptions 
of oncology nurses, and conversed with research staff, oncology staff, and a clinical nurse 
specialist within an oncology research program in a large outpatient oncology clinic. 
They identified three oncology nurse roles for involved with clinical trials: patient 
educator, patient advocate, and study coordinator. Nurses greatly effect prospective 
patients’ perceptions of clinical research. They explain technical and complex protocols 
in understandable terms. As patient advocates, nurses have a critical role with the 
informed consent process. They ensure that patients are treated with respect, dignity, and 
as autonomous individuals (Barrett, 2002). Therefore, nurses are in an ideal position to 
provide patients with information about informed consent, to facilitate physician-patient 
communication and to serve as patient advocates (Winslow, 1984).  
Berry, Dodd, Hinds, and Ferrell (1996) suggest thatinformed consent for 
oncology clinical trials is an ongoing process involving many steps. Establishing and 
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maintaining informed consent should be a multidisciplinary effort in cancer clinical trials. 
As patient educators and advocates, nurses have maximized patient understanding and 
minimized potential coercion. 
The actual act of obtaining a signature on the consent form is the physician’s legal 
responsibility, but nurses have a moral responsibility to ensure that patients have a good 
understanding of that to which they are consenting (Rosse & Krebs, 1999). To be 
effective in this role, nurses must be knowledgeabl out fundamental concepts 
associated with informed consent (Rosse & Krebs, 1999). As noted above in the study of 
Meropol et al. (2003), the differences in perceptions f adult patients and their physicians 
regarding treatment outcome expectations may be due to suboptimal patient-physician 
communication discussions of clinical trial participation. Nurses can play a key role in 
assessing and minimizing this discrepancy.  
Nurse-Patient Relationships 
Husted and Husted (2001) wrote extensively about the nurse-patient relationship 
and stress the nurse-patient agreement. They developed a theory called Symphonology 
which states; “Every human relationship arises from an explicit or implicit 
agreement….The principles by which a professional makes a decision ought to be 
derived from the actual dynamics of this agreement” (p. 9). The nurse is the “agent of a 
patient doing for a patient what he would do for himself if he were able” (Husted & 
Husted, 2001, p. 36). Husted and Husted (2001) prefer the term “agency” to “advocacy.” 
They define agency, “the power or capacity of an agent to initiate action” (Husted & 
Husted, 2001, p.285). A person’s agency is “the power to act on autonomous desires that 
spring from his or her own reasoning” (Husted & Husted, 2001, p. 195). Part of a nurse’s 
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role is to be an agent for his/her patient. The nurse agreed to protect the rights of the 
patient through the implicit agreement between them. This implicit agreement forms the 
basis of the oncology nurses’ role in discussing clinical trials with patients. As explained 
in section D, the role of the oncology nurse consists of educator, consultant, and patient 
advocate, or agent as Husted and Husted (2001) posit. The oncology nursing role as 
educator and agent of clinical trials patients are all part of the nurse-patient relationship. 
The nurse-patient relationship comprises the foundation for communication between 
nurse and patient. During the communication process, as agents for their patients, nurses 
provide clarification of information that a patient may not understand. This is especially 
important with regard to informed consent required for oncology patients and clinical 
trial participation. The nurse-patient relationship as stated by Husted and Husted enable 
oncology nurses to help patients become more effective partners in the clinical trial 
decision-making process. 
E. Summary of the Review of Literature 
The role of beliefs, attitudes and perceptions in the decision-making process and 
in predicting behavior forms the foundation for this study. The TRA proposes that 
attitudes guide behavior. It is a theoretical framework that was used in other nursing 
studies evaluating attitudes and perceptions. Additionally, if behavior were expected to 
be based on specific beliefs and attitudes, then measuring those beliefs and attitudes is a 
way of predicting behavior (Sanbonmatsu & Fazio, 1990).  
One way to begin to assess the actions of the oncolgy nurse towards patients 
contemplating or participating in clinical research is to investigate their attitudes and 
perceptions. Hence, the nurse’s perceptions and consequent attitudes regarding cancer 
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clinical trials may ultimately dictate their behavior towards patients enrolled in or 
contemplating enrollment into a cancer clinical trial. Within the practice of oncology 
nursing, these behaviors can include direct patient care, coordination of care, patient 
education, and patient advocacy.  
 Oncology nurses have a pivotal role when caring for patients considering 
participation in a clinical trial. Nurses provide education to patients and clarify 
information. This fact is underscored by the study by Aaronson et al. (1996). They 
utilized a nursing intervention which demonstrated a positive effect on cancer patients’ 
awareness of the most important issues surrounding cli ical trials participation. 
Additionally, nurses serve as patient educators and assist patients in the decision-
making process. Nurses perceive their role differently from that of other healthcare 
professionals in that, they concentrate on patient advocacy and caring (Krisjansdottir, 
1992). This caring focus enables nurses to ensure adequ te communication with patients 
about treatment regimens. Nurses may be more aware of patients’ attitudes towards 
research due to this type of patient-nurse relationship. Nurses’ attitudes and perceptions 
may influence patient’s opinions regarding participation and may reflect patients 
concerns in this area. The nursing role and caring focus outlined above are all part of the 
nurse-patient relationship. Within the nurse-patient r lationship, specific to oncology 
nursing, the nurse’s role consists of educator, counselor, patient advocate, direct 
caregiver and investigator. Exploring oncology nurses’ attitudes and perceptions toward 
clinical trials may help to predict the behaviors required to function optimally in these 
roles.  
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Studies show that patients often do not understand the purpose of clinical trials 
and may have unrealistic expectations regarding their benefits (Cassileth, Lusk, Miller, & 
Hurwitz, 1982; Daugherty et al, 1995). Nurses have n integral role in the informed 
consent process. Further exploration of oncology nurses attitudes toward clinical trials 
and their perceptions of patient understanding is needed. 
The oncology nurse has an important role in all aspects of clinical trials and the 
care of patients enrolled or contemplating enrollment. However, it is unfortunate that 
there is very little information concerning nurses’ attitudes and perceptions regarding 
cancer clinical trials. Only one study concerning ocology nurses’ attitudes towards 
cancer clinical trials in a comprehensive cancer center exists (Burnett et al., 2001). These 
data revealed that the majority of nurses feel that cancer clinical trials advance standards 
of cancer treatment. However, approximately half would recommend their patients for a 
clinical trial, most would not participate in a clinical trial if they had cancer. There 
appears to be a discrepancy between what these oncology nurses feel about clinical trials 
and what they would actually do. The authors’ recommendations for future research were 
the to replicate their study with other comprehensive cancer center nurses; to conduct a 
study with nurses from settings other than a comprehensive cancer center, and to compare 
the findings between these different groups, and to study current nursing educational 
methods and models of nurse-physician interaction in research settings. This study is an 
attempt to examine the attitudes and perceptions of a more heterogeneous group of 
oncology nurses.  
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 CHAPTER III: METHODS 
 The chapter explains the study design. Followed by a description of the sample, 
including sample size and the setting in which the data were collected. The information 
about the instruments used is in the next section. Finally, procedures for data collection, 
the protection of human subjects and the data analysis plan are the last three sections.  
A. Design 
This study was a descriptive, nonexperimental study of a sample of practicing 
oncology nurses that explored oncology nurses’ attitudes and perceptions toward clinical 
trial participation. The study further sought to understand factors that oncology nurses 
believe influence patients’ decisions to participate in cancer clinical trials, and to learn 
which nurses’ characteristics are predictive of positive attitudes towards cancer clinical 
trials and perception of patient understanding.  
  A survey method was employed. The purpose of a survey design is to generalize 
from a sample to a population, so inferences can be made about some characteristic, 
attitude, or behavior of this population (Babbie, 1990). As noted in the review of the 
literature, little is known about nurses’ attitudes and perceptions towards cancer clinical 
trials. Most literature evaluating attitudes and perceptions towards clinical trials has 
concentrated on patients, the community, and physicians, rather than on nurses. The 
investigator used mailed survey instruments. There are a number of advantages of mailed 
surveys. They allow for wide geographic coverage as compared with surveys 
administered in person. Another advantage of a mailed survey is 
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in the timing of the data collection. The assumption with a mailed survey is all the 
members of the sample receive it nearly simultaneously. Therefore, the potential 
influence on respondents’ experiences, opinions, or attitudes that might come from events 
outside of or unrelated to the study is reduced and c  be assumed to be equal for all 
recipients of the questionnaire (Bourque & Fielder, 2003).  
One of the greatest and most studied disadvantages of using mailed surveys is 
their low response rate (Bourque & Fielder, 2003). According to Krosnick (1999), the 
common thought when conducting a survey is to strive for a 70% response rate. He noted 
response rates on national surveys have fallen in the last four decades. Krosnick 
challenged the thought that high response rates correlate with a high degree of 
representativeness of the sample and cited results in relation to national studies of voters. 
When probability sampling was done, there was no loger a need to associate low 
response rates with low representativeness (Krosnick, 1999). Research shows that a 
second mailing approximately three weeks after the first mailing is more effective than 
any other technique for increasing response (Dillman, 2000; Schaefer & Dillman, 1998).  
Response rates reported from past mailed surveys sent to Oncology Nursing 
Society (ONS) members ranged as follows: 23% (Jerewski, Brown, Wu, Meeker, Feng, 
& Bu, 2005); 24% (Taylor, Highfield, & Amenta, 1994); 25% (Volker, 2001); 26% 
(Rutledge & Engelking, 1994); 30% (Bavier, 2003); and 37.7% (Sarna, Wewers, Brown, 
Lillington, & Brecht, 2001). The study by Jerewski, et al. (2005) used a stratified, random 
sampling approach and asked questions regarding knowledge, attitudes, and experiences 
about advanced directives analyzed with descriptive statistics and regression analysis. 
Taylor et al.’s (1994) study also used a stratified random sampling approach asking 
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questions about spiritual care analyzed using content analysis and descriptive statistics. 
Volker (2001) used a sequential mailing technique to gather stories of nurses in relation 
to requests for assisted dying. Rutledge and Engelking (1994) conducted a survey of 
randomly selected oncology nurses to describe theirexperiences with cancer related 
diarrhea, including occurrence and management. Bavier (2003) used a stratified random 
sampling approach in describing types of disclosure discussions between oncology nurses 
and patients/family members. Sarna et al. (2001) conducted a survey of randomly 
selected members of ONS about tobacco control and brriers and facilitators to delivering 
tobacco cessation interventions to patients. The authors do not state specific strategies 
used to maximize response to their surveys. Sarna et al. (2003) stated that a reminder 
postcard was sent to encourage return of the questionnaire but, when the postcard was 
sent was not reported. However, three to four weeks after the first mailing (N = 5,000), 
Rutledge and Engelking (1994) mailed another survey packet to nonrespondents. A total 
of 1,288 nurses (26%) responded, 600 to the first survey and 688 to the follow-up. It is 
encouraging to note that upon follow-up mailing Rutledge and Engelking (1994) yielded 
a greater number of respondents compared to the first mailing. This study planned on 
utilizing the same technique as Rutledge and Engelking (1994) to send a follow-up 
mailing to nonrespondents in case the minimum sample size was not obtained with the 
first mailing; however, a second mailing was not necessary (see Sample Size and 
Procedures for Data Collection sections).  
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B. Sample and Settings 
 In this study, a proportional stratified random sample of the membership of the 
ONS was used to make inferences between oncology nurses characteristics and their 
attitudes towards cancer clinical trials, their perception of patients’ knowledge of the 
treatment plan and information needed related to clinical trials. In a proportional, 
stratified random sample, the population is separated into groups based on their 
proportions represented in the general population. Then, a random selection is drawn 
from each group with the proportion from each stratum being the same as the overall 
population. The stratified random sampling technique is an attempt at sharpening the 
representativeness of the final sample (Polit & Beck, 2004).  
Sample Size 
 To assess instrument and subscales validity, the investigator performed a factor 
analysis of the data prior to the primary analysis evaluating the research questions (this 
will be explained fully in the data analysis section of this chapter). Factor analysis 
requires a minimum number of subjects per item for the instrument being utilized. 
Gorush (1983) and Hatcher (1994) recommend a minimum s bject per item ratio of at 
least 5:1. The consensus among three authors is (Gorush, 1983; Hathcer, 1994; Nunnally 
& Bernstein, 1994) the number of subjects per item should be 5:1 to 10:1. Other authors 
have reported that there may not be one ratio that will work in all cases and a rule of 
thumb is an N>100 and that most factor analytic studies use N>200 (MacCallum, 
Widaman, Preacher, & Hong, 2001).  
 For this study the investigator utilized a 26-item instrument (see appendix A and 
instrument section of this Chapter) and the investigator followed a 5:1 to 10:1 ratio of 
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subjects per item; therefore, the minimum number of subjects needed for this study 
was130. However, after consulting a statistician with over 20 years experience in 
designing surveys, it was decided that a sample size of 230 subjects would be better (B. 
Pearman, personal communication, April 24, 2006). It has been shown that larger 
samples (i.e., >200 subjects) are better than smaller samples, because larger samples tend 
to minimize the probability of errors, maximize the accuracy of population estimates, and 
increase the generalizability of the results (B. Pearman, personal communication, April 
24, 2006; Gorush, 1983; MacCallum et al., 2001).  
Sample 
A sample of registered nurse (RN) members of ONS who reside in the United 
States (US) and permit ONS to release their addresses was utilized. The total ONS nurse 
and non-nurse membership is approximately 32,000, approximately 23,000 members 
allow their names to be sold to outside organizations (ONS, 2006). There are 
approximately 16,150 nurse members who self-report their primary functional area as 
patient care or research with adults, excluding nurses who self-report their primary 
position as researcher/principal investigator. 
One thousand labels of names and addresses were purchased from ONS for nurses 
who reside in the U S and who self-report patient care or research with adults as their 
primary functional area, and are employed full, or pa t-time, . The investigator requested 
that the list excludes nurses who reported that their primary position as 
researcher/principal investigator. There may be nurses who identify their primary 
functional area as “research” but in fact are clinial trials nurses and the investigator 
wanted to include them. Additionally, the investigaor was interested in exploring the 
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attitudes and perceptions from oncology nurses who have direct patient care and whose 
primary position includes, but is not limited to, staff nurse, clinical nurse specialist, nurse 
practitioner, clinical trials nurse, and patient educator. This sample represents the 
majority of the population of nurses who care for onc logy patients and is an attempt to 
improve the generalizability of the study.  
The investigator requested ONS to stratify the 1,000 names by two variables: 1) 
primary work setting (e.g., in-patient hospital unit, outpatient facility or clinic, public 
health or visiting nurse service, hospice, etc.); and 2) highest degree attained (e.g., 
diploma, associate’s, bachelor’s, masters, doctorate). A random sample within each 
category was selected in proportion to the size of the group in that category. This group 
was a representative sample of the study population w th the above proportional 
categories. The study packet was mailed to all 1,000 selected members. A cover letter 
(see Appendix B) was included in the mailing. This over sampling was required due to 
previously reported response rates between 24-37% to ONS mailed surveys. 
C. Instruments 
The nurses were asked to complete two instruments, the modified Nurses’ 
Attitude Survey (NAS) (Appendix A), and a Demographic Information Form (see 
Appendix C). 
Nurses Attitude Survey 
The original NAS was survey tool developed by Meropol and colleagues (Burnett 
et al., 2001) that addresses nurses’ attitudes toward cancer clinical trials and their 
perceptions about patients’ reasons for participating as research subjects. The instrument 
was used only once at Roswell Park Cancer Institute (RPCI). RPCI is a freestanding 
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National Cancer Institute (NCI)-designated comprehensive cancer center. Between 
October 1996 and February 1997, 417 RNs employed at RPCI were surveyed. Nurses at 
RPCI care for a wide variety of patients in a array of settings, including outpatient and 
inpatient units, intensive care units (ICUs)/bone marrow transplant (BMT) units, and 
clinical research services. Two hundred-fifty (60%) of the 417 nurses responded. Ninety 
percent of the sample was female; 88% was white; the mean age of subjects was 42 
years; and 47% of subjects were educated at the bachelor’s or master’s level. Practice 
setting was distributed fairly evenly across inpatient facilities, outpatient clinics, and 
ICUs and BMT units. Twenty-seven (11%) subjects identifi d themselves specifically as 
research nurses. Approximately one third of the total respondents (n = 82) reported caring 
for at least 50 patients annually on clinical trials. 
The original NAS consists of a total of 59 consecutively numbered items 
including demographic information questions. The tool is divided into four sections: 
Section 1 (Clinical Research Using Patients as Research Subjects) consists of 15 items 
plus space for comments; Section 2 (Patient Care and P tient Communication) consists of 
11 items and a space for comments; Section 3 (Nurses’ Role in a Cancer Institute) is 
comprised of 16 items plus space for comments. To answer items in Sections 1 through 3, 
the participant chooses responses from a 5-point Likert scale (1 = strongly disagree, 2 = 
somewhat disagree, 3 = neither, 4 = somewhat agree, and 5 = strongly agree). Section 4 
(About You) consists of 17 demographic questions.  
Modification of the NAS. With permission from the authors (see Appendix D), the 
investigator modified the instrument for this study. This modification was requested 
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because certain items from the original instrument would obtain information that was 
outside the purpose of this study and only germane to the original study. 
The 15 items contained in Section 3 were statements tha  address issues related to 
the nurses’ employment, such as job satisfaction and support at work. Section 3 was 
deleted, because the information is outside the scope of this research. All demographic 
questions were included on a separate form (see Appndix C). Sections 1 and 2 of the 
NAS were modified and consisted of the 26 consecutively numbered items included in 
the original instrument (see Table 1). 
Table 1 
Modification of NAS 
___________________________________________________________________ 
 NAS section                                               Original NAS items          Modified NAS items 
___________________________________________________________________ 
Within the original instrument, the authors derived two subscales consisting of six 
items each. The authors used subscale one (Items 1, 5, 6 7, 8 and 11) to report nurses’ 
attitudes toward patient participation in clinical trials and, subscale two (Items 12, 13, 18, 
20, and 21) to report nurses’ perceptions about factors related to patient care issues (e.g., 
respect, understanding of the treatment regimen, and informational needs). Cronbach’s 
1. Clinical research using patients  
as research subjects 
 1–15              1–15 
 
















          Demographic  
          information  
          to be captured on  
          a separate form 
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alphas were reported for the two subscales as 0.78 and 0.63, respectively (Burnett et al., 
2001). A Cronbach’s alpha of 0.63 is lower than the widely-accepted social science 
minimum of 0.70. Usually an alpha level 0.70 and above is acceptable; however, it is a 
common misconception that if the alpha is low, it must be a poor test. Actually, the test 
may measure several attributes or dimensions rather than one and, thus, the Cronbach’s 
alpha is deflated (Santos, 1999).  
The authors of the NAS analyzed their data using the two subscales as outlined. 
Upon review of the instrument, the investigator found other items that could be grouped 
together to answer the research questions of this study and utilize all items in Sections 1 
and 2 (see Table 2). However, the grouping of items in table 2 was proposed before the 
factor analysis was executed. After the factor analysis, the investigator found that some 
of the proposed items grouped with each other, while others did not (see chapter 4, 
Results). The authors of the NAS report that they established face and content validity for 
the instrument by an extensive review of the literature and a review of the instrument by 
three medical oncologists and two oncology nurses (Burnett, et al., 2001). Therefore, it 
was prudent that the investigator psychometrically evaluate construct validity of the 
modified NAS to assess that the dimensions (attitudes and perceptions) are being 
measured by the instrument subscales (Waltz, Strickland, & Lenz, 1991). Factor analysis 
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Table 2 
Modification of the NAS Subscales to Match Research Questions 
__________________________________________________________________ 
Research questions                Modified NAS subscale items         Original NAS 
                                                                                                 subscale items 
__________________________________________________________________ 
 
1. What are oncology 
nurses’ attitudes toward 













2. What are nurses 
attitudes about how 
effective a research drug 
or experimental therapy 
should be shown to be 
before it is offered to 
patients? 
 
3. What are the nurses’ 
perceptions regarding 
patients’ understanding of 











5. Clinical research improves 
patient care for the patient 
involved.  
6. Hospitals that conduct clinical 
research have better standards of 
care than hospitals that do not. 
7. Clinical research in oncology is 
important in improving standards 
of care in oncology. 
8. Patients should be encouraged 
to participate in research. 
11. If I had cancer, I would prefer 
to be treated as part of a clinical 
trial. 
 
15. In your opinion, in order for a 
research drug or experimental 
therapy to be offered to patients, it 
should have at least a _____% 
chance of producing a desired 
effect (please insert a number) 
 
 
12. In general, patients are well 
informed when they choose to 
participate in a clinical trial. 
13. Patients are often unaware that 
their treatment is part of a research 
protocol. 
16. Patients’ wishes regarding 
treatment are respected by nurses 
19. Patients understand their 
prognosis and therapy goals. 
20. Patients’ prognoses are usually 
well explained. 
21. Patients want to be informed. 
 
1, 5, 6, 7,  













Reported as frequency 
and distribution table 
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Table 2 (continued) 
 
4. What factors do nurses 
perceive to influence a 
patient’s decision to 
















5. What are nurses’ 
perceptions of patients’ 
decision-making processes 
and the desire for 
information regarding 










6. What are the  
perceptions of nurses 
regarding where clinical 
research should be 
conducted and the role of 







14. Patients participate in research 
because: 
A. Wish for cure 
B. Wish for improved quality 
of life (i.e., symptom 
control) 
C. Hope for better medical 
care 
D. Desire to please their 
oncologist 
E. Pressure from oncologist 
F. Wish to help others 
G. No other option 
H. Family wishes 
I. Inability to accept that 
nothing else can be done 
J. Inability to accept  
      death       
 
22. When being told about their 
therapy, most patients pay more 
attention to potential benefits of 
therapy than side effects. 
23. Most patients are willing to 
accept side effects for even a small 
benefit if therapy. 
24. Patients are often frightened to 
ask questions. 
25. Patients’ decisions whether to 
accept or not accept toxic 
chemotherapy is  
strongly influenced by their family 
preferences. 
 
1. Conducting research is an 
important role of oncologists. 
2. Clinical research should be 
conducted only in cancer 
centers/institutes. 
3. It is appropriate for oncologists 
to invite their clinic patients to be 





Reported as a 
frequency distribution 











































   
59 
 
























7. Do the demographic 
variables of age, education 
level, number of years in 
oncology, position of 
oncology nurses, and 
practice setting serve as 
significant predictors to 





4. It is appropriate for oncologists 
to be the person consenting  
research subjects for their trials, if 
the research subjects are their own 
clinic patients 
9. Oncologists put too much 
pressure on patients to participate 
in clinical trials 
10. Nurses put too much pressure 
on patients to participate in clinical 
trials 
17. Patients’ wishes regarding 
treatment are respected by 
oncologists 
18. Patients understand their plan 
of care/treatment. 
26. Oncologists believe that 
patients are willing to accept side 
effects for even a small benefit of 
therapy.  
 
Were analyzed by regression 
equations based upon the 
























Predictors reported by 
original authors. 
___________________________________________________________________ 
Eight practicing masters prepared oncology nurses completed the modified 
instrument, as part of a field test of the instrument package and to provide feedback on 
the items. These nurses were not part of the primary study. Each nurse took fewer than10 
minutes to complete the instrument. They all felt that the instrument asked for their 
opinion regarding cancer clinical trials, including i formation specifically about patients 
who participate in these trials. In the unmodified instrument Item 1 states “Conducting 
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patient research is an important role of oncologists” and Item  9 states “Doctors put too 
much pressure on patients to participate in clinical tri ls.” The nurses recommended 
using similar language throughout the instrument. Therefore, wherever an item addressed 
doctor it was changed to “oncologist.” 
Demographic Information Form 
 The Demographic Information Form (DIF) was designed by the investigator using 
some of the demographic items contained on the original NAS and on the 2006 ONS 
membership application/renewal form. The DIF contained 10 items; six items were from 
a list of choices and four responses were open-ended requiring subjects to fill in a blank. 
One purpose of the DIF was to assist with the analysis of the sample characteristics in 
relation to the overall membership of ONS. Question e, three, four, seven, nine, and 
10 from the DIF were used in the evaluation of research question number seven that 
explored demographic variables (age, highest education level, whether or not the nurse 
actually works with patients contemplating enrollment or currently enrolled in a clinical 
trial, number of years in oncology, primary work setting, and primary position of 
oncology nurses ) and evaluated if they served as significant predictors related research 
questions one through six (see Table 3). The remaining four questions on the DIF were 
used to further describe the sample (gender, current certification in oncology nursing, 
number of years as an RN, and percentage of patients offered cancer clinical trials where 
the subject worked). The questions were based on the independent variables of interest 
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Table 3 
Independent Variables from DIF 
__________________________________________________________________ 
Independent variables (demographic categories) addressed 






Highest education. 3 
 
Working with patients contemplating enrollment or  




Number of years in cancer nursing. 7 
 






                              10 
___________________________________________________________________ 
D. Procedures for Data Collection 
The investigator obtained three duplicate sets of mailing labels from ONS, for a 
total sample of 1,000 members. This over-sampling was used with the goal of a 20-25% 
response rate in an attempt to yield 230 usable responses. All 1,000 names from the first 
set were mailed the study packet. The only identification was a numeric code on the 
return envelopes and corresponding numerical codes n the second and third mailing 
labels. When a subject returned the survey, his/her name was removed from the second 
and third sets of mailing labels and the envelopes shredded. The code did not appear on 
any of the instruments or cover letter. This was to ensure that names were not connected 
with answers in any way and to provide anonymity to the respondents. If there were 
fewer than 230 usable surveys 3 weeks after the first mailing, the investigator planned on 
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mailing a second survey packet with the instruments a d a new cover letter (Appendix E) 
to all remaining names (Dillman, 2000). This was not ecessary, because the investigator 
had received more than 230 usable surveys 3 weeks after the mailing (see chapter 4, 
Results). At the end of the study, the investigator destroyed all codes and remaining 
address labels.  
Additionally, the cover letter (see Appendix B) stated the inclusion criteria for 
this study as follows: (a) nurses whose primary functio al area is patient care or research 
with adult patients, and (b) any primary position other than researcher/principal 
investigator. There was a box on the cover letter for the subject to check if they do not 
meet these criteria with instructions to return the cover letter in the supplied stamped 
addressed envelope.  
After obtaining approval from the Institutional Revi w Board (IRB) of Duquesne 
University, survey packets were mailed (Appendix F). The packets contained: (a) an IRB 
approved cover letter (Appendix B), (b) the modified NAS (Appendix A), (c) the DIF 
(Appendix C), (d) and a stamped return envelope addressed to the investigator. 
E. Procedures for the Protection of Human Subjects 
The investigator requested approval for conducting the study from the  
IRB of Duquesne University, utilizing standard forms and procedures set forth by the 
committee. The investigator provided an overview of the research questions, design, 
methods, and a sample packet of data collection tools. The IRB approved the study on 
May 24, 2006. The investigator received a letter from the chair of the Duquesne 
University IRB, Dr. Paul Richer (Appendix F) stating that the study received expedited 
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approval as well as an IRB approved cover letter to be used in the survey packet (see 
Appendix B). 
Participation in the proposed study was voluntary, nd all subjects had the right to 
refuse. Potential subjects were informed that results would be reported in an aggregated 
format, with no information identifying any individual. The only identification was a 
numeric code on the return envelopes and a corresponding numerical code on the second 
and third set of mailing labels. As mentioned above, when a subject returned a survey the 
person’s name was removed from the mailing list and the envelopes shredded. The code 
did not appear on any of the instruments or cover letter. At the end of the study, all codes 
and remaining address labels were destroyed by the investigator.  
During the study the investigator, kept all of the returned instruments and address 
labels in a locked file cabinet separate from any data. The completion of the survey 
instrument and the mailing of the instrument to the investigator were considered to be 
consent by the individual to participate in the proposed study. The cover letter provided a 
means for individuals who had concerns about the study and wished to discuss issues a 
way to contact the investigator (Appendix B).  
F. Data Analysis Plan 
Data analysis occurred in two steps. In step one, the investigator psychometrically 
evaluated the survey instrument by completing a factor analysis of the data to confirm the 
validity of the grouped items with this population f oncology nurses and assessed 
reliability of the instrument and the subscales. Data were analyzed statistically using 
SPSS® (version 11.5) (SPSS Inc., Chicago, IL). 
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Upon receipt of each completed survey, a research assist nt entered the data onto 
a spreadsheet (Excel by Microsoft®, Redmond, WA) created by the study statistician. For 
quality control the investigator rechecked all data entered for each subject. The data were 
then exported to SPSS® for data analysis. 
As noted in the review of the literature in chapter 2, the NAS was used in one 
pilot study of oncology nurses in a comprehensive cancer center (Burnett et al., 2001), 
and the investigator could not find any other instruments that have been created to 
measure nurses’ attitudes and perceptions regarding ca cer clinical trials. As stated, the 
authors of the original instrument analyzed data using two subscales consisting of six 
items each, which are embedded within the entire NAS. The authors used Subscale 1 to 
measure nurses’ attitudes toward patient participation in clinical trials, and Subscale 2 to 
measure nurses’ perceptions about factors related to patient care issues (e.g., respect, 
understanding of the treatment regimen, and information l needs). In addition to the 12 
grouped items which make up Subscale 1 and 2 (six items for each subscale), the 
remaining items on the NAS were grouped together to address the research questions for 
this study. Therefore, all of the research question were evaluated by four subscales and 
two individual items, which contained all the 26 items of the NAS. This will be explained 
fully in the analysis of variables section of this chapter.  
In establishing six groupings of items to address six research questions, validity 
and reliability of the NAS was evaluated prior to addressing the research questions posed 
by this study. Psychometric evaluation of the NAS was accomplished by factor and 
reliability analysis. Factor analysis addresses the validity of a scale or subscale by 
evaluating the extent to which the abstract constructs purported to be measured, can be 
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inferred from the factors or subscales (Waltz et al., 1991). Reliability measures the 
internal consistency and reliability of a scale or subscale and was evaluated by 
calculating Cronbach’s alpha (Polit & Beck, 2004).  
Factor Analysis 
Factor analysis of the NAS was performed first to determine if the proposed items 
and subscale items grouped together. Factor analysis is a generic term for a family of 
statistical techniques concerned with the reduction of a set of observable variables in 
terms of a small number of latent factors or constructs (Hutcheson & Sofroniou, 1999). 
Factor analysis was developed primarily for analyzing relationships among measurable 
entities, such as survey items or test scores (Gorsuch, 1983). The underlying assumption 
is there exists a number of unobserved latent variables (or “factors”) accounting for the 
correlations among observed variables, such that if the latent variables are partialled out 
or held constant, the partial correlations among observed variables all become zero 
(Morrison, 1990). In other words, the latent factors determine the values of the observed 
variables. The main applications of factor analytic te hniques are (a) to reduce the 
number of variables and (b) to detect structure in the relationships between variables that 
classify similar variables together (Hutcheson & Sofroniou, 1999).  
The factors, then, are groups of variables measuring a common construct or 
factor. In a principal components factor analysis, all sources of variability (unique, 
shared, and error) are analyzed for each variable. In factor analysis, only shared 
variability is analyzed (Gorsuch, 1983). This is baed on the assumption error and unique 
variance which only serve to confuse the underlying structure of the variables. In this 
study, a principal components factor analysis was utilized. This study also utilized an 
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orthogonal or varimax rotation (Gorsuch, 1983). This rotation results in identifying 
factors that are uncorrelated with each other. The factor loadings or the matrix of 
correlations between all observed variables and factors was inspected, since the size of 
the loading is indicative of the relationship between each observed factor and variable. 
The interpretation of factors or analysis always involves a certain amount of subjectivity. 
In order to be effective and avoid potential bias, the minimum factor loading was set at 
0.30 (Gorsuch, 1983; Waltz & Bausell, 1981). Items or variables loading below 0.29 
were considered for elimination from the scale. It also was anticipated that items would 
load on one, and only one, factor (Gorsuch, 1983). This was accomplished before any 
further analyses of data, so that the grouped items could be evaluated and altered if 
necessary.  
It was anticipated that most of the proposed subscale items would factor together 
(Betsy Pearman, personal communication, April 24, 2006). However, the factor analysis 
revealed that some of the proposed item groupings (Table 2) factored together, while 
some items factored with others. The investigator planned on two strategies to address 
factor loading of an item or items below 0.30: (a) If new factor arrangements (subscales) 
were identified and provided useful information and evaluated the underlying constructs 
(attitudes and perceptions), then the investigator would utilize the new arranged factors to 
analyze the data; (b) if the constructs were not identified within a new factored 
arrangement then the investigator would evaluate reliability of the new factored 
arraignment and compare it to the reliability of the proposed subscales. The more reliable 
arrangement would then be used for the data analysis. The investigator found that some 
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items of the proposed subscales (Table 2) factored t gether, while other items factored in 
with different items (See chapter 4, Psychometric analysis section).  
Reliability 
Reliability of the NAS and the subscales of grouped it ms were measured with a 
Cronbach’s alpha. Cronbach’s alpha is a coefficient of reliability (or consistency) and is 
the most common estimate of internal consistency of items in a scale (Cronbach, 1951). 
Cronbach’s alpha measures how consistently a set of items is measured. In other words, 
upon repeated testing of a scale or subscale, the sam results are obtained, and to what 
extent the item responses obtained at the same time corr late with each other (DeVellis, 
2003). Three factors that can affect the size of an alpha coefficient include the number if 
items on the subscale, the ability of the person completing the items, and the method of 
computing reliability (Polit & Beck, 2004).  
Analysis of Research Questions 
Research Questions 1, 2, 3, 5, and 6 were analyzed by valuating the mean scores 
obtained from the survey items (summed subscale score  f r Questions 1, 3, 5, and 6 and 
mean percent for question 2) with p = 0.05 as the level of significance (see chapter 4 for 
results). Research Question 4 was analyzed using descriptive statistics and frequencies of 
Item 14 were reported.  
Stepwise multiple regression was used to analyze res a ch Question 7. For this 
analysis, regression was used to test the effects of six independent (predictor) variables 
(age, education level, number of years in oncology, whether nurses care for clinical trial 
patients or not, position of oncology nurses, and practice setting) on the dependent 
(criterion) variables, attitudes and perception, as measured by the NAS subscales. 
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Regression analysis measures the degree of influence of the independent variables on the 
dependent variables (Stevens, 2002). Multiple regression can establish that a set of 
independent variables explains a proportion of the variance in a dependent variable at a 
significant level (through a significance test of R2), and can establish the relative 
predictive importance of the independent variables (Brace, Kemp, & Snelgar, 2006). The 
adjusted R2 takes into account the number of variables in the model and the number of 
participants on which the model was based. The adjusted R2 value gives the most useful 
measure of the success of the model. However, theremay be very little difference 
between the R2 and adjusted R2, and some authors recommend checking for differences 
between the two and reporting only the R2 (Brace et al.; Stevens, 2002,). An R2 close to 
1.0 indicates that almost all the variability with the variables specified in the model have 
been identified. Therefore, a R2 close to 1.0 is desirable because it indicates that the 
predictor variables are a good predictor of the criterion (dependent variables). 
Conversely, a low R2 indicates the predictor variables account for little variance and there 
is variance in the model that is accounted for from an unknown source. When a 
regression model has a low R² there may be some other factor accounting for the 
variance. As an example, if the R² is 0.12, then only 12% of the variance is accounted for, 
and there is an unknown variable that will affect future results, if that regression model 
were being used to predict group scores on a subscale. It would be difficult to use the 
predictor variables to predict the scores on the subscale if the regression model is only 
accounting for 12% of the variance (Tabachnick & Fidell, 2001). 
Another important result from a multiple regression analysis is the standardized 
regression coefficient, beta (ß). The beta regression coefficient is a measure of how 
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strongly each predicator variable influences the dependent or criterion variable. The 
higher the beta value, the greater the impact of the predictor variable on the dependent 
variable (Brace, et al., 2006). Five stepwise multiple regression models were constructed 
to explore further the relationship of the independent variables and the outcome variables 
of attitudes and perceptions.  
As a general data analysis approach, bivariate comparisons of mean scores were 
performed using one-way analysis of variance (ANOVA) tests with age, educational 
level, whether the nurse works with a patient enrolled on or contemplating enrollment in 
a clinical trial, years in cancer nursing, primary work setting, and primary position as 
independent variables and the scores of the subscales as the dependent variables. When 
significant differences in mean scores were found within an independent variable a post-
hoc multiple comparison test then was performed. 
For independent variables where there were more than two groups, the data were 
further analyzed with a Bonferroni post-hoc multiple comparison test. The Bonferroni 
adjustment is a statistical adjustment for multiple comparisons (Seaman, Levin, & Serlin, 
1991). The Bonferroni post-hoc test uses t tests to perform pairwise comparisons between 
group means, but controls overall error rate by setting he error rate for each test to the 
level of significance (alpha level) divided by the total number of tests (Keppel & 
Wickens, 2002). Hence, the observed significance lev l is adjusted for the fact that 
multiple comparisons are done. 
The Bonferroni post-hoc test calculates an adjustmen  as a way of control when 
multiple tests of the data are analyzed, and accounts for testing the same population many 
times (Keppel & Wickens, 2002). For example, if five groups are being tested in a 
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pairwise fashion, there are10 possible combinations of pairwise comparisons. The alpha 
level of significance for this study was set at p = 0.05. With the Bonferroni adjustment 
the alpha level is divided by the number of pairwise comparisons. For 10 pairwise 
comparisons, the level of significance now becomes p = 0.005. This ensures that the 
overall chance of making a Type I error is still less than 0.05.  
Independent Variable Groupings 
 Age. The independent variables were placed into groups for data analysis. The 
sample was divided into two groups to evaluate age:Group 1 represents nurses’ less than 
or equal to 40 years old and Group 2 represents nurses greater than 40 years old. The cut 
point of 40 years of age was chosen for several reasons. Burnett, et al. (2001), found age 
greater than 40 years was a predictor of positive attitudes towards clinical research. 
Additionally, the investigators found that 236 (78.4%) nurses were 40 years or older with 
a mean age of 48. Both the sample and the ONS membership reflected the general 
nursing population with the majority over the age of 40 (Buerhaus, 2002). Moreover, 
66% of ONS members are over the age of 40 (Kristina Gantner, Personal 
Communication, July 19, 2006). 
 Educational level. To evaluate the independent variable of educational level it 
was classified into three different groups. Group 1 included nurses who had a diploma in 
nursing or an associate degree in nursing or any other field. Group 2 included subjects 
with a bachelor’s degree in nursing or any other fild. The third group included subjects 
with a master’s degree or higher in nursing or any other field. These groupings were 
chosen to see if there were differences in the responses of subjects with bachelor’s 
degrees compared to subjects with lower or higher educational degrees.  
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 Working with clinical trial patients. Question number four on the DIF asked 
subjects if they work with, or care for, patients contemplating enrollment in, or currently 
enrolled in, cancer clinical trials. The subjects re ponded either yes or no. For the data 
analysis the subjects were divided into two groups, Group 0 = no and Group 1 = yes. 
 Number of years in cancer nursing. To evaluate for differences in responses, the 
number of years a subject worked as an oncology nurse was divided into three groups. 
Group 1 were subjects who indicated less than ten years experience, Group 2, 11–20 
years experience, and Group 3 greater than 20 yearsexperience. The investigator decided 
upon three groups based upon the average number of y ars falling between 10–20 years. 
He felt that a group with less experience and a group with more experience than the 
average were warranted to provide meaningful comparisons. 
 Primary work setting. For primary work setting there were three main groups of 
subjects, inpatient setting, outpatient setting, and other. These groups were further 
separated into six different work settings. Group 1 consisted of bone marrow transplant 
unit/intensive care unit (BMTU/ICU) nurses; Group 2 consisted of nurses working on a 
medical surgical inpatient oncology unit and an inpatient oncology specialty unit 
(MSOU). The Group 3 consisted of nurses who stated th y work at a hospital based 
infusion center (HBIC). Group 4 consisted of nurses who reported they work in a 
physicians’ office (MDO); Group 5 reported they work in a corporate or industry setting 
(CI), and Group 6 were nurses who reported “other” (OTHER). These groups represent 
the majority of nurses working in oncology and in the ONS membership (Kristina 
Gantner, personal communication, July 19, 2006).  
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The investigator decided to include Group 5, corporate/industry practice setting, 
in the data analysis for several reasons. This variable is identical to a choice on the 2006 
ONS membership application. The cover letter informed subjects that they were selected 
to receive the survey based upon a random sample of nurses who self-report their primary 
functional area as patient care or research with adults, excluding those who self report 
researchers/principal investigators as their primary position (inclusion criteria). The cover 
letter gave the subjects the opportunity to check a box and return the letter if they did not 
meet these inclusion criteria. Lastly, it was impossible to differentiate between nurses 
who work in corporations and provide patient care, those who work in research 
organizations providing clinical trial support, and those who work in the pharmaceutical 
industry.  
 Primary position. The variable, primary position was divided into four groups for 
the analysis. This information was taken from the responses to question 10 on the DIF, 
which asked subjects to indicate their primary positi n. This question is identical to an 
item on the ONS membership application, asking for the same information. Group 1 
included nurses who indicated they were staff nurses; Group 2 included subjects who 
indicated they were clinical nurse specialists or nurse practitioners (CNS/NP); Group 3 
were subjects who reported they were clinical trials nurses (CTN), and Group 4 were 
subjects who indicated “other” primary position. The four primary positions represent the 
majority of nurses included in the 2006 ONS membership (Kristina Gantner, personal 
communication, July 19, 2006). 
                                                               
  73                                                                  
CHAPTER IV: RESULTS AND SUMMARY 
A. Introduction 
  This study examined oncology nurses’ attitudes toward cancer clinical trials, and 
identified nurses’ perceptions of the understanding that patients have about the clinical 
trial process and the reasons for patient participation in clinical research. This study also 
investigated factors which may influence oncology nurses’ attitudes and perceptions. 
These factors include age, educational preparation, length of time in oncology nursing, 
whether or not the nurse actually cares for patients contemplating enrollment or who are 
currently enrolled in a clinical trial, primary position, and work setting. The investigator 
believed that all of these factors could influence oncology nurses’ attitudes and 
perceptions. Data were collected from the nurses’ an wers to the items contained on the 
modified Nursing Attitudes Survey (NAS) and Demographic Information Form (DIF). 
This chapter includes the demographic characteristics of the oncology nurses 
sampled, psychometric analysis of the modified NAS, the results of the analysis of the 
research questions, and a summary.  
B. Sample 
This exploratory study obtained data from a national sample of oncology nurses 
who were members of the Oncology Nursing Society (ONS). One thousand surveys were 
mailed, and 357 nurses responded, giving a response rate of 35.7%. Fifty six respondents 
(15.6%) returned the cover letter and marked the box that indicated they did not meet the 
inclusion criteria for this study. Two surveys (0.5%) were returned by the U.S. postal 
service, because the addresses were not valid. The final sample consisted of 301 subjects 
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who completed the NAS and DIF; therefore, the actual response rate was 30.1%. Table 4 
lists the demographic characteristics of the oncology nurses sampled.  
Table 4 
Demographic Characteristics of Sampled Oncology Nurses (N = 301) 
Characteristic N % 
Gender   
   Male     6   2 
   Female 259 98 
Age (years)   
   20-39   64 21.3 
   ≥ 40 236 78.4 
   No answer     1   0.3 
Education level*   
   Diploma in nursing   40 13.3 
   Associate’s degree   46 15.3 
   Bachelor’s degree   83 28 
   Master’s degree   93 31 
   Doctoral degree   39 13 
Certification   
   OCN® 140 46.5 
   AOCN®   33 11 
   AOCNP®     7   2.3 
   AOCNS®     4   1.3 
   Other   34 11 
* Associate’s, bachelor’s, master’s and doctorate degrees totals combine nursing and other fields 
Ninety eight percent (n = 259) of the subjects were female, and 2% (n = 6) were 
male. The majority (n = 236, 78.4%) reported their age as 40 years old or greater. Thirty-
nine (13%) respondents reported that they had a doctoral degree in nursing or another 
field as their highest education level. The majority of subjects (n = 93, 28%) had a 
master’s degree in nursing or another field, followed by 28% (n = 83) of subjects who 
reported that they had a bachelor’s degree (in nursi g or another field) as their highest 
education level. Almost one-half (n =140, 46.5%) were OCN® certified. 
Demographic information regarding work setting and primary position was collected.  
                                                               
  
75 
                                                                                             
Table 5 lists work setting and primary position of the nurses sampled. 
Table 5 
Work Setting and Primary Position 
Work setting    N   % 
In-patient   
            BMTU   14   4.7 
            ICU     2   0.7 
            Medical-surgical unit-general     1   0.3
            Medical-surgical unit-oncology   54 17.9 
            Oncology specialty unit   25   8.3 
            Other   20   6.6 
            No answer     3   1 
Outpatient   
            Home Care     3   1 
            Hospital based clinic/infusion center   55 18.3 
            Physician office   46 15.3 
            Radiation oncology-Hospital based   11   3.7 
           Other   25   8.3 
           No answer     3   1 
Other   
            Corporate/industry   26    8.6 
            Extended care facility     1   0.3 
            HMO     3    1 
            School of nursing     6   2 
            Self employed     6   2 
            Other   12   4 
            No answer     3   1 
Primary position   
          Staff nurse 116 38.5 
          Nurse educator     8   2.7 
          Nurse manager   17   5.6 
          Clinical nurse specialist   35 11.6 
          Clinical trials nurse   17   5.6 
          Academic educator     4   1.3 
          Nurse practitioner   45 15 
          Nurse researcher     8   2.7 
          Case manager     7   2.3 
          Other   41 13.6 
          No answer     3   1 
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There were two questions on the DIF that asked the subjects to report the number 
of years as a RN and the number of years as a RN in cancer care. The mean number of 
years that subjects reported they had RN experience a d experience as a RN in cancer 
care was 20.5 years and 13.23 years, respectively. The minimum number of years as a 
RN that was reported was 1 year and the maximum was 51 years. For the variable years 
as a RN in cancer care, the minimum number of years th t was reported was 0 and the 
maximum was 36 (see Table 6). 
Table 6 





 Years as a RN 
valid    301 
missing    0 
Years as a RN in cancer care 
298 
    3 
Mean  20.50   13.23 
Median  20.00   12.00 
Standard deviation  11.019    8.807 
Range  50  36 
Minimum    1    0 
Maximum  51  36 
 
Nurses indicated “yes” or “no” to a question that asked if they worked with or 
cared for patients contemplating enrollment or enrolled in clinical trials. More than two 
thirds of subjects (n = 249) reported that they cared for patients contemplating enrollment 
in or currently enrolled in clinical trials (see Table 7). 
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Table 7 
Nurses Caring for Clinical Trial Patients 
    Response  n % 
 Yes 249   82.7 
 No   51   16.9 
 Total 300   99.7 
    Missing     1     0.3 
    Total 301 100 
 
Despite this large percentage, the respondents reported that approximately a third 
of patients (M =32.76%, SD=30.043) who they care for were offered cancer clinical tri l 
at the nurses’ place of employment. The minimum percent of patients offered any type of 
clinical trial was 0% and the maximum was 100%. However, these data should be 
interpreted with caution as 58 of the 301 subjects (19.2%) did not answer this question. 
C. Psychometric Analysis of the Modified NAS 
Factor analysis of the NAS was performed first to determine if the proposed items 
subscale items grouped together. The underlying assumption of factor analysis is that 
there exists a number of unobserved latent variables (or “factors”) accounting for the 
correlations among observed variables, such that if the latent variables are partialled out 
or held constant, the partial correlations among observed variables all become zero 
(Morrison, 1990). In other words, the latent factors determine the values of the observed 
variables. The main applications of factor analytic te hniques are (a) to reduce the 
number of variables and (b) to detect structure in the relationships between variables and 
to classify the variables (Hutcheson & Sofroniou, 1999).  
It was anticipated that most of the proposed subscale items would factor together. 
However, the factor analysis revealed that only some f the proposed item groupings 
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factored together, while some items factored with others. The investigator found that 
some items of the proposed subscales factored together, while some other items factored 
in with different items 
Cronbach’s alpha for the entire modified NAS, excluding Items 14 and 15, was 
0.72. Nunnally and Bernstein (1994) recommended that the alpha be between 0.70-0.90; 
therefore 0.72 is acceptable, especially for a new i strument used in only two research 
studies. These data support internal consistency for the total instrument. Any items 
negatively correlated to the total were rescaled to maintain consistency of attitudinal 
direction across items within each subscale and the total scale. There are certain 
circumstances in which the “alpha of some items maybe negative; therefore, the data 
should be recoded if necessary to assure that all items are coded in the same conceptual 
direction” (De Vellis, 2003, p. 92). Based on these results, the following items on the 
modified NAS were recoded and the scoring reversed: 2, 9, 10, 13, 22, 23, 24, 25, and 26. 
For example, the response of Strongly Agree was originally scored as a 5, Somewhat 
Agree was scored as a 4, Neutral was scored as 3, Somewhat Disagree was scored as a 2, 
and Strongly Disagree was scored as a 1. The new rescored items were as follows: 
Strongly Agree = 1, Agree = 2, Neutral = 3, Disagree = 4 and Strongly Disagree = 5.  
The construct evaluated by Item 14 was nurses’ perce tions of motivations for 
patient participation in clinical research. Item 14 stated, “Patients participate in research 
because of:” and 10 subitems (letters A-J) followed ith corresponding evaluations using 
a 5-point Likert scale. Item 14 was the single item to evaluate research Question 4: “What 
factors do nurses believe influence a patient’s decision to participate in a cancer clinical 
trial?” The Cronbach’s alpha for this item was 0.68. Furthermore, Item 15 asked the 
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subjects for their opinion and instructed them to write a whole number for percent chance 
that a research drug should have of producing a desire  effect before being offered to 
patients. Cronbach’s alpha coefficient reliability is not calculated on single numbers that 
are not scaled responses (DeVellis, 2003). When items are used to form a scale (or, as in 
this study, subscales) and the score from the individual item is combined into a single 
numerical value, the items need to have internal consistency and to be measuring the 
same thing (Bland & Altman, 1997).  
 Factor analysis of the modified NAS was computed using principal component 
factor analysis, and the factors were rotated by varimax rotation. The rotation converged 
in six iterations to produce four factors or subscales, explaining 40% of the variance. 
Although the analysis supported some of the original clustering or grouping of items, it 
showed some items belonged in a different factor (Table 8). Items loading greater than 
0.30 would be included in the subscales. Items or variables loading below 0.29 were 
considered for elimination. 
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Table 8 
 
Factor Loadings of the Items on the Modified Nurse’s Attitude Survey  
 
Subscale items Factor loadings 
 1 2 3 4 
19. Patients understand their prognosis and therapy goals. 0.771    
18. Patients understand their plan of care/treatment. 0.760    
17. Patients’ wishes regarding treatment are respected by 
oncologists. 
0.711    
20. Patients’ prognoses are usually well explained 0.689    
12. In general, patients are well informed when they choose 
to participate in a clinical trial. 
0.530    
16. Patient’s wishes regarding treatment are respected by 
nurses. 
0.492    
21. Patients want to be informed. 0.312    
     
5. Clinical research improves patient care for the patient 
involved. 
 0.682   
8. Patients should be encouraged to participate in r search.  0.612   
11. If I had cancer, I would prefer to be treated as p rt of a 
clinical trial. 
 0.572   
6. Hospitals that conduct clinical research have better 
standards of care than hospitals that do not. 
 0.541   
1. Conducting research is an important role of oncologists.  0.534   
4. It is appropriate for oncologists to be the person 
consenting research subjects for their trials, if the research 
subjects are their own clinic patients 
 0.463   
3. It is appropriate for oncologists to invite their cl nic 
patients to be subjects in trials that they conduct 
 0.456   
7. Clinical research in oncology is important in improving 
standards of care in oncology 
 0.339   
     
10. Nurses put too much pressure on patients to parici te 
in clinical trials 
  0.751  
9. Oncologists put too much pressure on patients to 
participate in clinical trials 
  0.724  
2. Clinical research should be conducted only in cancer 
centers/institutes 
  0.419  
13. Patients are often unaware that their treatment is part of 
a research protocol. 
  0.413  
     
22. When being told about their therapy, most patients pay 
more attention to potential benefits of therapy than side 
effects. 
   0.702 
26. Oncologists believe that patients are willing to accept 
side effects for even a small benefit of therapy 
   0.662 
23. Most patients are willing to accept side effects for even 
a small benefit if therapy. 
   0.611 
24. Patients are often frightened to ask questions.    0.504 
25. Patients’ decisions whether to accept or not accept toxic 
chemotherapy is strongly influenced by their family 
preferences. 
   0.361 
Extraction Method: Principal Component Analysis. Rotati n Method: Varimax with Kaiser Normalization. Rotation 
converged in 6 iterations. 
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 Each item loaded strongly on one and only one factor and lends to the validity of 
the subscales. A promax rotation of the principal components procedure also was 
investigated to determine whether the items consistently loaded on the same factors and 
to inspect the interfactor correlations. The items did load on the same factors, as in the 
varimax rotation, indicating that each subscale is measuring a unique and independent 
construct. The low correlation values (0.005 to 0.274) indicate very low to no correlation 
or little to no linear relationship between the four s bscales. Table 9 presents the 
interfactor correlations for the four subscales of the instrument. With these very low 
correlations in the factor analytic procedure, it is not necessary to discuss a total scale 
score since the factors are measuring unique and independent constructs (DeVellis, 
2003).  
Table 9 
Interfactor Correlation of Identified Factors  
 Subscale 1 Subscale 2 Subscale 3 Subscale 4 
Subscale 1 1.00    
Subscale 2 0.274 1.00   
Subscale 3 0.231 0.126 1.00  
Subscale 4 0.009 0.007 0.005 1.00 
 
There were four subscales created: Patient Understanding and Knowledge (PUK), 
Attitude Toward Clinical Research (ATCR), Roles and Location (RL), Information 
Needs of Patients (INP). Table 10 illustrates the details of the four subscales created from 
the factor analysis of the modified NAS.  
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Table 10 
Subscales Created After Factor Analysis 










1. Patient understanding and 
knowledge (PUK) 
7 0.74 0   SA 35 to  
SD 7 
2. Attitude towards clinical research 
(ATCR) 
8 0.66 0       SA 40 to  
   SD 8 
3. Roles and location (RL) 4 0.47 4 SA 4 to  
  SD 20 
4. Information needs of patients 
(INP) 
5 0.56 5 SA 5 to  
  SD 25 
*SA = strongly agree **SD = strongly disagree 
Subscale 1—Patient Understanding and Knowledge  
Items 12, 16, 17, 18, 19, 20, and 21 make up the Pati nt Understanding and 
Knowledge (PUK) subscale. This subscale measured a nurse’s perception of patient 
understanding and knowledge. For example, items on this subscale inquire about patients 
being well informed when they participate in clinical trials (Item 12), patients 
understanding their treatment plans and prognosis (Items 18, 19, and 20). The calculated 
Cronbach’s alpha for the PUK subscale was 0.74, indicating the PUK subscale has a 
fairly high level of internal consistency and reliability. The PUK subscale was used as the 
measure for research Question 3 (see Analysis of Research Questions in this chapter)  
Subscale 2—Attitudes Toward Clinical Research 
 Subscale 2, the Attitudes Toward Clinical Research subscale (ATCR) is 
comprised of  Items, 1, 3, 4, 5, 6, 7, 8, and 11. This subscale measures nurses’ general 
attitudes toward clinical research. For example, th items ask about: clinical research 
improving standards of care (Items 5, 6, and 7), if patients should participate in research 
(Item 8), and if a person completing the instrument would participate in a clinical trial if 
                                                               
  
83 
                                                                                             
they had cancer (Item 11). This subscale was the dep ndent variable to answer research 
Question 1 (see analysis of research questions in this chapter). Cronbach’s alpha for this 
scale was 0.66.  
Subscale 3—Roles and Location 
 Four items factored together to form Subscale 3, the Roles and Location subscale 
(RL), that is comprised of Items 2, 9, 10 and 13. These items measured clinical research 
location and the role of oncologists and nurses in patient enrollment. For example, some 
items asked if nurses or oncologists put too much pressure on patients to participate in 
clinical trials (Items 9 and 10), and if clinical research should be conducted only in cancer 
centers (Item 2). This subscale was used as the depen nt measure for research Question 
6 (see Analysis of Research Questions in this chapter). Cronbach’s alpha for this subscale 
was 0.47. The alpha was not as high as the first two subscales, but it has fewer items. 
Reliability is affected by the number of items in the subscale and the smaller number of 
items in this subscale may be reflecting this attribute (Ary, Jacobs, & Razavieh, 2002). 
Subscale 4—Information Needs of Patients 
 The final five items that factored together were 22, 3, 24, 25, and 26, forming the 
Information Needs of Patients (INP) subscale. This subscale measured a nurse’s 
perception of the informational needs of patients. Some items asked if most patients pay 
more attention to potential benefits of therapy than side effects (Item 22), if oncologists 
believe that patients are willing to accept side eff cts for even a small therapeutic benefit 
(Item 26), if most patients are willing to accept side effects for even a small benefit of 
therapy (Item 23), if patients are frightened to ask questions and if patients decisions are 
influenced by their family preferences (Items 24 and 25). This subscale was used as the 
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dependent variable to answer research Question 5 (see Analysis of Research Questions in 
this chapter). The calculated Cronbach’s alpha for the INP subscale was 0.56. While the 
alpha was not very high, it is acceptable for this ype of measure, because the few number 
of items may be affecting the reliability coefficients.  
 Reliability can be affected by several factors, the length of the test or number of 
items on a survey; the longer it is, the greater th reliability. Reliability also is a function 
of the person taking the test; a test may be reliabl  t one level of ability but unreliable at 
another level of ability. Finally, some variables will yield consistent measures more often 
than other variables. For example, academic achievem nt measures tend to have higher 
reliability compared to softer measures such as attitudes and personality which are often 
not as reliable (Ary, Jacobs, & Razavieh, 2002). 
D. Analysis of Data According to Research Questions 
Research Question 1 
Research Question 1 - What are oncology nurses’ attitudes toward the benefits of 
cancer clinical trials? This question was evaluated by the ATCR subscale. The nurses 
responded to these items using a 5-point Likert scale: 1 = strongly disagree; 2 = 
somewhat disagree; 3 = neither; 4 = somewhat agree and 5 = strongly agree. The 
outcome variables were created by summing across the items in each subscale. The mean 
summed scores were used for comparison. There are eight it ms that make up this 
subscale and the possible average score per respons are: 8 = strongly disagree, 16 = 
somewhat disagree, 24 = neutral, 32 = somewhat agree, and 40 = strongly agree. The 
possible range of scores is 8–40. The higher the score is, the more positive are the 
attitudes of nurses toward clinical research and clinical trials.  
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From this study population (N=301), 299 subjects responses were analyzed by the 
ACTR subscale. The mean and median scores obtained were 32, indicating, on the 
average, the oncology nurses had positive attitudes toward cancer clinical trials. When 
the mean and median values are the same number, it indicates that the sample distribution 
is symmetrical, as in a normal distribution curve (Stevens, 2002). The scores on the 
ATCR subscale ranged from 13 to 40.  
Research Question 2 
 Research Question 2 - What are nurses perceptions about how effective a 
research drug or experimental therapy should be before it is offered to patients? This 
question was evaluated by a single item on the NAS, item 15. This item states, “In your 
opinion, in order for a research drug or experimental therapy to be offered to patients, it 
should have at least ___________% chance of producing a desired effect (please insert a 
number).” In general, before a research drug or experimental therapy is offered to a 
patient, the subjects perceived that the benefit should be high, 288 (95.7%) answered this 
question. Approximately half of the respondents (49.7%) believed that a research drug or 
experimental therapy should have at least a 50% chance of benefiting the patient before 
being offered (M = 41.57, SD = 22.76). Subjects’ answers to Item 15 ranged from 0% to 
95%  
Research Question 3  
Research Question 3 - What are oncology nurses’ perce tions regarding patients’ 
understanding of clinical trials and the treatment r gimen? This question was evaluated 
by the PUK subscale, comprised of Items 12, 16, 17, 18, 19, 20, and 21. These items 
were evaluated using a 5-point Likert scale. The outcome variables were the sum scores 
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generated from the subscale, with a possible range of 7–35. Because there are seven items 
on this subscale, the possible average scores are: 7 = strongly disagree, 14 = somewhat 
disagree, 21 = neutral, 28 = somewhat agree, and 35 = strongly agree. A higher score 
suggests that nurses are more likely to believe that patients are well informed about 
clinical trials, understand the treatment regimen, and desire to be informed.  
 All 301 subjects completed the items on the PUK subscale. The mean score was 
27.6, and the median was 28, indicating this group f oncology nurses agreed that 
patients are well informed about clinical trials, understand the treatment regimen, and 
desire to be informed. The mean and median scores are ne rly identical indicating that 
the distribution of data are nearly symmetrical andfollow a normal distribution curve 
(Stevens, 2002).  
Research Question 4 
 Research Question 4 - What factors do nurses perceiv  influence a patient’s 
decision to participate in a cancer clinical trial? This question was evaluated by Item14 
on the NAS. The item asks, “Patients participate in research because of,” and there are 10 
subitems (letters A-J), with corresponding evaluations using a 5-point Likert scale. The 
10 subitems were ranked from highest to lowest according to the percentage of subjects 
who selected number 4 or 5 (somewhat agree or strongly agree) on the Likert scale. 
Ninety-three percent of nurses thought that patients participated in research with the 
expectation of cure; 87% reported that patients participated as a desire to help others; 
86% thought patients wanted an improved quality of life (see Table 11). 
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Table 11 
 Nurses’ Perceptions of Patient Motivation for Participation in Clinical Trials (N = 301) 
Motivation n % 
   Wish for cure 
 
280 93 
   Wish to help others 
 
262 87 
   Wish for improved quality of life 
 
261 86 
   Hope for better medical care 
 
229 76 
   No other option 
 
219 73 
   Inability to accept that nothing else can be done 
 
187 62 
   Family wishes 
 
169 56 
   Inability to accept death 
 
158 53 
   Desire to please their oncologist 
 
 85 28 
   Pressure from oncologist 
 
 39 13 
 
Research Question 5 
Research Question 5 - What are nurses’ perceptions of patients’ decision-making 
processes and the desire for information regarding cl ical trial participation? This 
question was addressed by Items 22, 23, 24, 25, and 26 of the INP subscale. After 
completing the factor analysis to confirm the items relationship with each other, the 
outcome variables were sum scored with a possible range of 5–25. The items on the INP 
scale were reverse coded (strongly agree = 1, somewhat agree = 2, neutral = 3, somewhat 
disagree = 4, and strongly disagree = 5). The possible cores for each Likert item follows: 
5 = strongly agree, 10 = somewhat agree, 15 = neutral, 20 = somewhat disagree, and 25 = 
strongly disagree, with a lower score suggesting that nurses perceive that patients have 
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enough information to make decisions regarding clinical trial participation. The minimum 
score on the INP subscale was 5 and the maximum 19. From the entire study population 
(N = 301), 299 (99.3%) responded to the items on the INP subscale. The mean score 
obtained was 10.9, and the median was 11, indicating that on average, this group of 
oncology nurses perceived that patients have enough information to make decisions 
regarding clinical trial participation. The mean and median scores almost are identical 
indicating that the distribution of data is nearly symmetrical and follows a normal 
distribution curve (Stevens, 2002).  
Research Question 6 
 Research Question 6 - What are the perceptions of urses regarding where 
clinical research should be conducted and the role of oncologists and nurses in clinical 
trials? This question was evaluated by the RL subscale, onsisting of items 2, 9, 10, and 
13. A 5-point Likert scale was used for these items. Items on the subscale were reverse 
coded, with strongly agree = 1, somewhat agree = 2, neutral = 3, somewhat disagree = 4, 
and strongly agree = 5. The outcome variables were sum scored with possible range of 4–
20. The possible average scores for each item are; 4 = strongly agree, somewhat agree = 
8, neutral = 12, somewhat disagree = 16, and strongly disagree = 20. A lower score 
suggests agreement with the items on the subscale, such as clinical research should be 
conducted only in cancer centers, oncologists and nurses put too much pressure on 
patients to participate in clinical trials, and patien s often are unaware that their treatment 
is part of a research protocol. Three hundred of the 301 subjects responded to the items 
on the RL subscale. The mean score was 15.4, and the median was 16, indicating this 
group of oncology nurses somewhat disagreed that clinical research should be conducted 
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only in cancer centers, oncologists and nurses put too much pressure on patients to 
participate in clinical trials, and patients often are unaware that their treatment is part of a 
research protocol. Consistent with the scores obtained on the ATCR, PUK, and INP 
subscales, the mean and median scores nearly are identical, indicating that the data follow 
a normal distribution curve (Stevens, 2002). 
Research Question 7 
 Question 7 - Do the independent variables of nurses’ age, education level, 
whether nurses directly work with clinical trial patients, number of years in oncology, 
primary work setting, and their primary position serve as significant predictors related to: 
1. Attitudes toward the benefits of cancer clinical trials, measured by ATCR 
subscale? 
2. Attitudes about how effective a research drug or experimental therapy should 
be shown to be before it is offered to patients, measured by Item 15 on the NAS? 
3. Perceptions regarding patients’ understanding of clinical trials and the 
treatment regimen, as measured by the PUK subscale? 
4. Perceptions of patients’ decision-making processes and the desire for 
information regarding clinical trial participation, as measured by the INP subscale? 
5. Perceptions regarding where clinical research should be conducted, patients’ 
awareness of their treatment, and the role of oncologists and nurses in clinical trials, as 
measured by the RL subscale? 
Oncology nurses’ attitudes toward the benefit of cancer clinical trials were 
evaluated by the ATCR subscale. Using the stepwise multiple regression method, nurse’s 
primary position entered the stepwise regression model as a significant predictor of 
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attitudes toward cancer clinical trials (as measured by the ATCR subscale), controlling 
for the other independent variables, F (1, 228) = 37.555, p <0.001. However, the R2 = 
0.141, indicated the model accounted for only 14.1% of variance in attitude scores. The β 
coefficient is 0.376, indicating primary position has a low effect on the ATCR subscale; 
however, the effect was statistically significant (t = 6.128, p<0.001) (see Table 12).  
Table 12 
Table 12 Stepwise Regression Model Summary for ATCR subscale 
Predictor R R2 R2adj Fchg p 
Primary 
position 
0.378 0.141 0.138 37.555 <0.001 
 B β t p 
Primary 
position 
1.466 0.376 6.128 <0.001 
 
 ANOVA demonstrated statistically significant differences between the mean 
scores of nurses grouped within the primary position variable, F (3,248) = 10.322, p = 
0.000 (Table 13).  This group included staff nurses, clinical trials nurses (CTN) , clinical 
nurse specialist/nurse practitioners (CNS/NP) and “other.”  
Table 13 




N M SD df F P 
Staff nurse 114 30.5 4.2 
CNS/NP   80 32.0 4.0 
CTN   17 33.6 2.9 
Other   41 34.1 3.5 
3, 248     10.322     0.000 
 
 A Bonferroni post-hoc multiple comparisons test between the primary position 
variables was conducted to determine which groups had statistically significant 
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differences in their mean ATCR scores (Table 14). CTN had statistically significant 
higher scores compared to staff nurses (p = 0.014) only. Nurses in “other” positions had 
significantly higher scores on the ATCR, compared to staff nurses and CNS/NP (p = 
0.000 and 0.026, respectively). 
Table 14 













ATCR subscale Staff nurse CNS/NP -1.4750 0.5734 0.064 
  CTN -3.1471(*) 1.0222 0.014 
  Other -3.6463(*) 0.7160 0.000 
 CNS/NP Staff nurse  1.4750 0.5734 0.064 
  CTN -1.6721 1.0500 0.675 
  Other -2.1713(*) 0.7551 0.026 
 CTN Staff nurse  3.1471(*) 1.0222 0.014 
  CNS/NP  1.6721 1.0500 0.675 
  Other -0.4993 1.1341 1.000 
 Other Staff nurse  3.6463(*) 0.7160 0.000 
  CNS/NP  2.1713(*) 0.7551 0.026 
  CTN  0.4993 1.1341 1.000 
* The mean difference is significant at < 0 .05 level. 
 Even though work setting was not a predictive variable for the ATCR subscale, 
nurses grouped by this setting also had significant differences in their ATCR scores, F 
(5,262) = 5.156, p = 0.000 (see Table 15).  This group included bone marrow 
transplant/intensive care unit nurses (BMTU/ICU), in-patient medical-surgical oncology 
unit and oncology specialty unit nurses (MSOU), hospital based clinic/infusion center 
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Table 15 
ANOVA for Primary Work Setting and ATCR Subscale 
Groups 
(work setting) 
N M SD df F P 









MDO 45 31.3 4.5 
CI 26 35.0 3.3 
Other 56 33.0 3.6 




To determine which of the five different practice setting groups had significant 
differences in their ATCR subscale scores, the datawere analyzed with a Bonferroni 
post- hoc multiple comparison test. Nurses who report d that they work in a 
corporate/industry (CI) work setting had significantly higher scores on the ATCR (M = 
35.0) compared to BMTU/ICU nurses (M = 30.7, p = 0.019), medical-surgical oncology 
unit (MSOU) nurses (M = 30.9, p = 0.000), and physician office (MDO) nurses (M = 
31.3, p = 0.003). Table 16 presents the results of the Bonferroni pairwise comparisons for 
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Table 16 













ATCR  BMTU/ICU MSOU -0.2111 1.1342 1.000 
    HBIC -1.4519 1.1663 1.000 
    MDO -0.5333 1.1914 1.000 
    CI -4.2282(*) 1.2956 0.019 
    Other -2.2488 1.1618 0.810 
  MSOU BMTU/ICU  0.2111 1.1342 1.000 
    HBIC -1.2407 0.7194 1.000 
    MDO -0.3222 0.7594 1.000 
    CI -4.0171(*) 0.9143 0.000 
    Other -2.0377 0.7120 0.068 
  HBIC BMTU/ICU  1.4519 1.1663 1.000 
    MSOU  1.2407 0.7194 1.000 
    MDO  0.9185 0.8066 1.000 
    CI -2.7764 0.9539 0.059 
    Other -0.7970 0.7621 1.000 
  MDO BMTU/ICU  0.5333 1.1914 1.000 
    MSOU  0.3222 0.7594 1.000 
    HBIC -0.9185 0.8066 1.000 
    CI -3.6949(*) 0.9844 0.003 
    Other -1.7155 0.8000 0.494 
  CI BMTU/ICU  4.2282(*) 1.2956 0.019 
  MSOU  4.0171(*) 0.9143 0.000 
  HBIC  2.7764 0.9539 0.059 
  MDO  3.6949(*) 0.9844 0.003 
  Other  1.9794 0.9483 0.567 
 Other BMTU/ICU  2.2488 1.1618 0.810 
   MSOU  2.0377 0.7120 0.068 
   HBIC  0.7970 0.7621 1.000 
   MDO  1.7155 0.8000 0.494 
   CI -1.9794 0.9483 0.567 
* The mean difference is significant at < 0 .05 level. 
 
Item 15 on the NAS asked subjects their perceptions on the effectiveness 
(expressed in percent benefit) of a research drug o experimental treatment before it is 
offered to patients. The multiple regression analysis revealed a significant model, primary 
position, years experience as a cancer RN, work setting, and educational level were 
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predictors of the nurse’s opinion of the effectiveness of a research drug or experimental 
treatment before being offered to a patient, F (4, 218) = 9.164, p = 0.000 . However, the 
R2 was 0.144, indicating the model has accounted for only 14.4% of the variance in 
perceived benefit estimates (see Table 17). 
Table 17 
Stepwise Regression Model Summary for Perception of Benefit  
Predictor R R2 R2adj Fchg p 
Primary position 
Years cancer RN 
Work setting 
Education level 
0.379 0.144 0.128 4.373 0.038 
 
Despite this model being statistically significant for predicting the opinion of the 
perceived benefit of the effectiveness a research drug or experimental treatment should 
have before being offered to a patient, the β r gression coefficients were low for each 
predictor variable (see Table 18). This indicates primary position, years in cancer 
nursing, work setting, and education level had a low effect on the perceived benefit. Only 
the effect of years a cancer RN, work setting, and education level were statistically 
significant (t = 2.091, p = 0.038; t = 2.417, p = 0.016; t = 2.091, p = 0.038 respectively).  
Table 18 
Stepwise Regression Coefficients for Perception of Benefit Model 
 B β t P 
Primary position 
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In addition to the variables of primary position, years as a cancer RN, work setting and 
educational level, being predictors of the nurses’ p rceptions of the benefit of 
effectiveness a research drug or experimental treatment should have before being offered 
to a patient, statistically significant differences were found between these groups of 
nurses’ responses when ANOVA was performed.  
Primary position. Staff nurses reported the highest perception of benefit regarding 
the effectiveness of a research drug or experimental therapy, before being offered to 
patients compared to nurses in other positions. According to the results from the ANOVA 
of primary position and the opinion of the benefit o  an  experimental treatment before 
being offered as part of cancer therapy, there were statistically significant differences in 
this group F (3, 239) = 8.499, p = 0.000 (see Table 19). 
Table 19 







































3, 239      8.499            0.000 
 
 The investigator performed a Bonferroni multiple comparisons for primary 
position and nurse’s opinion of the effectiveness of a research drug or experimental 
therapy before being offered to a patient (see Table 20). Staff nurses had significantly 
higher perceptions of the benefit a research drug o experimental therapy should have 
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before being offered to patients, compared to CNS/NPs (p = 0.000) and nurses in “other” 
positions (p = 0.004), but not between any other positions (seeTable 20).  
Table 20 
Bonferroni Multiple Comparisons for Primary Position and Perception of Benefit 
  * The mean difference is significant at < 0 .05 level. 
Number of years in cancer nursing. Nurses with 10 or less years of experience 
had the highest perception of benefit of cancer therapy prior to being offered as part of 
research. This group reported that a research drug,o  experimental therapy, should have 
at least a 46.2% (mean) chance of producing a desired effect before being offered to 
patients. In contrast, nurses with greater than 20 years experience in cancer nursing had 
the lowest perceived benefit. They reported that a therapy should have at least a 35% 
(mean) chance of producing the desired effect. Nurses with 11-20 years of experience in 
cancer nursing reported a research drug, or experimental therapy, should have at least a 
40.2% (mean) chance of producing the desired effect. The ANOVA for number of years 















Staff nurse CNS/NP  14.72(*) 3.31 0.000 
    CTN  13.09 5.93 0.169 
  Other  14.29(*) 4.12 0.004 
  CNS/NP Staff nurse -14.72(*) 3.31 0.000 
    CTN  -1.63 6.12 1.000 
  Other  -0.43 4.39 1.000 
  CTN Staff nurse -13.09 5.93 0.169 
    CNS/NP   1.63 6.12 1.000 
  Other   1.20 6.59 1.000 
 Other Staff nurse -14.29(*) 4.12 0.004 
  CNS/NP   0.43 4.39 1.000 
  CTN   -1.20 6.59 1.000 
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part of research revealed statistically significant differences between the three groups F 
(2, 281) = 5.318, p = 0.005 (see Table 21). 
Table 21 
ANOVA for Number of Years in Cancer Nursing and Perception of Benefit   
Groups 




SD df F P 
130 46.2 22.2 2, 281       5.318         0.005 
  98 40.2 23.1 
<1–10 
11–20 
>20   56 35.1 21.2 
 
 
In order to examine which group had statistically significant differences in their 
perception of benefit a research drug or experimental therapy should have before being 
offered to patients, a Bonferroni multiple comparison  test was performed (see Table 22). 
This test revealed that nurses with greater than 20 years experience had a statistically 
significant difference in their opinion compared to nurses with 10 years or less 
experience (p = 0.006), but not with nurses who had 11–20 years xperience (p = 0.522). 
Moreover, there was no a statistically significant difference in the opinions of nurses with 
10 or less years experience compared to nurses with 11–20 years experience (p = 0.134).  
Table 22 
Bonferroni Multiple Comparisons for Years in Cancer Nursing and Perception of Benefit 
* The mean difference is significant at < 0 .05 level. 
Dependent 
variable 







<1-10 11-20   6.03 2.99 0.134 
    >20  11.12(*) 3.57 0.006 
  11-20 <10  -6.03 2.99 0.134 
    >20   5.10 3.74 0.522 
  >20 <1-10 -11.12(*) 3.57 0.006 
    11-20  -5.10 3.74 0.522 
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Primary work setting. There were statistically significant differences found in the 
responses of the subjects, grouped by work setting, regarding the desired effect a research 
drug, or experimental therapy should have, before being offered to patients in the subjects 
grouped by work setting F (5, 253) = 6.450, p = 0.000 (see Table 23).  
Table 23 





SD Df F P 
14 48.9 24.4 
71 51.4 22.6 
51 35.1 20.1 
46 41.2 23.8 






OTHER 52 39.0 19.4 
 5, 253     6.450         0.000 
 
The nurses who reported that they worked in a corporate /industry (CI) setting had 
perceived a lower benefit (M = 27.2%) of the effectiveness a research drug or 
experimental therapy should have before being offered to patients, compared to all other 
nurses in this group. Furthermore, nurses who report d that they worked in an inpatient 
setting on a medical-surgical oncology unit or an oncology specialty unit (MSOU) had 
the highest perceived benefit (M = 51.4%), compared to other nurses in this group  
Nurses working in an inpatient setting on MSOU had a statistically significant 
higher perception of benefit of the effectiveness a research drug or experimental therapy 
should have before being offered to patients, compared to HBIC nurses (p = 0.001), to 
nurses in a CI setting (p = 0.000) and to nurses in other settings (p = 0.030). Nurses 
working in BMTU/ICU as well as MSOU nurses statistically had a significant higher 
perception compared to nurses in a corporate/industry se ting (p = 0.045 and p = 0.000, 
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respectively). All other comparisons between the groups were not statistically significant 
(see Table 24).  
Table 24 













Opinion BMTU/ICU MSOU   -2.44 6.36 1.000 
  HBIC  13.87 6.56 0.532 
  MDO    7.75 6.64 1.000 
  CI  21.73(*) 7.26 0.045 
  Other    9.95 6.55 1.000 
MSOU BMTU/ICU    2.44 6.36 1.000 
  HBIC  16.31(*) 3.99 0.001 
  MDO  10.19 4.11 0.209 
  CI  24.17(*) 5.06 0.000 
  Other  12.39(*) 3.97 0.030 
HBIC BMTU/ICU -13.87 6.56 0.532 
  MSOU -16.31(*) 3.99 0.001 
  MDO   -6.12 4.42 1.000 
  CI    7.86 5.31 1.000 
  Other   -3.92 4.28 1.000 
MDO BMTU/ICU   -7.75 6.64 1.000 
  MSOU -10.19 4.11 0.209 


















    CI  13.97 5.40 0.154 
  Other    2.19 4.40 1.000 
CI BMTU/ICU -21.73(*) 7.26 0.045 
  MSOU -24.17(*) 5.06 0.000 
  HBIC   -7.86 5.31 1.000 
  MDO -13.97 5.40 0.154 
  Other -11.78 5.29 0.403 
OTHER BMTU/ICU   -9.95 6.55 1.000 
  MSOU -12.39(*) 3.97 0.030 
  HBIC     3.92 4.28 1.000 







  CI   11.78 5.29 0.403 
* The mean difference is significant at <0.05 level. 
 Education level. Nurses with a bachelor’s degree had the highest perce tion of 
benefit of a research drug or experimental treatmen producing a desired effect before 
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being offered to patients (M = 47.4%, SD = 22.3), compared to other nurses in this 
sample. In contrast, nurses with a master’s degree or higher indicated the lowest 
perception of the three groups (M = 35.6%, SD = 21.1). There was a statistically 
significant difference in the responses of the three groups according to education 
preparation F (2, 284) = 8.087, p = 0.000 (see Table 25).  
Table 25 
ANOVA for Educational Level and Perception of Benefit 
     Education groups   N   M %   SD    df      F        P 
Diploma or associate’s   86 45.0 23.6 
Bachelor’s degree   79 47.4 22.3 
 
Master’s or higher 122 35.6 21.1 
  2, 284     8.8087      0.000 
  
 Nurses with a master’s degree or higher statistically h d a significant difference in 
their mean responses when compared to nurses with a bachelors degree and nurses with 
any degree less than a bachelor’s (p = 0.001, p = 0.009, respectively). This result 
indicates that nurses with a master’s degree or higher perceived the least necessary 
benefit compared to other nurses with lesser educational degrees.  They reported a 
research drug or experimental therapy should have a 35.6% (mean) chance of producing a 
desired effect before being offered to patients (see Table 26). 
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Table 26 
Bonferroni Multiple Comparisons for Education Level and Perception of Benefit 
  * The mean difference is significant <0.05 level 
 Nurse’s perception of patient knowledge and understanding of the treatment 
regimen was evaluated by the PUK subscale. Multiple regression analysis revealed 
nurse’s education level, work setting, and whether y work with clinical trial patients or 
not were significant predictors of their perceptions of patient knowledge and 
understanding, F (3, 228) = 4.846, p = 0.003. The R2 was 0.060, indicating the model 
accounted for only 6% of the variance in perceptions (see Table 27). 
Table 27 
Stepwise Regression Model Summary for PUK subscale 
Predictors R R2 R2adj Fchg p 
Education level,  
Work setting, 
Trials 
0.245 0.060 0.048 5.705 0.018 
 
The β regression coefficients for the model were low (see Table 28), indicating 
educational level, work setting, and working with clini al trial patients or not had a low 
Dependent 
variable 















  9.34(*) 3.13 0.009 
  Bachelor’s Diploma or 
associates 





11.76(*) 3.21 0.001 
Master’s or higher Diploma or 
associates 
 -9.34(*) 3.13 0.009   
  
  Bachelor’s 11.76(*) 3.21 0.001 
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effect on perceptions. However, the effect of education level, work setting and whether 
they work with clinical trial patients or not was significant (t = 2.432, p = 0.016; t = 
2.442, p = 0.015; and t = 2.388, p = 0.00018, respectively). 
Table 28 
Stepwise Regression Coefficients for PUK Model 








   0.159 








Despite education level being a significant predictor for oncology nurses’ 
perceptions regarding patients’ understanding of clinical trials and the treatment regimen, 
there were no significant differences between the scores on the PUK subscale in this 
group. However, after performing ANOVA for nurses working with clinical trial patients 
or not, and nurses grouped by work setting revealed significant differences in their scores 
on the PUK subscale. 
 Working with clinical trial patients. Nurses who work with clinical trial patients 
had a higher mean score on the PUK subscale compared to nurses who do not (27.9 and 
26.5, respectively), indicating that nurses who work with clinical trial patients perceive 
patients understand their treatment goals, plan, and prognosis, and their wishes are 
respected by oncologists and nurses. The differences i  their scores were statistically 
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Table 29 
ANOVA for Working with Clinical Trial Patients or Not and PUK Subscale 
Groups 
 
N M    SD Df F P 
No   51 26.5 4.5 
Yes 249 27.9 3.6 
1,298     5.292     0.022 
 
Work setting. Two groups of nurses reported they worked in an outpatient setting, 
HBIC and MDO nurses, had higher scores on the PUK (28.8 and 28.2, respectively) 
compared to the other nurses. This result suggests HBIC and MDO nurses perceive that 
patients are well informed when they participate in cl ical trials and patients understand 
their treatment plan and prognosis, compared to BMTU/ICU, MSOU, and CI nurses. The 
nurses working in BMTU/ICU, MSOU, CI and nurses in other settings all had similar 
scores on the PUK (26.2, 27.0, 26.5, and 28.0, respectively). ANOVA was calculated for 
differences between the subjects grouped by work setting and a statistically significant 
difference was found, F (5, 264) = 2.516, p = 0.030 (see Table 30). 
Table 30 
ANOVA for Work Setting and PUK Subscale 
Groups 
(work setting) 
N M  SD df F P 






HBIC 54 28.2 3.6 
MDO 46 28.8 4.1 
CI 26 26.5 4.3 
Other 56 28.0 3.2 
  5, 264         2.516           0.030 
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Despite finding a statistically significant difference in the groups’ scores by 
ANOVA, surprisingly the Bonferroni post-hoc multiple comparisons test failed to 
identify which group differed from which. This discrepancy may be explained by two 
factors. First, the variance between groups is not big enough to make a difference. With 
unequal sample sizes within each group, the small differences between groups may be 
cancelled in the post-hoc, pairwise comparisons. Secondly, the more groups that have a 
large variation in sample size, the harder it is to detect significant differences between 
groups, especially with a rigorous and conservative test such as Bonferroni to avoid type 
I error (Keppel & Wickens, 2002). 
The INP subscale measured nurse’s perceptions of patients’ perceptions of the 
treatment and research process and influences in patients’ decisions. As stated above, the 
items on this subscale were reverse coded (strongly agree = 1, somewhat agree = 2, 
neutral = 3, somewhat disagree = 4, and strongly disagree = 5) with a lower score 
suggesting that nurses perceive that patients have enough information to make decisions 
regarding clinical trial participation. 
The multiple regression analysis revealed a significant model, whether nurses 
work with clinical trials patients or not, F (1, 228) = 5.798, p =.017. The R2 = 0.025, 
indicating the model accounted for only 2.5% of the variance in perceptions (see Table 
31). 
Table 31 
Stepwise Regression Model Summary for INP Scale  
Predictor R R2 R2adj Fchg p 
 Trials 0.157 0.025 0.021 5.798 0.017 
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 The β regression coefficient for the predictor variable was 0.157 (see Table 32). 
This indicates that the variable (nurse’s working with clinical trial patients or not) had a 
low effect on perceptions, as measured by the INP subscale despite a statistically 
significant multiple regression model. 
Table 32 
Stepwise Regression Coefficients for INP Model 
Predictor B β t P 
 Trials 1.058 0.157 2.408 0.017 
 
 Nurses grouped by whether or not they work with clini al trial patients was the 
only significant predictor of perceptions of patiens’ decision-making process and desire 
for clinical trial information. However, in evaluating differences in the mean scores 
among the oncology nurses in this study grouped by the independent variables, 
statistically significant differences were found in this group and nurses grouped by work 
setting. 
 Working with clinical trial patients. Nurses who reported that they do not work 
with or care for clinical trial patients had a lower score (M = 10.1), compared to nurses 
who do (M = 11.0). This result suggests nurses who do not work ith clinical trial 
patients perceive that most patients pay more attention to potential benefits of therapy 
than side effects, oncologists believe that patients are willing to accept side effects for a 
small therapeutic benefit, patients are frightened to ask questions, and patients’ decisions 
are influenced by their family’s preferences, compared to nurses who do work with 
clinical trial patients. This difference was statistically significant, F (1, 296) = 5.872, p = 
0.016 (see Table 33).  
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Table 33 
ANOVA for Working with Clinical Trial Patients or Not and INP Subscale 
Groups 
 
N M SD df F P 
No   50 10.1 2.4 
Yes 248 11.0 2.6 
1, 296     5.872    0.016 
 
 Work setting. There were statistically significant differences in the scores on the 
INP subscale between nurses based upon their work setting, F (5, 262) = 2.762, p = 0.019 
(see Table 34). 
Table 34 





N M SD Df F P 
BMTU/ICU 15 9.5 2.6 
MSOU 73 10.8 2.2 
HBIC 54 11.0 2.5 
MDO 45 11.9 3.0 
CI 26 10.9 2.5 
 
Other 55 10.5 2.6 




 Nurses working in BMTU/ICU had a lower score (M = 9.5) on the INP subscale 
compared to all other nurses by work setting. This indicates that BMTU/ICU nurses 
perceive, more than the other four groups, that patients are willing to accept side 
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effects, pay more attention to the benefits of therapy, have their decisions influenced by 
their families and are frightened to ask questions. There were statistically significant 
differences in the scores of BMTU/ICU nurses (M = 9.5) compared to MDO nurses (M = 
11.9, p = 0.025). There were no statistically significant differences in the mean scores of 
the other subjects (see Table 35).  
Table 35 





(J) Work setting Mean 
difference (I-
J) 
Std. error P 
INP Subscale BMTU/ICU MSOU -1.2475 0.7171 1.000 
    HBIC -1.4481 0.7383 0.763 
    MDO -2.4000(*) 0.7541 0.025 
    CI -1.3513 0.8201 1.000 
    Other -0.9212 0.7368 1.000 
  MSOU BMTU/ICU   1.2475 0.7171 1.000 
    HBIC -0.2007 0.4540 1.000 
    MDO -1.1525 0.4794 0.254 
    CI -0.1038 0.5777 1.000 
    Other   0.3263 0.4516 1.000 
  HBIC BMTU/ICU   1.4481 0.7383 0.763 
    MSOU   0.2007 0.4540 1.000 
    MDO -0.9519 0.5106 0.951 
    CI   9.687E-02 0.6038 1.000 
    Other   0.5269 0.4846 1.000 
  MDO BMTU/ICU   2.4000(*) 0.7541 0.025 
    MSOU   1.1525 0.4794 0.254 
    HBIC   0.9519 0.5106 0.951 
    CI   1.0487 0.6231 1.000 
    Other   1.4788 0.5084 0.059 
 CI BMTU/ICU   1.3513 0.8201 1.000 
   MSOU   0.1038 0.5777 1.000 
   HBIC -9.6866E-02 0.6038 1.000 
   MDO -1.0487 0.6231 1.000 
   Other   0.4301 0.6020 1.000 
 Other BMTU/ICU   0.9212 0.7368 1.000 
   MSOU -0.3263 0.4516 1.000 
   HBIC -0.5269 0.4846 1.000 
   MDO -1.4788 0.5084 0.059 
   CI -0.4301 0.6020 1.000 
* The mean difference is significant at <0.05 level 
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The RL subscale evaluated nurses’ perception of patients’ awareness of their treatment 
and the role of oncologists and nurses in clinical tri s. As with the INP subscale, the RL 
subscale was reverse coded (strongly agree = 1, somewhat agree = 2, neutral = 3, somewhat 
disagree = 4, and strongly disagree = 5) with a lower score suggesting that nurses perceive 
clinical research should only be conducted primarily in cancer centers, oncologists and nurses 
put too much pressure on patients to participate in clinical trials, and that patients often are 
unaware that their treatment is part of a research p otocol.  
The multiple regression demonstrated that, years of experience as a cancer RN and 
whether a nurse works with clinical trial patients as predicators of the perception measured by 
the RL subscale, F (2, 229) = 6.813, p=.001. The R2 = 0.056 indicating the predictor variables 
accounted for only 5.6% of the variance of perceptions (see Table 36). 
Table 36 
Stepwise Regression Model Summary for RL Subscale  
Predictors R R2 R2adj Fchg p 
Years cancer RN 
Trials 
0.237 0.056 0.048 4.630 0.032 
 
 The β regression coefficients for the predictor variables of years experience as a cancer 
RN and whether a nurse worked with clinical trial ptients were low (0.182 and 0.139, 
respectively) (see Table 37). This indicates that while there was statistical significance of the 
predictor variables, the variables had a low effect on he measurement of perceptions measured 
by the RL subscale. However, the effect was statistically significant for number of years as a 
cancer RN and whether or not nurses work with clinical trial patients (t = 2.830, p = 0.005 and 
t = 2.152, p = 0.32, respectively). 
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Table 37 
Stepwise Regression Coefficients for RL Model 
Predictors   B    β   t   P 











There were significant differences in the mean scores measured by the RL subscale in the 
nurses grouped by years as a cancer RN and whether or not nurses work with clinical trial 
patients, but not in any other variables. 
Working with clinical trial patients.  The ANOVA for this variable demonstrated a 
statistically significant difference in mean scores of nurses who do and do not work with 
clinical trial patients, F (1,297) = 10.165, p = 0.002 (see Table 38).  
Table 38 
ANOVA for Working With Clinical Trial Patients or Not and RL Subscale 
RL subscale Groups 
 
N M SD  df F P 
No   51 14.4 2.8  
Yes 248 15.6 2.5 
1, 297   10.165      0.002 
 
Nurses who do not work with or care for clinical trial patients had lower scores on the 
RL subscale (M = 14.4), compared to nurses who do (M = 15.6). This result suggests nurses 
who do not work with clinical trial patients perceiv  that clinical research should be conducted 
only in cancer centers, oncologists and nurses put too much pressure on patients to participate 
in clinical trials, and patients are often unaware that their treatment is part of a research 
protocol, compared to nurses who do work with clinial trial patients.  
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Years experience in cancer nursing. Nurses with less that one to ten years of 
experience in cancer nursing had lower scores on the RL subscale (M = 14.8), compared to 
nurses with nurses with 11-20 years of experience (M = 15.8) and nurses with greater than 20 
years of experience (M = 15.9). The differences between groups were statistically significant as 
measured by ANOVA, F (2,294) = 6.027, p = 0.003 (see Table 39).  
Table 39 
ANOVA for Years in Cancer Nursing and RL Subscale 
RL subscale Groups 
years a cancer RN 
N M  SD df F P 
<1–10 136 14.8 2.7 
11–20   98 15.8 2.6 
 
>20   62 15.9 2.4 
2, 294     6.027      0.003 
 
Nurses with less that one to ten years of experience in ancer nursing had a statistically 
significant difference in their mean score on the RL subscale, compared to nurses with 11–20 
years of experience and nurses with greater than 20 years of experience (p = 0.013, p = 0.014, 
respectively). Nurses with <1-10 years experience, on average, perceived that clinical research 
should be conducted only in cancer centers, oncologists and nurses put too much pressure on 
patients to participate in clinical trials, and patien s are often unaware that their treatment is 
part of a research protocol, compared to nurses with 11 years or greater experience in cancer 
nursing (see Table 40).  
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Table 40 
Bonferroni Multiple Comparisons for Years in Cancer Nursing and RL Subscale 
Dependent 
variable 
(I) Years cancer 
RN 








RL Subscale <1–10 11–0 -0.9696(*) 0.3361 0.013 
 >20 -1.1049(*) 0.3888 0.014 
11–20 <1–10  0.9696(*) 0.3361 0.013 
 >20 -0.1353 0.4122 1.000 
>20 <1–10  1.1049(*) 0.3888 0.014 
 
 11–20  0.1353 0.4122 1.000 
* The mean difference is significant at <0.05 level. 
 
Additional Information 
The following information was not part of the research questions; however, interesting 
data related to individual items within the subscales were found. Although 98.3% of the 
subjects agreed that clinical research was important in improving future standards of care and 
75.4% agreed that patients should be encouraged to participate in research, only 51.5% of 
subjects responded that they would prefer treatment in a clinical trial if they had cancer.  
 The nurses in this study drew distinctions between th mselves and oncologists in terms 
of patient decision-making. Ninety-eight percent of he nurses stated that nurses respected 
patients’ wishes, whereas 82.7% thought that oncologists respected patients’ wishes. Overall, 
8.6% of the nurses agreed with the statement “oncolgists put too much pressure on patients to 
participate in clinical trials.” Only 3.3% of the nurses agreed with the statement that “nurses 
put too much pressure on patients to participate in clinical trials.” 
 The nurses expressed minor concern about patients’ u derstanding of treatment and 
prognosis. Approximately three quarters of the nurses perceived that patients understand their 
plan of care (76.4%). Eighty-seven percent of all nurses thought that patients want to be 
informed, and 80.7% thought that patients actually were well informed when they chose to 
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participate in a clinical trial. Twenty percent of the nurses disagreed, and 68% agreed with the 
statement “patients understand their prognosis and goals of therapy.” Only 58% of the nurses 
agreed that patients’ prognosis are well explained to them. Overall, 11% of the nurses agreed 
with the statement “patients are often unaware that their treatment is part of a research 
protocol.” Finally, 66% of the nurses responded that patients are frightened to ask questions. 
E. Summary of Results 
 The nurses in this study, on average, had positive a titudes toward cancer clinical trials. 
They perceived high benefit levels were necessary before a research drug or experimental 
therapy is being offered to patients. Approximately half of the respondents (49.7%) believed 
that an experimental therapy should have at least a 50% chance of producing a desired effect, 
before being offered to patients. In general, the nurses perceived that patients are well informed 
about clinical trials, understand the treatment regim n, and have a desire to be informed. On 
average, this group of oncology nurses perceived that patients have enough information to 
make decisions regarding clinical trial participation. They somewhat disagreed that; clinical 
research should be conducted only in cancer centers, oncologists and nurses put too much 
pressure on patients to participate in clinical trils, and patients are often unaware that their 
treatment is part of a research protocol. 
 Stepwise multiple regression models found the following significant predictors to 
attitudes and perceptions. Primary position was a significant predictor for attitudes toward 
cancer clinical trials as measured by the ATCR subscale. CTN had more positive attitudes 
compared to staff nurses, but not other nurses in this group. Nurses in “other” positions had 
more positive attitudes compared to staff nurses and CNS/NP. Additionally, nurses who 
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reported that they work in a CI work setting had more positive attitudes toward cancer clinical 
trials compared to BMTU/ICU nurses, MSOU nurses, and MDO nurses. 
Primary position, years as a cancer RN, work setting a d educational level were 
significant predictors of the perception of the benefit a cancer therapy should offer if included 
in a clinical trial. Staff nurses had the highest expectations regarding the effectiveness of 
cancer therapy offered as part of a clinical trial, compared to nurses in other positions. The 
differences were statistically significant between staff nurses compared to CNS/NPs and nurses 
indicating “other” as position on the DIF, but not among any other nursing positions.  
Nurses with 10 or fewer years of experience as a nurse in cancer care had the highest 
perception of benefit regarding the effectiveness of cancer therapy to be offered as part of 
research. In contrast, nurses with greater than 20 years of experience in cancer nursing had the 
lowest perception. There was a statistically signifcant difference in their opinions compared to 
nurses’ with 10 years or less experience, but not with nurses who had 11–20 years of 
experience. Moreover, there was no statistically significant difference in the opinions of nurses 
with 10 or fewer years of experience compared to nurses with 11–20 years of experience. 
Nurses who reported that they work in a CI setting had the lowest expectations of the 
effectiveness of cancer therapy offered as part of a clinical trial compared to all other nurses. 
Furthermore, nurses who reported they work in an inpatient setting on a MSOU had the highest 
expectations compared to other nurses. There were statistically significant differences in the 
opinion of nurses working on a MSOU compared to HBIC nurses, nurses in a CI setting and to 
nurses in indicating “other” work setting on the DIF. Nurses working in BMTU/ICU as well as 
MSOU nurses had statistically significant higher expectations, compared to nurses in a CI 
setting.  
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 Nurses with a bachelor’s degree perceived the highest benefit of an experimental 
treatment producing a desired effect before being offered to patients compared to the other 
nurses in this group. This was in contrast to nurses with a master’s degree or higher who 
indicated the lowest perception of benefit of the tree groups. The nurses with a master’s 
degree or higher had a statistically significant difference in their mean responses, compared to 
nurses with a bachelor’s degree or less. 
 Multiple regression analysis revealed nurse’s education level, work setting, and 
whether they worked with clinical trial patients or not were significant predictors of their 
perception of patient knowledge and understanding. Compared to nurses who do not work with 
clinical trial patients, nurses who work with clinical trial patients perceive that patients 
understand their treatment goals, plan and prognosis and that their wishes are respected by 
oncologists and nurses. The differences in the PUK subscale scores were statistically 
significant. When grouped by work setting, nurses who reported they worked in an outpatient 
setting (HBIC and MDO) had higher scores on the PUK compared to the other nurses. Even 
though the ANOVA was statistically significant for the group, the post-hoc multiple 
comparison test failed to reveal which work settings explained significant differences. 
The variable of whether a nurse works with clinical trial patients or not was a 
significant predictor for perceptions of informational needs of patients, as measured by the INP 
subscale. Nurses who work with, or care for, clinical trial patients had a statistically significant 
higher score compared to nurses who do not. This ind cates that nurses who do not work with 
clinical trial patients perceive that patients are willing to accept side effects, pay more attention 
to the benefits of therapy, have their decisions influenced by their families and are afraid to ask 
questions. Additionally, statistically significant differences in the INP mean scores were found 
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between the nurses by work setting groups. BMTU/ICU nurses perceive, more than the other 
four groups, that patients are willing to accept side effects, pay more attention to the benefits of 
therapy, have their decisions influenced by their families and are afraid to ask questions. There 
were statistically significant differences in their scores on the INP subscale compared to MDO 
nurses.  
The variables, number of years experience as a cancer RN and whether or not a nurse 
works with clinical trial patients, were significant predicators of the RL subscale.  Specifically, 
differences existed in the perception that nurses have regarding where clinical research should 
be conducted, patients’ awareness of their treatments, a d the role of oncologists and nurses in 
clinical trials. Significant differences were found in the mean scores of nurses who do not work 
with, or care for, clinical trial patients compared to nurses who do. This suggests nurses who 
do not work with clinical trial patients perceive tha  clinical research should be conducted only 
in cancer centers, oncologists and nurses put too much pressure on patients to participate in 
clinical trials, and patients often are unaware that eir treatment is part of a research protocol, 
compared to nurses who work with clinical trial patien s. Finally, nurses with ten or fewer 
years of experience, on average, perceived that clinica  research should be conducted only in 
cancer centers, oncologists and nurses put too muchpressure on patients to participate in 
clinical trials, and patients are often unaware that eir treatment is part of a research protocol, 
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CHAPTER V: DISCUSSION AND RECOMMENDATIONS 
A. Summary and Discussion of Results  
Demographics 
The following information regarding the demographic characteristics of the sample is 
noteworthy. In terms of gender, this sample was consistent with the membership of ONS, the 
majority of ONS members are female and only 3% of its members are male (Brown, 2003; 
Kristina Gantner, Personal Communication, July 19, 2006). In this study (N = 301), 98% (n = 
295) of the subjects were female and 2% (n = 6) were male. Both the sample and the ONS 
membership reflected the general nursing population with the majority over the age of 40 
(Buerhaus, 2002). Sixty-six percent of ONS members are over the age of 40 (Kristina Gantner, 
Personal Communication, July 19, 2006).  
 The proportion of master’s prepared nurses in this study is a larger proportion than 
reported in the ONS membership (ONS, 2004). Nurses in this study with a master’s degree (in 
nursing or any other discipline) as their highest education level, (n = 85) represented 28.2% of 
the sample. The proportion of subjects with the diploma and associate’s degree and bachelor’s 
degrees in nursing in this study was lower than that of the ONS membership.  
 The major certification category of subjects was OCN®, with 46.5% of the subjects (n
= 140) reporting that they had this credential. This is comparable to the proportion of OCN® 
certified nurses in the ONS membership where 46% report that they have this credential 
(Kristina Gantner, personal communication, July 19, 2006).  
The largest primary work area reported in the study was the outpatient setting 47.3% (n 
= 141), which is similar to the ONS membership, 51% (Kristina Gantner, personal 
communication, July 19, 2006). The proportion of nurses working in an in-patient setting was 
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38.9% (n = 116), which was also similar to the ONS membership, 39%. Finally, the largest 
proportion of subjects reported that their primary position was staff nurse, 38.5% (n = 116). 
Proportionally, this is similar to the ONS membership in which staff nurses make up the largest 
position (Kristina Gantner, personal communication, July 19, 2006).   
Relevance of Research to Prior Literature 
Research Question 1.– What are oncology nurses’ attitudes toward the benefits of cancer 
clinical trials? The only statistically significant differences found in attitudes toward cancer 
clinical trials were between nurses grouped by prima y position and work setting. Nurses who 
reported they work in a corporate/industry (CI) setting had a more positive attitude compared 
to nurses in bone marrow transplant/intensive care unit (BMTU/ICU), in-patient medical-
surgical oncology unit/oncology specialty unit (MSOU) and physician office (MDO). Clinical 
trials nurses (CTN) and nurses who reported “other” for primary position on the DIF had more 
positive attitudes compared to staff nurses. Additionally, nurses who reported “other” for 
primary position had a more positive attitude compared to clinical nurse specialists/nurse 
practitioners (CNS/NP).  
Burnett et al. (2001) reported in their study that research nurses had statistically 
significantly higher mean scores on their attitude subscale, compared to BMTU/ICU nurses, 
who had the lowest mean scores on attitudes toward clinical trials. There are several reasons 
for the differences found in the measurement of oncology nurses’ attitudes between Burnett et 
al. (2001) and this study. First, Burnett et al. (2001) had one demographic question that asked 
nurses to indicate their main area of work (i.e., inpatient floor [not ICU/BMTU], ICU or 
BMTU, research nurse, etc.). The demographic independent variables in this study were set a 
priori and separated work setting and primary position (2 questions on the DIF), which is 
                                                               
  
118 
                                                                                                                                  
identical to the way the 2006 ONS membership application captures this information. 
Therefore, nurses who indicated they work in BMTU/ICU setting were captured under the 
primary work setting variable and clinical trial nurses (research nurses) were captured under 
primary position variable. It is interesting to note that clinical trial nurses in this study had a 
higher mean score (33.6) than BMTU/ICU nurses (30.7) on the ATCR subscale.  This result 
suggests that clinical trial nurses, in this study, had more positive attitudes toward the benefit 
of cancer clinical trials compared to BMTU/ICU nurses.  The clinical trial nurses, on average, 
agreed more than BMTU/ICU nurses, that clinical research improves standards of care, 
patients should participate in research, and would participate in a clinical trial if they had 
cancer. However, because they were part of two different independent variables, they were not 
tested against one another with ANOVA. Another reason for the differences in nurses’ 
attitudes in this study compared to results described by Burnett et al. (2001) could be related to 
the subscales used to measure attitudes toward clinical trials. Burnett et al. (2001) used six 
items from the NAS to make up their subscale. This study used eight items to measure nurses’ 
attitudes toward clinical trials, the same six items as in Burnett et al. (2001) plus two additional 
items that factored together to make up the ATCR subscale. 
Research Question 2.– What are nurses’ perceptions about how effective a r search 
drug or experimental therapy should be before it is offered to patients? Consistent with the 
study by Burnett et al. (2001) this study found nurses perceived the benefit of an experimental 
therapy should be high prior to being offered to patients. This perceived benefit exceeded the 
historical effectiveness of experimental anticancer agents. There have been significant 
improvements in treatment for patients with advanced cancer over the past 5 years with 
improvements in overall response rates and survival; yet the rates of complete responses have 
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been lower than 10% for these palliative treatments (Chu & DeVita, 2005). For earlier stage 
cancers the absolute improvements in survival are also small. For example, adjuvant 
chemotherapy for breast cancer achieves absolute 10 y ar reductions in breast cancer mortality 
of 5.3% for lymph node positive disease and 12.2% for lymph node negative disease (Early 
Breast Cancer Trialists’ Collaborative Group [EBCTCG], 2005). Additionally, in a pooled 
analysis of Stage II and III colon cancer patients, overall survival was increased form 64% to 
71% with fluorouracil-based chemotherapy, an absolute improvement of 7% (Gill et al., 2004).  
Studies evaluating perceptions of the benefits of investigational treatments among 
patients with cancer also have demonstrated high expectations regarding clinical cancer 
research (Cassileth et al., 1982; Cheng et al., 2000; Daugherty et al., 1995; Meropol et al., 
2003). For example, Meropol et al. (2003) reported that 77% (252 of 338) of patients entering a 
Phase I cancer clinical trial estimated their chance of benefit being at least 50%. The 
expectations of nurses in this present study parallel these findings.  
In this study, nurses with educational degrees other than master’s or doctorate’s had 
significantly higher perceptions of the effectiveness a research drug or experimental treatment 
should have before being offered to a patient, compared to nurses with master’s degrees or 
higher. Additionally, nurses with fewer than 1–10 years experience as a cancer RN had 
significantly higher perceptions of benefit compared to nurses with greater than 20 years 
experience. Nurses grouped by work setting also demonstrated significant differences in their 
perceptions. Nurses working in MSOU had significantly higher perceptions compared to 
nurses in HBIC. Nurses in BMTU/ICU and MSOU had significantly higher perceptions 
compared to nurses in the corporate or industry setting. Nurses who work in MSOU reported 
higher perceptions compared to nurses who reported “o her” for work setting on the DIF. 
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Finally, staff nurses had significantly higher expectations compared to CNS/NP and nurses 
who reported “other” for primary position on the DIF.  
Why nurses with fewer than 1–10 years experience as a cancer RN had significantly 
higher perceptions of benefit compared to nurses with greater than 20 years experience is 
unclear.  One explanation may be that the longer an oncology nurse is in practice, the more 
experience they may have with clinical trials, and, as a result, they have seen experimental 
therapies produce benefits in the single digits.  The investigator was unable to identify other 
research addressing this issue.   
Burnett et al. (2001) reported that research nurses believed a new therapy should have a 
25% (median) chance of benefit before entering a clinical trial. For BMTU/ICU nurses, 
outpatient and inpatient nurses, and operating room nurses, the response median was 50%. The 
use of reporting the median response in the study by Burnett et al. (2001) makes it difficult to 
compare to the present study which reported mean response. Mean responses were used 
because ANOVA tests for significant differences in mean scores between groups as opposed to 
a median score. 
Research Question 3.– What are oncology nurses’ perceptions regarding patients’ 
understanding of clinical trials and the treatment r gimen? Statistically significant differences 
were found in the mean scores on the PUK subscale in nurses who worked with clinical trial 
patients compared to those who did not. The only other group that demonstrated significant 
differences in their perceptions of patient understanding and knowledge of the treatment 
regimen was the variable of work setting. Surprisingly, the post hoc test for multiple 
comparisons failed to demonstrate which of the work settings (nurses who reported being 
employed in these work settings) had significant differences in their PUK scores. However, 
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nurses in MDO had the highest mean score compared to all other nurses in this group. This 
indicates that these nurses had greater agreement with i ems relating to patients understanding 
their treatment goals, plan and prognosis, and their wishes being respected by oncologists and 
nurses compared to other nurses. These findings may reflect MDO nurses’ involvement with 
patient education.  In many oncology physicians’ offices, the nurse provides additional 
education related to the treatment goals. Perhaps MDO nurses had more extensive experience 
observing physicians providing patients with information. 
Daugherty et al. (1995) conducted a pilot survey study of 30 cancer patients who had 
given informed consent to participate in a Phase I clinical trial. Concurrently, the oncologists 
identified by the surveyed patients as responsible for their care were surveyed as well. 
According to Daugherty et al. (1995) cancer patients who participate in Phase I clinical trials 
appear to have an adequate self perceived knowledge of th  risks of experimental therapy; 
however, only a minority has an adequate understanding of the purpose of these trials.  
Research Question 4.– What factors do nurses perceive influence a patients’ decision 
to participate in a cancer clinical trial? Nurses’ perceptions of patient expectations and reports 
of patient expectations of the outcomes of a cancer clinical trial are consistent. There was 
agreement between this study and other studies (Daugherty et al., 1995; Yoder et al., 1997; 
Meropol et al., 2003) on several factors that nurses believed influenced patient participation in 
clinical trials. Ninety-three percent of nurses in this study reported that patients entered a 
clinical trial with a belief of a cure for their cancer. According to published literature, which 
examined patients’ perceptions and motivations to participate in Phase I cancer clinical trials, 
most patients with cancer reported that their decision to participate in a Phase I clinical trial 
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was based on the hope of therapeutic benefits (Daugherty et al., 1995; Schuta & Burnett, 2000; 
Yoder et al., 1997).  
Daugherty et al. (1995) conducted a pilot survey study of 30 cancer patients who had 
given informed consent to participate in a Phase I clinical trial. Concurrently, 18 oncologists 
identified by the surveyed patients as responsible for their care were surveyed as well. 
Daugherty et al. (1995) reported that 85% of patients decided to participate in a Phase I clinical 
trial for reasons of a possible therapeutic benefit.  
Consistent with this finding, Yoder et al. (1997) described the expectations and 
experiences of patients entering Phase I clinical studies. A convenience sample of 37 patients 
who already had agreed to participate in a Phase I clinical trial were interviewed using 
structured entry and exit questionnaires. Yoder et al. (1997) reported at the time patients 
entered a clinical trial, 85% expected a decrease in tumor size. Although these studies did not 
specifically address the issue of “cure,” an expectation of tumor shrinkage and expectation of 
cure were viewed by patients as an expectation of therapeutic benefit from a clinical trial.  
Schuta and Burnett (2000) explored the factors that influenced a patient’s decision to 
participate in a Phase I cancer clinical trial. Two focus groups were conducted with six patients 
participating in the first and two patients in the second focus group (total N = 8). The authors 
reported that participants in their study expressed hope for a cure and trusting the oncologist’s 
advice as the primary factors for participating in a Phase I clinical trial. The majority (87.5%, n 
= 7) expressed surprise that anyone would participae in an experimental study for altruistic 
reasons. Moreover, Meropol et al. (2003) described and compared the perceptions of cancer 
patients and their physicians regarding Phase I clinical trials. Eligible patients had been offered 
participation in a Phase I trial but had not yet begun treatment. Each patient’s physician also 
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served as a study subject. Forty eight physicians and 128 patients completed surveys with 
domains including perceptions of potential benefit and harm from treatment (experimental and 
standard), relative value of quality and length of life, and perceived content of patient-
physician consultations. Meropol et al. (2003) repoted that 39% of patients entering a Phase I 
trial believed they would be totally cured; 26% believed their cancer would be reduced, and 
30% believed it would be controlled.  
Research Question 5.– What are nurses’ perceptions of patients’ decision-making 
processes and the desire for information regarding cl ical trial participation? The nurses’ 
perceptions of patients’ perceptions of the treatmen  and research process and influences in 
patient’s decisions were measured by the INP subscale. The INP subscale was reverse coded; 
therefore a lower score indicated more agreement with the items on the subscale. This 
translates to a lower score indicating more agreement with statements that patients are 
frightened to ask questions, patients decisions regarding therapy is strongly influenced by their 
family preferences, and patients are willing to accept side effects for a small benefit in therapy. 
Two groups emerged as having significant differences in their perceptions, whether nurses 
work with clinical trial patients (or not), and work setting. Nurses who reported they did not 
work with clinical trial patients had a significantly lower mean score than nurses who did, and 
BMTU/ICU nurses had a significantly lower mean score compared to MDO nurses but not to 
nurses in any other work setting.  This indicates that BMTU/ICU nurses agreed more with 
statements that patients are frightened to ask questions, patients decisions regarding therapy is 
strongly influenced by their family preferences, and patients are willing to accept side effects 
for a small benefit in therapy.  This may be inherently related to the type of nurse-patient 
relationship in the BMTU/ICU setting.  Patients usually are more gravely ill, and may, be 
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incapable or less interested in having treatment rela ed knowledge (Ende, Kazis, Ash, & 
Moskowitz, 1989; Leydon et al., 2000).  
Research Question 6.– What are the perceptions of nurses regarding where clinical 
research should be conducted and the role of oncologists and nurses in clinical trials? The RL 
subscale evaluated nurses’ perceptions of the role oncologists and nurses in clinical research, 
awareness of patients and location of clinical trias. The RL subscale was reverse coded; 
therefore a lower score indicated more agreement with items such as oncologists and nurses 
put too much pressure on patients to participate in r search, patients are unaware that their 
treatment is part of a research protocol and clinical research should only be conducted in 
cancer centers. Two groups emerged having significat differences in their mean RL scores, 
nurses working with clinical trial patients (or not) and years of experience as a cancer RN. 
Nurses who did not work with clinical trial patients had lower mean scores on the RL subscale 
compared to nurses who do and nurses with less than 1–10 years experience as a cancer RN 
had significantly lower scores compared to nurses with more experience. The reason why 
nurses with less than 1–10 years experience and nurses who did not work with clinical trial 
patients had more agreement with items such as, oncologists and nurses put too much pressure 
on patients to participate in research, patients are unaware that their treatment is part of a 
research protocol and clinical research should onlybe conducted in cancer centers may be 
explained by the fact that these groups may have less experience with clinical trials and have 
not experienced patient-oncologist interaction regading  participation in clinical trials.   
Research Question 7.Five stepwise multiple regression models were constructed to 
determine if the independent variables (age, education level, number of years as a cancer RN, 
whether nurses care for clinical trial patients [or n t], work setting, and primary position) serve 
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as significant predictors related to attitudes and perceptions as measured by the four subscales 
(ATCR, PUK, INP and RL) and Item 15 on the modified NAS. The variables of primary 
position, years a cancer RN, work setting, education l level, and whether or not a nurse works 
with clinical trial patients were significant predictors of attitudes toward cancer clinical trials, 
perceptions of patients’ knowledge of clinical trials, treatment plans, need for information, and 
perceived benefit about how effective a research drug o  experimental therapy should be shown 
to be before it is offered to patients. However, caution is needed in interpreting the data, as it is 
difficult to make definitive statements that the prdictors identified in this regression analysis 
serve as great predictors of attitudes and perceptions, since all of the regression models 
accounted for so little variance. The R² values for the five regression models ranged from 0.025 
to 0.144, indicating the models accounted for 2.5% to 14.4% of the variance in attitude and 
perception scores.  This indicates there are other variables that predict attitudes and perceptions 
better than the independent variables chosen for this s udy, and these variables are unknown. 
  Burnett et al. (2001) found that practice setting a d older age predicted nurses’ 
positive attitudes and perceptions toward clinical tri s.  However, they also had low R² values 
for their subscales (10%). Older age as a predictor of positive attitudes and perceptions is in 
contrast to the findings of this study; age was not found to be a predictor for attitudes and 
perceptions from the multiple regression models constructed for this study.  The reason for this 
difference is unclear and the investigator was unable to identify any other research addressing 
this issue.  
Additional information. The oncology nurses in this study were supportive of the 
importance of cancer clinical trials improving stand rds of care in oncology, but not 
necessarily willing to participate as research subjects if they had cancer. This finding is 
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consistent with the findings by Burnett et al. (2001) but not to the same magnitude. In both 
studies greater than 95% of nurses agreed that clinical research improves standards of care in 
oncology. Burnett et al. (2001) found 56% of nurses agreed that patients should be encouraged 
to participate in research, while only 35% of nurses tated that they would prefer treatment in a 
clinical trial. This study found 75% of nurses agreed that patients should be encouraged to 
participate in research while 51% of nurses stated that they would prefer treatment in a clinical 
trial. More nurses in this study agreed that patients should be encouraged to participate in 
research compared to Burnett et al. (2001), 75% vs. 56%.  Furthermore, more nurses in this 
study were willing to participate in a cancer clinical trial if they had cancer compared to 
Burnett et al. (2001), 51% vs. 35%.  These differences may be due to the timing of the data 
collection; Burnett et al. (2001) collected their data more than 5 years before data collection for 
this study. Within that time, the NCI has developed an  advertised a Clinical Trials Education 
Series (NCI, 2006) and the ONS has updated its position statement on Cancer Research and 
Cancer Clinical Trials three times.  A paragraph contained in the position statement relative to 
this study states: “Barriers to access and environment include system barriers, healthcare 
barriers, and patient barriers.  Modifying attitudes, changing perceptions, and increasing 
awareness about clinical trials among these groups are paramount to overcoming many of the 
present barriers” (ONS position statement, 2004, p. 2).  
 Because of these initiatives, nurses may have a greater awareness of the importance of 
cancer clinical trial participation.  Also, this study collected data from oncology nurses who 
practice in varied work settings compared to Burnett et al. (2001), they collected data from 
nurses who only worked in a comprehensive cancer center and this may also be a reason for the 
differences in how many nurses agree that patients should be encouraged to participate in 
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research and how many nurses themselves would partici te in a clinical trial if they had 
cancer.  Cassileth et al. (1982) found that willingness to participate in research varies 
depending on whether a subject considers the question of participation as referring to 
hypothetical individuals rather than themselves.   
 There were striking differences between the nurses’ p rceptions of the influence of 
nurses and oncologists on patients’ decisions to enter clinical trials between this study and the 
only other study to report on oncology nurses attitudes toward cancer clinical trials (Burnett et 
al., 2001). Almost all the nurses in both studies agreed that nurses respected patient wishes. 
However, Burnett et al. (2001) reported that 62% of nurses thought that physicians respected 
patients’ wishes, whereas in this study approximately 83% of nurses agreed with this. Also, 
more than 25% of nurses in the Burnett et al. (2001) study agreed that doctors put too much 
pressure on patients to participate in clinical trils. In this study less than 10% of nurses agreed 
with this statement. More than 80% of the nurses in this study perceived that patients were 
actually well informed when they chose to participate in a clinical trial. This is higher than 
what has been reported by Burnett et al. (2001) who rep rted that only 56% of nurses thought 
that patients were well informed when they chose to participate in a clinical trial. Additionally, 
Burnett et al. (2001) reported that less than 50% of the nurses they surveyed agreed with the 
statement “patients understand their prognosis and goals of therapy” (p.1190) whereas, this 
study found 68% of the nurses agreeing with this statement. Finally, almost one quarter of the 
nurses surveyed by Burnett et al. (2001) agreed that patients are often unaware that their 
treatment is part of a research protocol, and approximately 10% of nurses in this study agreed 
with this statement.  
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The investigator acknowledges that the responses by the nurses surveyed by Burnett et 
al. (2001) and the nurses in this study cannot be directly compared. Burnett et al. (2001) 
surveyed the nurses employed at one comprehensive canc r center. This study surveyed a 
random sample of oncology nurses who are members of ONS living in the U.S. Also, Burnett 
et al. (2001) published their data 5 years before this study, as such, attitudes can change over 
time. Additionally, the NAS had been used in only one prior pilot study (Burnett et al., 2001) 
and was modified with permission from the authors (see Appendix D). This modification of a 
relatively new and infrequently used instrument may also explain the low reliability of the INP 
and RL subscales.   
Study Results and Theoretical Framework 
The theoretical framework on which this study was bed was the Theory of Reasoned 
Action (TRA) by Ajzen and Fishbein (1980). This study was descriptive and exploratory and 
was not designed to fully test the TRA.  According to the theory, in general, an individual will 
hold a favorable attitude toward a given behavior if he/she believes that the performance of the 
behavior leads to mostly positive outcomes. Conversely, if the individual believes that mostly a 
negative outcome will result from the behavior, he/s  will hold a negative attitude toward it. 
Concepts of the theory define the nurse’s own beliefs, as well as, the perceived beliefs 
of those groups that are in a position to influence the ideas and actions of the nurse. These 
beliefs and actions pertain to the nurse’s relationship with the patient contemplating enrollment 
or already enrolled in a cancer clinical trial. Therefore, the combination of the nurse’s beliefs 
and the group belief could lead one to action depending upon which set of beliefs are valued 
more (or is perceived to lead to a positive outcome) by the nurse, thus forming an attitude on 
the part of the nurse. Behavior, in turn, is deemed a function of intention.   
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Therefore, factors associated with intention need to be evaluated to understand and 
predict behavior (Levin, 1999). One way to evaluate in ntion is to assess attitudes and 
perceptions, and this study was an exploration of oncology nurses attitudes and perceptions 
toward cancer clinical trials. Attitudes need to be evaluated before predictions can be made as 
to how an individual may behave. One behavior that nurses may perform is to provide 
education to patients and to clarify information that a patient may not understand. This fact is 
underscored by the study by Aaronson et al. (1996). The authors evaluated a strategy of 
providing additional information to patients considering entry into Phase II or III trials at the 
Netherlands Cancer Institute (N = 180). Patients were randomized to the standard consent 
interview, or the standard interview followed by a telephone call several days later from a 
clinical trials nurse to further discuss the information provided in the consent interview. This 
nursing intervention was shown to have a positive eff ct on cancer patients’ awareness of the 
most important issues surrounding clinical trials in which they are asked to participate. 
Overall, oncology nurses in this study had positive attitudes toward cancer clinical 
trials. Moreover, 98% of nurses in this study agreed that clinical research was important in 
improving future standards of care. It is impossible to make direct correlations that the 
oncology nurses surveyed in this study will perform positive behaviors because, in general, 
they have positive attitudes toward cancer clinical tri s. Further research is needed to construct 
a model or study design that will measure attitudes, the perceived beliefs of significant others, 
and intentions, and correlate them with a behavior, such as, educational information given by 
oncology nurses to clinical trial patients.    
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B. Additional Limitations 
 After all the data from this study were analyzed there were several additional 
limitations that became clear.  
1. This study used a mailed survey design to collect data from a national sample of 
oncology nurses. Three hundred and one surveys were us d in the analysis equating to 30% of 
the population sampled. Despite using a stratified random sample design to attempt to obtain a 
representative sample of oncology nurses who were ONS members, the results may not be 
representative of entire approximate 32,000 members of ONS. Thus, an inherent limitation 
with mailed surveys is nonresponse bias (Dillman, 2000). As such, nonresponse bias could 
have reduced the random probability sample of this study to essentially a convenience sample 
and consequently, the conclusions become much weaker. It is unknown if nonresponders 
would have answered the items on the NAS differently from responders.  
2. The population studied was a defined group of oncology nurses who are ONS 
members who allowed their names and addresses to be mad  public. Their attitudes and 
perceptions may not necessarily parallel those of nono cology nurses, oncology nurses not 
members of ONS, or ONS members who did not allow their contact information to be made 
public. Additionally, geographic diversity is unknown from this population of nurses, and there 
may have been differences in patterns of care of cancer patients based on where they live 
(Gregorio et al., 2001; Hanlan et al., 1995). There are standards of care that have been defined 
by cancer research leaders; however, there remains a “gap” between the recommended 
standards and oncology care delivered by community o cologists (Love, 2005). Therefore, 
nurses from one part of the country may approach cancer clinical trials differently than nurses 
in another part of the country. Geographic information was not captured on the DIF.  
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3. The modified NAS may have been a limitation in the conclusion drawn from the data 
analysis. This is based upon the low coefficient of determination (R²) found in this study and 
its ability to define variables (groups of nurses) that predict positive attitudes toward clinical 
trials. There may be other variables that were not cap ured on the DIF that serve as better 
predictors of attitudes and perceptions, such as geographic location of employment. Along the 
same line, the DIF questions for work setting and primary position are identical to the ONS 
membership application, and there was no way to differentiate between nurses working in a 
comprehensive cancer center and nurses in other setting . In retrospect, the investigator could 
have included a yes/no question on the DIF that asked “Do you work in a comprehensive 
cancer center?”  
4. The original NAS used two subscales to measure attitudes and perceptions and was 
designed to measure two constructs (attitudes and perce tions) and used one 6-item subscale to 
measure attitudes and another 6- item subscale to masure perceptions. In retrospect, it may 
have been more appropriate to perform a factor analysis to evaluate two subscales. This is 
supported by the fact that the INP and RL subscales, d termined by the factor analysis had low 
Cronbach’s alpha.  
5. The TRA attempts to predict human behavior, based on concepts of personal beliefs, 
which lead to attitudes toward the behavior, and perceived beliefs of others, which lead to 
subjective norms.  The attitudes and subjective norms lead to behavioral intention and then 
finally to performing a behavior. This study was based on one side of the TRA and addressed 
nurses’ attitudes only. It did not take into account the nurses perceived beliefs of others and 
subjective norms  
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6. Finally, the inclusion of nurses from the corporate/industry setting may have 
confounded the generalizability of the results, because it is hypothesized that this group works 
in the research field and may have very strong positive attitudes toward clinical trials. 
C. Implications 
Oncology nurses play a key role in the clinical and research settings by serving as direct 
caregivers, patient advocates, educators, counselors, as well as facilitators of clinical trials. As 
such, nurses have a major role in cancer clinical trials, yet not much research into their 
attitudes and perceptions has been undertaken.  Nurses’ attitudes and perceptions regarding 
cancer clinical trials may ultimately dictate their behaviors towards patients enrolled in or 
contemplating enrollment in such trials. By investiga ng oncology nurses attitudes and 
perceptions toward cancer clinical trials this study may begin to assess the behavior of 
oncology nurses towards clinical trial patients. These behaviors can include direct patient care, 
coordination of care, patent education, and patient advocacy.  The findings of this study have 
implications for nursing education, nursing practice, and the conduct of clinical trials.  For 
example: In-patient nurses (BMTU/ICU & MSOU) compared to MDO & HBIC were less 
likely to agree that patient understood their management plan, understood their prognosis and 
therapy goals, and patients are well informed when t y choose to participate in a clinical trial. 
Patient care and the conduct of clinical trials may be improved if these concerns are reconciled. 
D. Recommendations for Further Research 
Based on the results obtained from this study the inv stigator recommends the 
following areas that need to have further exploratin. 
The entire modified NAS had high internal consistency, with a Cronbach’s alpha of 
0.72; however, the Cronbach’s alpha of RL and INP subscales were 0.47 and 0.56, 
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respectively, indicating that the subscales had fair to poor reliability. Because of this, further 
research is needed to develop an improved instrument to measure oncology nurses’ attitudes 
and perceptions of the informational needs of patients involved in clinical trials. One option is 
to conduct a qualitative study using focus groups for the purpose of exploring common themes 
related to nurses’ attitudes and perceptions toward c ncer clinical trials. It might be 
advantageous to use focus groups to collect these data using nurses from the ONS clinical trial 
nurses special interest group (SIG) and from the pharmaceutical/industry nursing (PIN) SIG. 
The reason for inclusion of this later group is this study revealed that nurses in the CI setting 
and CTN had more positive attitudes toward cancer clinical trials and more realistic 
expectations of the benefit of cancer therapy offered as research. Nurses who are members of 
the clinical trials SIG and PIN SIG most likely repsent CI nurses from this study. From this 
qualitative study there may be items that are common to themes found on the modified NAS; 
these items could then be incorporated into the NAS. The NAS could continue to be modified 
and pilot tested for measuring nurses’ attitudes and perceptions.   
Once an instrument measuring nurses’ attitudes and perceptions has been refined,  a 
further recommendation would be to construct a model that will measure attitudes, the 
perceived beliefs of significant others, and intentions, then correlate them with a behavior, such 
as, educational information given by oncology nurses to clinical trial patients, to formally test 
the Theory of Reasoned Action. Finally, an intervention study could be undertaken looking at 
providing educational strategies that may change the a titudes and behaviors of oncology 
nurses working with clinical trial patients. This may help with increasing the number of 
patients into clinical trials. 
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E. Conclusion 
 This study was only the second and largest study to a e exploring oncology nurses’ 
attitudes toward clinical trials and their perceptions of patient understanding and knowledge. 
This is underscored by the fact that a systematic review of the relevant literature from 1996 to 
2006, relating to the barriers, modifiers and benefits involved in participating in randomized 
controlled trials of cancer therapies as perceived by healthcare providers and p tients, was 
undertaken by the Center for Reviews and Disseminatio  (CRD), University of York (Fayter, 
McDaid, Ritchie, Stirk, & Eastwood, 2006).  In their review, the authors found 17 studies 
examining attitudes of health professionals to participation in cancer clinical trials.  However, 
there was only one study which explored the views of oncology nurses, and that study was by 
Burnett, et al. (2001). 
Despite high internal consistency of the entire modifie  NAS, the four subscales 
derived from the factor analysis revealed varying de rees of internal consistency. This study 
discovered significant predictors to attitudes and perceptions; however, all R² (coefficient of 
determination) values were very low, indicating that there were some other unknown variables 
that could be better predictors than the ones used in this study. On average, oncology nurses 
had positive attitudes towards cancer clinical trias. However, statistically significant 
differences were found between nurses grouped by primary work setting and primary position. 
Additionally, as a whole, these nurses perceived that patients have enough information to make 
decisions regarding clinical trial participation and they somewhat disagreed that clinical 
research should be conducted only in cancer centers, oncologists and nurses put too much 
pressure on patients to participate in clinical trils, and patients are often unaware that their 
treatment is part of a research protocol. Significant differences in these perceptions were found 
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between the following variables: primary work setting, number of years in cancer nursing, and 
whether or not a nurse works with clinical trial patients. Consistent with prior research, 
oncology nurses perceived that experimental cancer treatments should have a large benefit 
before being offered to patients. Moreover, there were statistically significant differences in 
this perceived benefit between the nurses grouped by number of years in cancer nursing, 
primary work setting and highest education level. More research is needed to explore the 
reasons for these differences in attitudes and perce tions. Finally, more research is needed to 
truly evaluate the TRA as a model of educational behaviors nurses use providing education to 
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Survey of Nurses Attitudes Toward Cancer Clinical Trials v.4 
Modified with permission (Burnett et al. 2001).  
 
I. Clinical research using patients as research subjects. 
For the following statements please mark the category cl sest to your opinion.  
                                                                      Strongly   Somewhat       Neutral       Somewhat       Strongly                                                                                                              
                                                                              disagree   disagree                                 agree            agree                                                                  
                                                                1             2                 3                4                5 
1. Conducting patient research is an 
important role of oncologists. 
                                                                      1              2              3                4                5 
2. Clinical research should be conducted 
only in cancer centers/institutes.        
                                                                      1              2             3                4                5 
3. It is appropriate for oncologists to invite 
their clinic patients to be subjects in trials 
that they conduct. 
                                                                      1              2             3                4                5 
4. It is appropriate for oncologists to be the 
person consenting research subjects for 
their trials, if the research  
subjects are their own clinic patients. 
                                                                      1              2             3                4                5 
5. Clinical research improves patient 
 care for the patient  involved.      
                                                                      1              2             3                4                5 
6. Hospitals that conduct clinical  
research have better standards of care  
than hospitals that do not.  
                                                                1              2                3               4                 5 
7. Clinical research in oncology is 
important in improving  future standards of 
care in oncology.  
                                                                      1              2             3               4                 5 
8. Patients should be encouraged to 
participate in research.                                                                                                                                            
                                                                      1              2              3               4                5 
9. Oncologists put too much pressure on 
patients to participate in clinical trials. 
                                                                      1              2             3               4                 5 
10. Nurses put too much pressure on 
patients to participate in clinical trials. 
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                                                               Strongly     Somewhat       Neutral     Somewhat        Strongly                                                          
                                                                                   disagree      disagree                               agree              agree                                           
 
                                                                      1              2             3               4                 5 
11. If I had cancer, I would prefer to be 
treated as part of a clinical trial.                                                                                                             
                                                                      1              2              3              4                 5 
12. In general, patients are well informed 
when they choose to participate in a 
clinical trial. 
                                                                      1               2              3              4                5 
13. Patients are often unaware that their 
treatment is part of a research protocol. 
                                                                                          
14. Patients participate in research  
because of:                                                  1               2                3                4                5  
          A.     wish for cure                                 
                     
                                                                      1               2             3                4                5 
          B.     wish for improved quality 
                   of life (i.e., symptom 
                   control)                    
                                                                      1               2             3                4                5                                                                                                                                                
          C.     hope for better medical    
                   care                                 
                                                                      1              2              3                4                5                                                                                                                                                            
          D.     desire to please their 
                    oncologist                               
                                                                      1              2              3                4                5                     
          E.      pressure from oncologist                                           
                                                                    
                                                                      1               2             3              4                5                             
          F.      wish to help others                                               
                                                                                 
                                                                      1               2             3                4                5                    
          G.     family wishes                                                        
                                                                              
                                                                      1               2             3                4                5                    
          H.     no other option                                                           
                                                                                      
                                                                     1               2             3                4                5 
          I.      inability to accept that 
                   nothing else can be  done       
                                                                     1               2             3                4                5 
          J.       inability to accept death                                      
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15. In your opinion, in order for a research drug or experimental therapy to be offered to 
patients, it should have at least ___________% chance of producing a  desired effect (please 
insert a number) 
 
II. Patient care and communication 
For the following statements please mark the category cl sest to your opinion. 
                                                           Strongly     Somewhat     Neutral        Somewhat      Strongly                                                                                                              
                                                                                     disagree      disagree                              agree             agree                                                                  
                                                                      1               2             3               4                 5 
16. Patients’ wishes regarding treatment are 
respected by nurses.                                                                                    
                                                                      1              2             3                4                5 
17. Patients’ wishes regarding treatment are 
respected by oncologists.                                         
                                                                      1              2              3                4                5 
18. Patients understand their plan of 
care/treatment.                   
                                                                      1               2             3                4                5                                                                                                             
19. Patients understand their prognoses and 
therapy goals.         
                                                                     1              2                 3                4                5 
20. Patients’ prognoses are usually well 
explained.                     
                                                                      1               2             3                4                5 
21.  Patients want to be informed.                     
                    
                                                                      1               2             3                4                5 
22. When being told about their therapy, 
most patients pay more attention to 
potential benefits of therapy    
 than side effects.                                                                          
                                                                      1             2              3                4                5 
23. Most Patients are willing to accept side 
effects for even a small benefit of therapy. 
                                                                      1              2             3                4                5 
24. Patients are often frightened to ask 
questions.                        
                                                                      1             2              3                4                5 
25. Patients’ decisions whether to 
accept or not accept toxic chemotherapy is 
strongly influenced  
 by their family preferences.                                                                                                                                                                          
                                                                      1              2              3               4                5 
          26. Oncologists believe that patients are 
          willing to accept side effects for even a 
          small benefit of therapy. 
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Demographic Information Form 
 The following information is requested so that the investigator may gain a better 
understanding of demographic characteristics related to the nurse-patient. Please answer 
all questions by checking the appropriate box or filling in the blank 
 
 
1. What is your age? __________ years old (p ease insert a number) 
 
 
2. Your gender:   Female   Male 
 
 
3. Indicate your highest level of nursing education. 
 
 Check  Educational       
 Level  Level       
    Diploma in nursing                                                    
    Associate degree in nursing                                     
    Associate degree in another field                            
    Baccalaureate degree in nursing                             
    Baccalaureate degree another field                         
    Master’s degree in nursing                                                                      
    Master’s degree in another field                                     
    Doctoral degree in nursing                                       
    Doctoral degree in another field                               
 
4. Do you work with or care for patients contemplating enrollment in or currently 
enrolled in cancer clinical trials? 
     Yes  No 
 
5. What certifications do you have in oncology nursing? (Check all that apply, if none go 
to question #6). 
  
 Certification Type 
 Oncology Certified Nurse              Advanced Oncology 
 (OCN)          Yes      Certified Nurse (AOCN)         Yes 
  
Advanced Oncology Nurse    Advanced Oncology Clinical 
 Practitioner (AOCNP )      Yes  Nurse Specialist (AOCNS)  Yes 
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6. Number of years an RN 
Please indicate your total number of years of experience as a RN where you had direct 
patient contact at least 8 hours per week. (Round to the nearest whole 
year)._______________years (please insert a number). 
 
7. Number of years an RN in Cancer Care  
Please indicate your total number of years of experience as a RN in CANCER care where 
you had direct patient contact at least 8 hours per we k.  
(Round to the nearest whole year)._______________years (please insert a number) 
  
8. Percentage of patients offered cancer clinical tri ls 
At your place of employment/practice setting, what percentage of patients are offered any 
type of cancer clinical trials? (eg. NCI sponsored, in ustry sponsored, investigator 
initiated studies).____________________ % (please insert a number) 
  
 
9. What is your primary work setting? (Select one) 
 In-patient   
 Bone Marrow Transplant Unit 
 Intensive Care Unit 
 Medical/Surgical Unit- General 
 Medical/Surgical Unit-Oncology 
 Oncology Specialty Unit 
  Other__________________________________ (please specify) 
Outpatient  
  Home Care 
  Hospice 
  Hospital Based Clinic/Infusion Center 
  Physician Office 
  Radiation-Free Standing 
  Radiation-Hospital Based 
  Other__________________________________ (please specify) 
 Other 
 Corporate/Industry 
  Extended Care Facility 
  HMO/Managed Care 
  School of Nursing 
  Self Employed 
  Other__________________________________ (please specify) 
  
 
10. What is your primary position? (Select one) 
  Staff Nurse  Clinical Nurse Specialist   Nurse Practitioner  
  Nurse Educator  Clinical Trials Nurse   Nurse Researcher 
  Nurse Manager  Academic Educator   Case Manager 
  Other____________________________________ (please specify)
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Paul D’Amico  
From:   Meropol, M.D., Neal [NJ_Meropol@fccc.edu]  
Sent:   Monday, September 20, 2005 9:52 AM  
To:   ‘Paul D’Amico’  
Subject:  RE: Dissertation  
 
Paul, 
Thank you for the follow up again, and good luck wi th your thesis. 
Feel free to modify the instrument as you propose. I’ll be most 
interested in your results. 
This e-mail should be sufficient for you to proceed  comfortably. 
 
Neal J. Meropol, M.D. 
Fox Chase Cancer Center 
333 Cottman Avenue 





From: Paul D’Amico [ mailto:damicop@duq.edu ] 




Dear Dr. Meropol, 
 




As I previously informed you, I want to use your Nu rses’ Attitude 
Survey in my data collection and want to modify it by removing the 
section on “Nurses’ Role in a Comprehensive Cancer Center” since this 
is beyond the scope of my study. 
 
Additionally, I want to remove the areas for writte n comments (have the 
subjects only answer the Likert scale items) and I want to capture the 
demographic information on a separate form and remo ve it from the 
Nurses’ Attitude Survey. 
 
If you think we can modify the tool as outlined abo ve, then I will need 
a signed letter from you, giving me permission to u se your tool in a 
modified form for my dissertation. 
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      DUQUESNE UNIVERSITY 
School of Nursing                                                       600 FORBES AVENUE    ♦    PITTSBURGH, PA 15282 
 Graduate Programs 
5th Floor Fisher Hall 
Telephone: 412.396.6550 
                                               
Dear Oncology Nurse, 
 
Three weeks ago a survey packet was mailed to you. I am conducting research for my doctoral 
dissertation and I am seeking your attitudes toward c ncer clinical trials and your perceptions of patient 
understanding.  Your participation in this study is voluntary. 
 
You were randomly selected to participate in this survey from ONS members who indicated that their 
primary functional area was patient care or research with adult patients and any primary position other 
than researcher/principal investigator.  If you do not meet these criteria please place a check mark in this 
box       and mail this letter back to me in the enclosed tamped addressed envelope. If you do meet 
these criteria please complete the study forms as outlined below 
 
 If you have completed and returned your survey to me, please accept my sincere thanks.  If     
not, please do so today.  I am grateful for your help b cause your attitudes and  
perceptions regarding clinical trials are important to oncology nursing and to help us  
understand this aspect of cancer care.  
 
If you have misplaced the survey another one is included with a stamped, addressed return envelope. 
 
 There are two forms for you to complete. 
• The Nurses’ Attitudes Survey (modified) contains statements regarding your attitude towards 
benefit of clinical trials, your perceptions of patient understanding, and your perceptions about patients’ 
reasons for participating as research subjects. 
• Demographic Information Form which asks for information such as age, education level, 
functional role, practice setting etc. 
 
It should take you less than 10 minutes to complete the forms. 
 
When you are finished, place all the materials in the stamped, addressed envelope provided and mail it to 
me.  Your response will be your implied consent.  If you have any questions, please at 631-987-4695 or 
my dissertation chair Dr. Gladys Husted at 412-396-6544.  If you have any further questions about your 
rights regarding this study you may call Dr. Paul Richer, Chair of the Duquesne University Institutional 
Review Board (IRB) at 412-396-6326. 
. 
In advance, thank you for helping to describe this aspect of cancer nursing practice. 




Paul G. D’Amico, RN, MS, OCN, PhD(c) 
Doctoral Student Duquesne University School of Nursing 
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